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Abstract 
Obesity is a key risk factor for cardiovascular disease (CVD). The aim of this PhD study was 
to investigate the associations of obesity and adiposity with carotid atherosclerosis, and, in 
particular, to examine the effect of general vs abdominal adiposity on the burden of carotid 
plaque. These associations were investigated in the Tromsø study in Norway and in the Know 
Your Heart study in Russia. These populations have very different cardiovascular mortality 
rates, with Russia having one of the highest rates in the world. In this context, the thesis 
looked at whether differences in carotid plaque burden between these populations can be 
explained by adiposity. 
Four anthropometric measures of adiposity were included, which involved body mass index, 
waist circumference, waist-to-hip ratio, and waist-to-height ratio. Carotid plaque burden, i.e. 
the presence of plaques, number of plaques, and total plaque area (TPA), was assessed using 
carotid ultrasound. In the Tromsø Study 5th survey (2001), there was strong evidence of an 
association between TPA and adiposity, especially abdominal adiposity, after adjustment for 
potential confounders (sex, smoking status, education). This association was largely mediated 
by cardio-metabolic CVD risk factors (blood pressure, cholesterol, glycosylated 
haemoglobin). These findings were confirmed in a prospective analysis assessing changes in 
plaque burden between the Tromsø Study 4th (1994-95) and 5th surveys.  
Comparison of the cross-sectional results from the Know Your Heart study (KYH) and 
Tromsø Study 7th wave (Tromsø 7) showed that women in KYH had higher levels of 
adiposity than in Tromsø 7, while levels were similar for men. Despite evidence that 
adiposity was associated with carotid plaque (presence of plaques and number of plaques), 
adiposity failed to explain the high burden of carotid plaque in KYH compared to Tromsø 7 
in women as well as men. Explanations for the greater carotid plaque burden in Russia must 
be sought elsewhere, although reducing levels of obesity in Russia and Norway must be a 
priority for other reasons.  
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1 Introduction 
1.1  Background 
Although the burden of cardiovascular disease (CVD) in Europe, as well as other high-
income countries, has been decreasing for decades, a huge inequality exists in the CVD 
burden across the European region. While high-income Western European countries enjoy 
unprecedentedly low CVD mortality rates, the rates in Russia are among the highest in 
Europe. The European Society of Cardiology categorises Russia as a very-high-risk country 
with CVD risk levels more than double of those in low-risk countries (1). The gap between 
the CVD mortality rate among people of working-age in Russia and elsewhere is even wider, 
resulting in low life expectancy for this industrialised country (2). Furthermore, the estimated 
Disability-Adjusted Life Years (DALY) for CVD in Russia is among the highest in Europe 
(1, 3). The reasons for this high CVD burden and associated risks of carotid atherosclerosis 
are not well understood.  
Previous studies have suggested that differences in the prevalence of conventional CVD risk 
factors such as hypertension, hyperlipidemia, and smoking status do not fully explain this gap 
in CVD burden between Russia and high-income Western Europe (4, 5). However, these 
studies are relatively old. In spite of its high CVD burden, CVD risk factors have not been 
systematically monitored in the general population in Russia, which makes understanding of 
the distribution and trends of risk factors challenging (6). Further, little research has 
investigated the association between CVD risk factors and CVD burden over the past 10-15 
years. Up-to-date information on the distribution of CVD risk factors and estimation of its 
impact on CVD burden will be an important step towards implementing a tailored strategy to 
improving cardiac health in Russia and to reducing excess CVD mortality. 
Among risk factors for CVD, obesity is one of few that is increasing not only Russia but also 
in high-income Western European countries (7). Obesity and its consequent type 2 diabetes 
may reverse the downward trend in CVD burden in Western Europe and further add to the 
considerable burden in Russia. Obesity can, thus, be considered as a critical CVD risk factor 
in the European region. So far, no attempt has been made to investigate to what extent the 
differences in CVD burden between Russia and high-income Western European countries can 
be explained by differences in their obesity levels. 
Yume Imahori  
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Atherosclerosis is a major cause of CVD both through ischemic heart disease and ischaemic 
stroke, being responsible for over 80% of CVD deaths (8). Atherosclerotic changes occur far 
in advance of CVD events, having been found even in young adults (9-11). Therefore, the 
identification of sub-clinical atherosclerosis holds great promise as an effective biomarker of 
CVD. Several non-invasive imaging modalities have the potential to predict CVD risk 
beyond conventional CVD risk factors by capturing regional atherosclerotic changes (12, 13). 
Among them, carotid atherosclerosis can be easily and safely assessed at relatively low-cost 
using ultrasound, making it suitable for large studies using healthy populations. In particular, 
detection of carotid plaque is promising with its good predictive ability for future CVD 
events (14). While increased intima-media thickness (IMT), a widely-used measure of carotid 
atherosclerosis, does not necessarily indicate atherosclerotic changes, carotid plaque is 
characteristic of a later stage of atherosclerosis, outperforming IMT regarding predictive 
value for CVD (15). Not only can carotid plaque be used as an imaging biomarker of CVD 
burden, but can also potentially be used to compare CVD burden directly across different 
populations with different CVD risks. 
The Know Your Heart (KYH) Study is a population-based cross-sectional study conducted in 
two Russian cities during the years 2015-18 (2). In this study, data were collected on carotid 
plaque variables and several anthropometric adiposity measures, along with data on 
traditional CVD risk factors, from a random population-based sample aged 35-69 years. 
Efforts were made to align the main protocols of KYH with those of a concurrent population-
based study in Norway: the Tromsø Study seventh survey (Tromsø 7) conducted in 2015-16, 
with the aim of increasing the validity of planned comparisons between the two study 
populations. In the Tromsø 7 study, data were collected on similar variables to KYH, 
including carotid plaque variables and adiposity measures from a random population sample. 
Norway is a typical Western European country with moderately low CVD mortality. 
However, the CVD mortality rate at working age is eight times higher in Russia than in 
Norway (2). Thus, KYH and Tromsø 7 provide a unique opportunity to examine differences 
in carotid plaque burden and the associations with adiposity in untreated older people across 
two populations with a contrasting CVD risk. Furthermore, analysis of the two studies 
enables us to examine whether excess carotid plaque burden in Russia, if any, can be 
explained by adiposity level. 
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1.2 Aims and Objectives 
The aim of this thesis is to examine the contribution of adiposity to atherosclerotic changes in 
the carotid artery in a general population in Russia compared to that in Norway, a low CVD 
risk European country. A further aim is to determine whether adiposity explains the 
difference in carotid plaque burden between the two populations. 
The thesis has two main objectives: 
1) To investigate the role of general and abdominal adiposity on measures of carotid 
plaque  assessed by ultrasound in population-based studies from Norway (the Tromsø 
study seventh survey: Tromsø 7) and Russia (Know Your Heart Study: KYH); 
2) To determine whether differences in carotid plaque burden (the presence of plaques, 
number of plaques) between the two populations, if any, can be statistically accounted 
for by various measures of adiposity  
1.3 Structure of the thesis 
This thesis has been organised as follows. After this introduction, I review the literature on 
CVD/atherosclerosis, adiposity, and the association between them to provide the overall 
context of this thesis (Chapter 2: literature review). This is followed by a systematic review 
of the published evidence on the association between ultrasound-assessed carotid 
atherosclerosis and adiposity, which identifies knowledge gaps in this area (Chapter 3: 
systematic literature review). In the next two chapters, I describe the study setting and design 
of the two population studies I use (KYH and the Tromsø Study) (Chapter 4: Study setting 
and design) and their main exposures and outcomes (Chapter 5: Main exposure, outcome, and 
other variables).  
I report the results of my analyses in four chapters (6 to 9). In Chapter 6, I investigate the 
cross-sectional association between carotid plaque burden and four adiposity measures to 
confirm the pathway between adiposity and carotid atherosclerosis in the fifth survey of the 
Tromsø study. In Chapter 7, I investigate the same issue using longitudinal rather than cross-
sectional data from the Tromsø study to investigate the prospective association between the 
progression of carotid atherosclerosis and baseline adiposity. In Chapter 8, I examine and 
compare the general/abdominal adiposity level and the prevalence of obesity in KYH and the 
Tromsø 7 study. Finally, I compare the association of carotid atherosclerosis with 
general/abdominal adiposity in KYH and Tromsø 7, leading onto an analysis of whether 
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adiposity explains the difference in carotid atherosclerosis between these two population-
based studies (Chapter 9). 
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2 Literature review (CVD, adiposity, the association between 
adiposity and CVD) 
This chapter aims to provide the context of the thesis with a literature review on 
cardiovascular disease (CVD)/ atherosclerosis, adiposity, and the association between 
adiposity and CVD. In the first section, current knowledge about the burden of CVD 
worldwide, in Western Europe and in Russia is summarised. This is followed by an overview 
of the pathology of atherosclerosis, a major cause of CVD, and imaging techniques to assess 
atherosclerosis. In the second section, the burden of obesity in Western Europe and Russia is 
described, followed by a discussion of the complexity of obesity, its assessment, and risk 
factors for obesity. In the final section, the current evidence on the association between 
adiposity and CVD is reviewed. 
2.1 Cardiovascular disease (CVD) 
2.1.1 Cardiovascular disease (CVD) and atherosclerosis 
 CVD is a leading cause of death worldwide. In 2015, it was estimated that nearly a third of 
all global deaths (17.7 million) were attributable to CVD (16). CVD not only has a negative 
impact on the lives of individuals due to premature mortality or disability but also imposes a 
huge economic burden on society. Further effort is needed to reduce the CVD burden.  
Atherosclerosis is a major cause of CVD. Atherosclerotic CVD mainly comprises two major 
conditions: ischemic heart disease (IHD) and cerebrovascular disease, particularly ischemic 
stroke. IHD and stroke accounted for 84.5% of CVD deaths in 2013 (8).  
Atherosclerosis is a chronic inflammatory disease of the arteries, which narrows or blocks 
important vessels such as coronary and cerebral arteries with serious consequences. The 
major risk factors for atherosclerosis are well established and preventable. Thus, major 
guidelines aiming to reduce CVD focus on the prevention of atherosclerotic CVD (12, 17, 
18).  
Broadly, risk factors for atherosclerosis are divided into two groups: behavioural risk factors 
and cardio-metabolic risk factors. The American Heart Association has specified four health 
behavioural factors (smoking, obesity, physical activity, diet) and three cardio-metabolic 
factors (cholesterol, blood pressure, blood glucose) which have significant impacts on 
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cardiovascular health (19). Similarly, the European Society of Cardiology specifies eight 
major CVD risk factors: four behavioural risk factors (diet, low physical activity, smoking, 
alcohol use) and four medical risk factors (high systolic blood pressure, high total cholesterol, 
high fasting plasma glucose, high body mass index) (20). Among them, blood pressure, 
cholesterol, and smoking are particularly important. These three, along with age, are included 
in main CVD score systems to predict future CVD risks (12). The control of these cardio-
metabolic and behavioural risk factors is a vital step to achieving a reduction in CVD. 
Fortunately, CVD mortality has experienced a dramatic decrease since 1980, particularly in 
high-income countries (21-24). This reduction has largely been due to two factors: reduction 
in major risk factors and evidence-based medical and surgical treatment. The improvement in 
hypertension treatment, widespread statin use and a decrease in the prevalence of smoking 
have resulted in the reduced distribution of CVD risk factors (22). The analysis of the 
prospective population-based cohort Tromsø Study revealed that change in CVD risk factors 
contributed to 66% of the reduction in CVD deaths between 1995 and 2010 (25). At the same 
time, appropriate delivery of evidence-based treatment played a significant role in reducing 
CVD mortality rates, including secondary preventive therapies after myocardial infarction, 
revascularisation, initial treatments for coronary artery disease, and treatment for heart failure 
(22). 
In spite of this success story in CVD control in high-income countries, there remain two 
major concerns which must be addressed. First, CVD mortality rates show a huge regional 
difference with some countries still suffering from a heavy burden of CVD compared to their 
neighbours. Second, although some risk factors such as blood pressure and hyperlipidemia 
are well-controlled with a sustained reduction in the prevalence in high-income countries, the 
prevalence of obesity has increased, accompanied by an increase in type 2 diabetes in almost 
all countries. This increase in obesity and diabetes might offset or reverse the downward 
trend of the CVD burden. Indeed, signs of deceleration have already been observed (26).  For 
example, analysis of the US national data showed that the decline in CVD in the US has 
substantially decelerated since 2011, which may be attributable to a rapid increase in obesity 
and diabetes (27). Therefore, the prevention and treatment of obesity might be crucial to 
further success in the control of CVD.   
The European region faces both problems: a huge gap in CVD burden between regions and 
an increasing obesity burden. Although the CVD mortality rate has decreased dramatically in 
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high-income Western European countries, Russia still suffers from a high but declining CVD 
burden which results in low life expectancy for such an industrialised country (65.2 years for 
men and 76.5 years for women) (28). Detailed information on CVD burden and the 
distribution of risk factors in the European region was provided in the next section. 
2.1.2 Russia and Western Europe: Comparison of CVD burden and CVD risk factors 
A huge difference in CVD burden exists between Western Europe and non-EU countries, 
although the CVD mortality rate has decreased overall in the European region (Figure 2-1). 
According to a recent report, there are 4 million CVD deaths per year in Europe as a whole, 
accounting for 45% of total deaths (1). Furthermore, 1.4 million of these deaths occur in 
people under 75 and 700,000 in people under 65. However, as Table 2-1 shows, the  CVD 
burden varies widely according to the European region. The CVD burden in EU-28 countries 
and non-EU members is clearly higher than that in high-income Western Europe. In Western 
European countries, deaths from CVD make up 33% of total deaths, which is a lower 
percentage than in other European regions with lower age-standardised death rates (ASDRs). 
On the other hand, in non-EU countries, 54% of deaths are attributable to CVD with higher 
ASDRs. In Russia, ASDRs in men and women are 1423.1/100,000 and 914.0/100,000, 
respectively. This exemplifies the enormous inequality of the CVD burden among European 
countries. 
Regarding trends in CVD mortality, there has been a substantial decrease in Western Europe, 
ranging from 25.2% in Austrian men to 49.7% in Luxembourger men, and from 25.3% in 
Italian women to 42.9% in Portuguese women. Non-EU countries also show downward 
trends generally, but the decrease is not as sharp as in Western European countries, and there 
is wide variation. Since 2005 there has been a 10-year decrease in the Russian Federation of 
19.0% in men and 23.9% in women. There is also a large difference in Disability-Adjusted 
Life Years (DALY) attributable to CVD between European countries with Russia having the 
second-highest (181 per 1000 population) (1). 
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Data from European Cardiovascular Disease Statistics 2017 edition (29) 
Figure 2-1 Age-standardised death rates from ischemic heart disease under 65 years, 1980 to 2015 
(upper panel: males, lower panel: females)  
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Table 2-1 Differences in the burden of CVD: Range of ASDRs according to EU regions  
 (over ten years)  
 Percentage of 
CVD/total 
deaths 
ASDRs per 100,000 for 
CVD in men  
 
ASDRs per 100,000 for 
CVD in women 
 
  Minimum  Maximum Minimum Maximum 
EU-15 
countries 
33% 
 (1.3 million) 
France 
275.2 
Finland 
480.7 
France 
174.1 
Greece 
391.3 
EU-28 
countries 
38% 
(1.9 million) 
Malta 
407.7 
Bulgaria 
1299.5 
Malta 
317.0 
Bulgaria 
959.6 
Non-EU 
member 
54% 
(2.1 million) 
Israel 
255.0 
Ukraine 
1544.9 
Israel 
194.9 
Kyrgyzstan 
1087.4 
Data taken from Townsend et al. (1) 
The distribution of traditional CVD risk factors is an important determinant of CVD burden, 
which may explain the gap in CVD burden between Western Europe and Russia. Recently, 
the European Society of Cardiology reported detailed data on the distribution and trend of 
CVD risk factors in Europe (20). They concluded that the prevalence of some risk factors has 
shown a downward trend in Europe. For example, the prevalence of raised systolic blood 
pressure has decreased over the last three decades, although the extent of this decline varies 
widely by country and national income with high-income countries showing lower 
prevalence. In high-income Western European countries, the mean prevalence of raised blood 
pressure (systolic blood pressure >=140 mmHg or diastolic blood pressure>=90 mmHg) was 
27.3% in men and 18.3% in women according to data from the WHO Global Health 
Observatory in 2014. On the other hand, there is a higher prevalence of raised blood pressure 
in Russia for both men and women at 33.5% and 24.5%, respectively. Similarly, blood 
cholesterol concentration levels in Europe have decreased over the last 30 years. The age-
standardised prevalence of raised blood cholesterol (>6.2 mmol/l) in Western Europe was 
19.0% in men and 18.9% in women. Interestingly, Russian men had a much lower prevalence 
at 12.3% than their Western European counterparts, while Russian women also showed a 
slightly lower prevalence (17.1%) (20).   
In contrast to hypertension and hyperlipidemia, there has been a marked rise in the 
prevalence of obesity in both high- and middle-income European countries in the past three 
decades (30). This may sound paradoxical, considering obesity is a risk factor for 
hypertension and hyperlipidemia. However, the control of obesity seems more difficult than 
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that of hypertension and hyperlipidemia: a meta-analysis shows that the long-term 
maintenance of weight-loss by lifestyle change or medication is challenging (31), which 
makes prevention and treatment of obesity difficult compared to other CVD risk factors. The 
increase in obesity could potentially hinder the decline in CVD mortality and could, in the 
future, result in a reversal of the progress made. The prevalence of general obesity assessed 
by BMI was 23.1% in men and 22.9% in women in Western Europe. Russian men had lower 
general obesity prevalence at 20.3%, whereas Russian women showed a higher prevalence at 
27.4% (20).     
Another increasing risk factor for CVD is type 2 diabetes, which can be a consequence of 
increasing obesity. Diabetes is characterised by hyperglycemia and the development of 
microvascular pathology; this results in detrimental health conditions, including blindness 
and renal dysfunction. In addition, diabetes contributes to the acceleration of atherosclerotic 
disease, leading to CVD events (32). A recent meta-analysis from 68 prospective studies 
showed that men with diabetes have almost two times higher risk of deaths from occlusive 
vascular diseases such as ischemic heart disease and stroke while the risk among women 
tripled after adjustment for traditional CVD risk factors (33). Although currently available 
data appear to show a higher prevalence of diabetes in high-income than middle-income 
European countries, the prevalence of raised blood glucose is higher in middle-income than 
high-income European countries, suggesting either underdiagnosis or poor control of existing 
diabetes in middle-income European countries (20). The prevalence of raised blood glucose 
in men and women was 7.2% and 5.2% respectively in Western Europe while it was 7.4% 
and 8.0% respectively in Russia, suggesting the burden of diabetes may be higher in Russia 
than Western Europe, especially for women (20).  
With respect to health behaviours, smoking prevalence shows the most dramatic difference 
between Western European men (26.3%) and Russian men (55.0%). Smoking prevalence in 
women is similar at 17.0% in Western Europe and 16.3% in Russia (29, 34). However, 
increasing smoking prevalence among Russian women is a concerning trend (34). 
Information on other behaviours such as physical activity and diet may be less reliable 
because of self-reporting nature and measurement error. Caution is needed when interpreting 
these data. Regarding alcohol consumption patterns, there are some differences between 
Western Europe and Eastern Europe including Russia. Although recorded per-capita 
consumption of alcohol is similar between Western Europe and Eastern Europe, Eastern 
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Europe is characterised by high consumption of unrecorded intake, including home-made 
alcohol, resulting in higher per-capita consumption of alcohol in Eastern Europe (26.4 
l/drinker) than Western Europe (15.0 l/drinker). Furthermore, heavy drinking is more 
common in Eastern Europe (17.7%) (35). 
To summarise, available data suggest a higher prevalence of smoking, hypertension, and 
heavy drinking among Russian men and higher prevalence of hypertension, raised glucose, 
and obesity among Russian women than their Western European counterparts when the 
distributions of CVD risk factors are compared (20). However, it should be noted that 
evidence from Russia is limited compared to Western Europe. In spite of its high CVD 
burden, there is no systematic monitoring system for CVD risk factors in the general 
population in Russia. Updated epidemiological data on CVD risk factors would be of the 
utmost importance in any investigation of the reasons behind the high CVD burden in Russia. 
2.1.3 Pathology of atherosclerosis and its non-invasive assessment using imaging 
modality 
In the following section, I briefly summarise the pathology of atherosclerosis and its 
assessment using imaging techniques. I also describe current evidence on how imaging 
modality predicts future CVD risks.  
Pathology of atherosclerosis 
Atherosclerosis is a chronic condition which occurs in the large and medium-sized arteries. 
Normal large and medium-sized arteries have three layers: the innermost layer is the intima, 
which is a monolayer of endothelial cells and is in contact with blood. The second layer, the 
tunica media, consists of smooth muscle cells which control vessel tone. The intima and 
media layers are separated by the internal elastic lamina. The role of the outer layer, the 
adventitia, is not clear, although it contains the vasa vasorum and nerve endings in addition to 
collagen fibrils (36). The main location of atherosclerosis is the intima. The following is a 
brief description of the development of atherosclerosis, divided into two steps: atherosclerosis 
initiation and evolution of atheroma. 
First step: atherosclerosis initiation: The process of atherosclerosis begins with the 
accumulation of lipoprotein particles in the intima (36). They bind to proteoglycans and 
become more susceptible to various modifications, especially oxidative modification. A 
further important step is the recruitment and retention of leukocytes. They enter the intima, 
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accumulate lipids, and create foam cells. While monocyte and T lymphocytes are both 
involved in this process, the main player is the monocyte. Monocytes receive the signal to 
penetrate the endothelial monolayer from the chemoattractant cytokines and enter the arterial 
wall, where they differentiate into inflammatory macrophages and become lipid-rich foam 
cells by digesting oxidized lipoproteins, starting the formation of the fatty streak (37, 38). At 
this stage, the structure of the fatty streak is not complicated and may be reversible to some 
extent (36). 
Second step: evolution of atheroma: It is widely accepted that inflammation plays a critical 
role in the evolution of early atheroma to the more complex plaque (39). Macrophage-derived 
foam cells synthesise inflammation mediators, which promote inflammation. Another 
important player is the smooth muscle cell; these cells migrate from the media into the 
intima, gathering, and producing extracellular matrix molecules. These processes make 
simple fatty streaks into complicated fibrofatty lesions (39). These atherosclerotic changes 
progress slowly, often for decades during which patients usually have no symptoms (36).  
Eventually, narrowing (stenosis) of the affected artery prevents blood flow when the demand 
for oxygen increases. This can cause, for example, stable angina if it occurs in the coronary 
artery. However, even if the stenosis is not severe, the rupture of smaller non-occlusive 
plaques may cause thrombosis and occlusion of the artery, resulting in acute coronary 
syndrome. Indeed, it is well-known that plaque stability and vulnerability play an important 
role in CVD events (40).  
Imaging techniques to identify atherosclerosis 
As mentioned above, atherosclerosis occurs far in advance of CVD events. Thus, it is 
expected that detection of an atherosclerotic change in arteries can predict future CVD events 
in an apparently healthy population. Various imaging techniques can detect sub-clinical 
atherosclerosis non-invasively, and some can predict future CVD events beyond conventional 
CVD risk factors. As a result, they have been receiving considerable attention recently as a 
way to identify individuals at high CVD risk. 
Among a variety of non-invasive imaging techniques, MRI and CT can provide accurate 
information on atherosclerosis but are costly. On the other hand, B-mode ultrasound is widely 
available, relatively cheap and less time-consuming, and may be more suitable for large-scale 
epidemiological studies. The following section describes the main imaging techniques used to 
Yume Imahori  
25 
 
evaluate atherosclerosis in the carotid and coronary arteries, which are the main arteries 
affected by atherosclerosis. 
Non-invasive assessment of Carotid artery atherosclerosis:  
Intima-media thickness (IMT): Ultrasound has been used to assess carotid atherosclerosis for 
more than three decades. Assessment of the carotid artery using ultrasound is easy due to the 
superficial location of the artery. Most traditional ultrasound measurement is the IMT; this 
technique has been used since the mid-1980s in numerous studies. IMT is a double-line 
pattern visualised by ultrasound, with the lines representing the lumen-intima and the media-
adventitia interfaces (41). Due to the low frequency of the ultrasound, it is not possible to 
resolve the media and intima separately. The Mannheim consensus recommends that IMT is 
measured on the far wall of the common carotid artery (CCA) where the most accurate 
measurement can be made (41). 
Assessment of IMT shows high reproducibility when being measured at the CCA. IMT has 
consistently shown a good predictive ability for future CVD events, but a recent meta-
analysis showed that there is little added predictive value above traditional risk assessment, 
such as the Framingham Risk Score (42). As a result, IMT was downgraded to class III 
evidence (no benefit): not recommended in clinical practice for risk assessment for a first 
atherosclerotic CVD event in the 2013 ACC/AHA Guideline on the assessment of 
cardiovascular risk (43). This relatively weak predictive ability for CVD events may be 
attributed to two drawbacks of IMT. First, because IMT measurement cannot distinguish the 
intima from the media, increased IMT does not necessarily reflect atherosclerotic changes 
which mainly occur in the intima. Media hypertrophy or adaptive intimal thickening caused 
by ageing and shear stress can also cause an increase in IMT (44). Second, progressive 
atherosclerotic changes are more likely to occur at the location of nonlaminar turbulent flow 
such as the bifurcation or internal carotid artery (ICA) than at the CCA where progressive 
changes are rare (44). Thus, the CCA is not the best site to observe atherosclerotic changes in 
the carotid artery. 
Carotid plaque assessed by ultrasound: carotid plaque is also detected using ultrasound. The 
definition of carotid plaque in the ultrasound examination varies in the literature (45). 
However, the Mannheim consensus definition is increasingly used as the standard recently: it 
is defined as a focal structure that encroaches into the arterial lumen of at least 0.5 mm or 
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50% of the surrounding IMT value or demonstrates a thickness > 1.5 mm as measured from 
the media-adventitia interface to the intima-lumen interface (41). While IMT adds little 
predictive value for future CVD events beyond traditional CVD risk factors, carotid plaque 
appears to be more powerful predictor (15). A meta-analysis showed that carotid plaque 
predicts future CVD events more accurately than IMT. This higher predictive value of carotid 
plaque over IMT is understandable from the pathological point of view: as discussed above, 
IMT may increase due to age-related thickening of intimal and hypertensive thickening in the 
medial layers of the CCA which can occur without atherosclerosis (44, 47) whereas carotid 
plaque represents a later stage of atherosclerotic change. Currently, the guidelines of the 
European Society of Cardiology categorise ultrasound examination of carotid plaque as Class 
IIb:  carotid plaque assessment may be considered as a risk modifier in CV risk assessment 
whereas IMT is not recommended for additional risk stratification (Class III) (12). 
Although many of previous studies with carotid plaque use the presence of plaques (Yes/No) 
as an outcome, quantitative carotid plaque variables such as plaque height, number of 
plaques, and plaque area may be more informative than the binary presence of plaques (14). 
For example, the number of plaques is simple to assess, yet may be a useful measure of 
carotid plaque burden. Stork et al. showed that the number of plaques predicted 
cardiovascular mortality beyond traditional CVD risk factors in 367 elderly men (48). A more 
sophisticated quantitative plaque measure, total plaque area (TPA), entails the evaluation of 
two-dimensional plaque area. It is obtained by outlining the longitudinal image of the plaque 
using dedicated software. Previous studies have shown that subjects in the top tertile of  TPA  
had an increased risk of myocardial infarction and ischemic strokes compared to those 
without plaque while the association between IMT and these events was weaker than that 
with TPA (49, 50). 
Furthermore, TPA measurement may be useful in detecting the progression of the plaque 
burden because plaque grows along the axis of an artery 2.4 times faster than it changes in 
thickness (44). Thus, TPA could be a good candidate as a CVD surrogate endpoint in large-
scale epidemiological studies. In addition, in spite of its simplicity, number of plaques may 
also be a good marker: a recent study showed that the number of plaques correlated with TPA 
well and showed the similar predictive ability for future cardiovascular events to TPA (24). 
Total plaque volume, three-dimensional measurement of carotid plaque, may be even more 
accurate and sensitive to the progression of atherosclerosis than TPA: plaques typically have 
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a complex three-dimensional structure which two-dimensional measurement cannot capture. 
Three-dimensional volumetric measures allow the detection of progression of plaque in all 
directions. However, three-dimensional carotid ultrasound is not as widely available as two-
dimensional ultrasound and generally involves time-consuming three-dimensional 
reconstruction of swept two-dimensional imaging. Thus, a carotid plaque variable using two-
dimensional ultrasound is currently more practical in large epidemiological studies. 
 The limitation of carotid plaque measurements mentioned above is that they cannot assess 
the quality of the plaque which characterises the vulnerability of the plaque such as 
intraplaque haemorrhage and lipid-rich necrotic core. This is due to the relatively low 
frequency of the ultrasound along with acoustic shadowing. Other imaging modalities such as 
CT and MRI are more suitable for this purpose. 
CT, MRI:  MRI is the gold standard imaging modality: It not only evaluates plaque burden 
accurately, but it also detects plaque neovascularity, necrotic core, and fibrous tissue, the 
characteristics of which are related to plaque vulnerability when used with gadolinium-based 
contrast (51). CT can also evaluate plaque morphology as well as the precise plaque burden 
in spite of some weaknesses (51). Although MRI and CT are desirable tools to examine 
carotid atherosclerosis in individuals with some CVD risks in a clinical setting, it is often 
unrealistic to use them for large studies of general population samples or apparently healthy 
individuals due to their cost and, in the case of CT, exposure to radiation. 
Non-invasive assessment of coronary artery atherosclerosis 
Atherosclerotic change in a coronary artery is extremely important as it can lead to angina 
pectoris and myocardial infarction. Invasive angiography is the gold standard for clinical 
diagnosis of severe coronary artery disease (52). However, other invasive methods such as 
fractional flow reserve and instantaneous wave-free ratio have recently been receiving 
attention as they can be used to assess the functional severity of carotid lesions with stenosis 
beyond angiography (53, 54). However, these methods are only indicated for symptomatic 
patients with an intermediate-high probability of significant disease (52). Other non-invasive 
technologies are also available to detect coronary atherosclerosis in individuals with lower 
risk. 
The rapid technical development of cardiac CT and MRI technology has enabled us to 
evaluate coronary atherosclerosis non-invasively and reliably. Coronary computed 
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tomographic angiography and magnetic resonance angiography can accurately reveal 
coronary regions responsible for symptoms (55). Tarkin et al. review other promising 
imaging techniques in addition to CT and MRI thoroughly (55). However, regarding the 
improvement of CVD risk stratification, a great deal of attention has been paid to coronary 
artery calcium (CAC) scanning. CAC is a non-contrast, limited chest computed tomography 
scan which can assess the plaque burden in the coronary artery. Coronary calcium is defined 
as a lesion above a threshold of 130 Hounsfield units: scores of 0 mean the absence of 
calcified plaque and scores>400 means severe plaque (56). Among novel risk markers, CAC 
seems the strongest predictor of future CVD events (57). Although it is an attractive option, 
the cost, exposure to radiation, and limited access to CT are issues, especially for large 
epidemiological studies. 
2.2 Adiposity and obesity 
2.2.1 Defining overweight, obesity, and adiposity 
In this section, I define the terms “overweight”, “obesity”, and “adiposity” as used in this 
thesis. Conventionally, body mass index (BMI) cut-offs are used to define overweight (BMI 
25-29.9 kg/m2) and obesity (BMI>=30 kg/m2) in the adult population (58). The 2013 
AHA/ACC/TOS Guideline for the management of overweight and obesity in adults 
recommends using the BMI cut-off to identify patients with overweight and obesity based on 
a thorough review of available evidence (59). On the other hand, the term “adiposity” is used 
to express the state of fatness, but there is no strict definition in the literature. Therefore, in 
this thesis, I define overweight and obesity (or general obesity) using the BMI cut-off points 
(overweight: BMI 25-29.9 kg/m2, obesity or general obesity: BMI>=30 kg/m2). Similarly, 
abdominal obesity is defined using the WHO cut-off points of waist circumference (WC) 
(>102 cm for men, >88 cm for women) or waist-to-hip ratio (WHR)(>=0.9 for men, >=0.85 
for women). However, the term adiposity is used to describe the extent of adipose/fat tissue 
in absolute or relative terms.  
2.2.2  Global burden of obesity 
Obesity is a worldwide epidemic. According to WHO data, 39% of adults were overweight, 
and 13% were obese in 2016. Obesity has various medical consequence such as CVD, 
diabetes, hypertension, hyperlipidemia, sleep apnoea, osteoarthritis, chronic kidney diseases, 
some cancers, and musculoskeletal disorders (60). In 2015, 4.0 million deaths and 120 
million DALYs were attributed to high BMI (26). Among them, the most concerning 
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consequence is CVD. CVD was the leading cause of death and DALYs related to high BMI, 
followed by diabetes, with 2.7 million deaths and 66.3 million DALYs being associated with 
high BMI (26). It can be said that obesity is now the number one health problem in high- and 
middle-income countries. 
 The general population is getting more and more obese. The prevalence of obesity is almost 
three times higher than 30 years ago and continues to increase (61). Figure 2-2  shows age-
standardised BMI in 1975 and 2014 (30). As can be seen from the figure, not only high-
income countries but also middle- and low-income countries have experienced a substantial 
increase in age-standardised BMI during the past three decades. For instance, in 2014 China 
had the highest number of people with obesity and the second-highest number with severe 
obesity (BMI>=35 kg/m2)  followed by the US, while India moved from 16th place for both 
sexes in 1975 to 5th place for men and 3rd place for women in 2014 regarding the ranking of 
the number of people with obesity (30).  It is expected that a rise in obesity in middle- and 
low-income countries will contribute to a sharp rise in obesity in the future. The global 
prevalence of obesity has already surpassed that of underweight, and it is expected that the 
prevalence of severe obesity will surpass that of underweight by 2025 (30). 
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Figures taken from NCD Risk Factor Collaboration (30) 
Figure 2-2 Age-standardised mean BMI in 1975 (upper panels) and 2014 (lower panels) (Left: men, Right: women):
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In general, obesity affects women more than men, and the middle-aged are the most affected. 
Figure 2-3 shows the prevalence of obesity in 195 countries according to age and 
sociodemographic index quintile, which is a proxy for the national level of development (26). 
High sociodemographic index means the country is highly developed. As can be seen in 
Figure 2-3, overall patterns are similar regardless of the development level of the country. 
The prevalence of adult obesity constantly rises from adolescence and reaches a peak at 60-
64 years of age in women and 50-54 years in men, declining thereafter.  
 
Figure taken from Afshin et al. (26) 
Figure 2-3 Obesity prevalence according to age group by sociodemographic index quintile 
2.2.3 The burden of obesity: Western Europe and Russia 
In this section, I review the available evidence on obesity in Western Europe and Russia. 
Europe is a region with a heavy burden of obesity. According to 2016 WHO data, Europe had 
the second-highest prevalence of overweight (male 63.1% female 54.3%) and obesity (male 
21.9% female 24.5%) among WHO regions, after Americas (62). The population-attributable 
fraction for all-cause mortality due to overweight or obesity in Europe was 14%, following 
North America (19%) and Australia/New Zealand (16%) (63).  
As in other countries, in Russia, there is a sex difference in obesity burden, although the 
differences are more pronounced than in many other parts of Europe. Russian women have a 
higher burden of obesity than Western European women while it is similar or lower in 
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Russian men. The prevalence of obesity based on WHO data was 20.3% and 27.4% in men 
and women, respectively, in Russia, while it is 22.9% and 23.1% in Western European 
countries (20).  
The prevalence of obesity in Russia does not seem very problematic compared to Western 
Europe for men. However, it should be noted that Russia is the tenth most populous country 
in the world and the most populous in Europe, which means Russia makes a major 
contribution to the absolute numbers of people with obesity in Europe. In 2014, Russia was 
ranked fourth in the world for the number of people with obesity for both sexes, and in third 
place for the number of people with severe obesity for both sexes (30). Further, it seems that 
high BMI is a greater contributor to health risk in Russia than in Western Europe. In 2015, 
Russia had the highest rates of BMI-related death (>140 deaths per 100,000 population) and 
DALYs among the world’s 20 most populous countries (26). 
Like the rest of the world, both Russia and Western Europe have experienced a significant 
rise in the burden of obesity in the past three decades. The prevalence of obesity increased 
steadily in high-income European countries for both men and women during this period (30). 
On the other hand, as shown in Figure 2-4, the prevalence of obesity in Russian women was 
relatively stable although it was constantly higher than in Western European women, and the 
prevalence of severe obesity (BMI>=35 kg/m2) increased. Regarding Russian men, the 
prevalence of obesity showed a steady increase (Figure 2-4). If this trend continues, the 
increase in obesity in men and severe obesity in women could result in a further burden of 
CVD in Russia.  
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Figure taken from NCD Risk Factor Collaboration (30) 
Figure 2-4 Trends in age-standardised prevalence of BMI categories in Russia (1980-2010) (left 
panel: men, right panel: women) 
Thus far, I have described the burden of obesity in Europe and Russia. However, it is 
important to note that there are two limitations to the data presented above. First, Russia does 
not have an established monitoring system of obesity and other CVD risk factors, which 
makes it difficult to accurately capture the prevalence of obesity and trends in the country. 
Only limited data are available on obesity in the general population (6, 64, 65). As a result, 
the data for Russia may not be as reliable as that from Western European countries which 
have an established system for monitoring CVD risks.  Second, overweight and obesity are 
defined using BMI cut-off points, and this has some important limitations for assessing 
adiposity, which may result in the underestimation of adiposity-related health risks. The 
limitations of BMI and other adiposity measures will be discussed in detail in the next 
section. 
2.2.4  Complexity of adiposity assessment 
In the history of obesity, it is not so long since humankind predominantly suffered from food 
shortage and undernutrition. Historically, the term “obesity” originated from Latin obesus 
‘having eaten until fat’ and gained usage in the mid-17th century, but obesity was not 
recognised as a cause of illness until the mid-19th century (66). In the late 20th century, a large 
shift in diet and physical activity occurred, which triggered a global epidemic of obesity. 
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As mentioned before, overweight and obesity are conventionally defined using BMI cut-off 
points. BMI is very convenient and easily available in a wide setting. In clinical guidelines, 
assessment of BMI is the first step in obesity management (59). The assessment of adiposity 
level with BMI is undoubtedly important. However, adiposity is too heterogeneous and 
complex to understand based on BMI alone. 
The heterogeneity of obesity has confused clinicians for a long time: at the individual level, 
the health status of those in the same BMI category varies widely. Some people with obesity 
have multiple CVD risk factors such as hypertension and diabetes, while others appear to be 
healthy without any CVD risk factors. An extreme example is Japanese Sumo wrestlers. 
Although Sumo wrestlers are highly obese according to their BMI category, most of them 
have normal plasma glucose and low total-cholesterol levels (67). The key to understanding 
this heterogeneity of obesity is visceral adipose tissue, i.e. adipose tissue located in the 
abdominal cavity. 
Since the mid-1980s, it has become increasingly clear that regional adipose tissue plays a 
more important role in metabolic abnormalities than mere excess of the total body adipose 
tissue. In 1984, the Gothenburg group in Sweden sparked interest in fat distribution by 
showing that abdominal adiposity assessed by WHR was more strongly associated with CVD 
events and deaths than BMI (68, 69). Subsequently, the development of imaging technologies 
such as CT and MRI enabled us to distinguish visceral adipose tissue from subcutaneous 
adipose tissue. Visceral adipose tissue appears to be strongly associated with a wide range of 
disorders including insulin resistance, hyperglycaemia, lipid disorder, hypertension and all-
cause mortality (70-72) and is thus considered as a key player to link adiposity with CVD 
(72). Even among people who are equally obese in terms of BMI, increased visceral adiposity 
is associated with increased CVD risks, whereas an increase in subcutaneous adipose tissue is 
not (73). The previously mentioned Sumo wrestlers with favourable metabolic profiles have 
relatively low visceral fat despite having high BMI, which reinforces the importance of the 
role of visceral adipose tissue (74). 
Visceral fat is considered as dysfunctional adipose tissue. Normal adipose tissue is not just a 
storage space for excess energy; it is also an active endocrine organ and releases bioactive 
substances: adipokines (74). These adipokines are involved in the regulation of glucose level, 
lipid metabolism, blood pressure, inflammation, and oxidative stress. An increase in 
dysfunctional adipose tissue leads to the dysregulation of these adipokines, which disturbs 
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this highly controlled system and contributes to the development of CVD through 
atherosclerosis (75). Dysfunctional adipose tissue affects the cardiovascular system through 
multiple direct and indirect pathways: direct pathways involve various factors such as 
adipokine dysregulation and inflammation, and indirect pathways are mediated by 
hyperlipidemia, hyperglycaemia, and high blood pressure (76). 
A growing body of evidence suggests that the assessment of visceral adiposity is important to 
assess obesity risk.  However, the assessment of visceral adiposity is challenging: CT and 
MRI can provide accurate information on visceral adiposity, but the cost, availability, and the 
radiation exposure for CT, make them unrealistic for use for a large general population or 
among healthy participants. Therefore, in the following section, I describe alternative 
adiposity measures that are both more cost-effective and widely-available and discuss 
whether they are suitable for large-scale epidemiological studies. The alternative measures 
are broadly categorised into two groups: anthropometric measures of adiposity and body 
composition. 
Anthropometric measures of adiposity  
BMI is easy to obtain in epidemiological studies as it is based on measurements of height and 
weight. As previously mentioned, BMI is highly useful for the screening of obesity and has 
been used in numerous clinical and epidemiological studies. However, BMI is a relatively 
crude measure of excess fat and has certain important limitations. First, it cannot distinguish 
fat mass from lean mass. In fact, a meta-analysis evaluated the ability of BMI to assess excess 
body fat and showed that BMI could not identify half of the people with excess body fat (77). 
This can be especially problematic in the older population because lean mass decreases and 
fat mass increases in accordance with age, even if the BMI does not change (78). Second, 
BMI does not reflect body fat distribution. In short, it cannot differentiate general obesity 
from abdominal obesity. Abdominal obesity may be more strongly associated with various 
health issues such as hypertension and diabetes (79). Finally, BMI cannot distinguish 
between visceral adipose tissue and subcutaneous adipose tissue. One study showed that 
although BMI showed a good correlation with total fat mass (0.91-0.94) and subcutaneous 
adipose tissue (0.86-0.93), its correlation with visceral adipose tissue was weaker (0.61-0.69) 
(80). Here, the use of other adiposity measures in combination with BMI may be helpful in 
terms of compensating for the weakness of the latter. 
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Indeed, several anthropometric measures of abdominal adiposity may provide additional 
information on adiposity when used with BMI. Waist circumference (WC), waist-to-height 
ratio (WHtR) and waist to hip ratio (WHR) are examples of such abdominal adiposity 
measures. They are easy to obtain in a wide variety of study settings. While WC is a simple 
and crude way to assess abdominal adiposity, several guidelines recommend its use in 
estimating the risk of adiposity-related diseases (81, 82). WHR and WHtR are other widely 
used measures. These abdominal adiposity measures may be advantageous to BMI because 
they can estimate fat distribution. However, it should be noted that these measures cannot 
distinguish subcutaneous adipose tissue from visceral adipose tissue, and generally reflecting 
total fat mass rather than visceral adipose tissue (83). For example, WC is correlated with 
visceral adipose tissue only moderately better than BMI (83). In fact, it has been suggested 
that a less common anthropometric measure of abdominal adiposity, namely, sagittal 
diameter, predicts visceral adipose tissue better because, in the supine position, hard visceral 
fat contributes to sagittal diameter, while soft subcutaneous adiposity tissue falls aside. 
However, whether sagittal diameter does indeed predict visceral adipose tissue better than 
WC remains unclear (84, 85). Overall, none of the anthropometric measures of abdominal 
adiposity described above would appear to be perfect in terms of predicting visceral adipose 
tissue. Nevertheless, some studies have suggested that the combination of BMI and WC 
predicts visceral adipose tissue better than a single adiposity measure (83, 86). Furthermore, 
only a tape measure is needed for the measurement, which does not require special skills or 
qualifications. Overall, it may be informative to use WC, WHR, and WHtR to complement 
BMI in large epidemiological studies.  
One example of how abdominal adiposity measures can be more informative than the single-
use of  BMI is the trend in obesity prevalence shown using US NHANES data. Flegal et al. 
implied that the increase in obesity appeared to have slowed down after 2003 in the US based 
on BMI using NHANES survey data (87). However, analysis of the same data using WC 
showed that the prevalence of abdominal obesity was still increasing over the same period 
(88). Indeed, several contemporary prospective studies suggest the increase in WC/abdominal 
obesity is more substantial than in BMI/general obesity. This trend is of concern because the 
larger increase in WC level/abdominal obesity than BMI level/general obesity may reflect a 
negative change in fat distribution in the population. For example, an analysis of the 
population-based cohort study, the Tromsø Study, showed a dramatic increase in abdominal 
obesity in every gender and age group, and especially among young groups between 1994 
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and 2008 (89). Other prospective studies conducted in Norway (1984-2008), Scotland (1998-
2008) and China (1993-2009) have also shown that populations experienced a greater 
increase in WC than BMI, suggesting a change in fat distribution (90-92). Assessment based 
on BMI alone might lead to misunderstanding of adiposity-related risks in the contemporary 
population by ignoring the fat distribution. 
Body composition 
While the simple adiposity measures described above cannot estimate fat mass directly, body 
composition analysis can do this by breaking down the human body into several 
compartments such as fat mass and lean mass. Here, since fat mass includes both visceral fat 
and subcutaneous fat, it may be not very informative compared to anthropometric measures 
of adiposity discussed above. However, lean mass, which is a proxy of skeletal muscle mass, 
may play an important role in a wide range of health conditions. Like visceral adipose tissue, 
skeletal mass is considered to be an endocrine organ, affecting metabolism through various 
complicated pathways (93). It is suggested that a decrease in muscle mass or sarcopenia – 
which is characterised by low muscle mass and function –  is associated with decreased 
insulin sensitivity and metabolic syndrome and induces an increase in visceral fat (93, 94). In 
addition, it would appear that obesity has a negative impact on skeletal muscle mass. 
Proinflammatory adipokines produced by visceral fat may reduce skeletal muscle mass and 
its function (95). Thus, adiposity and muscle mass are closely intertwined. Body composition, 
especially lean mass and its ratio to fat mass, could be an informative variable in adiposity-
related studies.  
To assess body composition in large-scale epidemiological studies, realistic approaches 
would include the use of bioelectric impedance analysis (BIA) and dual-energy X-ray 
absorptiometry (DXA). Although measurement using MRI and CT shows excellent accuracy, 
the use in large studies is not realistic due to the costs. BIA estimates body composition on 
the basis of a two-compartment model. Based on the electrical conductivity of the human 
body, total body water is estimated, and fat and fat-free mass are calculated using a specific 
equation based on the assumption of standard levels of tissue hydration (96). Muscle mass 
can be also predicted using an equation. The device is non-invasive, portable and relatively 
inexpensive. However, the alternation of hydration can make the estimation inaccurate. In 
addition, the selection of the estimation equation is extremely important because the validity 
of the estimation equation is affected by numerous factors such as age and ethnic group. In 
Yume Imahori  
38 
 
short, it is necessary to validate the equation in accordance with the study population being 
investigated (96), which will make the comparison of body compositions among different 
populations complicated. Overall, while BIA could be useful for assessing body composition 
in large studies or in low-cost settings, its estimation is not as reliable as those of DXA, CT, 
and MRI. Caution is required when interpreting body composition data obtained using BIA. 
DXA can estimate body composition based on the attenuation of calibrated X-ray beams. The 
degree of attenuation can be used to divide the body into three compartments: fat mass, lean 
mass, and bone mineral. The precision of the fat mass determined by DXA would appear to 
be good within the existing literature (97), while DXA can also provide reliable estimates of 
lean mass (98). Furthermore, it is possible to estimate visceral adipose tissue and total body 
skeletal muscle mass using DXA. It is also relatively low-cost and less time-consuming 
compared to the measurement using MRI or CT. These advantages make the estimation of 
body composition using DXA an attractive option. However, DXA also has certain 
limitations. For one, as previous research has shown, DXA underestimates fat mass in lean 
subjects (97), while another limitation lies in the considerable measurement variation among 
different machines and different software.  
None of the adiposity measures discussed above is ideal for large-scale epidemiological 
studies. However, simple anthropometric measures of adiposity have clear advantages in that 
they are easily measured in a wide variety of study settings with no additional expenditure in 
terms of money or time. Although they are crude measures of adiposity, the use of abdominal 
adiposity measures combined with BMI will provide complementing information that will 
allow for a more accurate understanding of the adiposity level compared to a single adiposity 
measure.  Thus, it would appear to be good approach to use multiple anthropometric 
measures in large epidemiological studies of an apparently healthy population. Furthermore, 
if a DXA machine is available, the body composition data estimated using DXA could prove 
to be highly informative. 
2.2.5  Risk factors for obesity 
To prevent obesity, an understanding of its determinants is important. In this section, I briefly 
summarise the current understanding of obesity determinants. Fundamentally, obesity is 
caused by an energy imbalance between calories consumed and calories expended (99). 
There are three major factors that determine obesity in adults. The first is lifestyle: dietary 
factors, lack of physical activity, sedentariness, lack of sleep, and night shift-work result in 
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weight gain. These lifestyle factors are modifiable. Secondly, genetic factors interact with 
lifestyle factors and accelerate weight gain, but susceptibility can be attenuated by an 
improvement in lifestyle factors. Third, built environments, such as urban sprawl and 
walkability, are also important, to improve which upstream intervention would be needed 
(100, 101).  
Smoking also affects adiposity level, but it is likely to affect general and abdominal adiposity 
differently. Previous studies consistently show that smokers have lower BMI than non-
smokers (102-105). However, increased WC/WHR seems more common in smokers than in 
non-smokers (103, 106). In particular, WHR is higher in smokers (103). The link between 
smoking and adiposity is complicated and unclear. One potential mechanism is the negative 
effect of smoking on appetite. Unhealthy lifestyle accompanied by smoking might explain 
abdominal adiposity in spite of low BMI. Alternatively, a high adiposity level might increase 
nicotine dependence, resulting in a high prevalence of smoking in the population with high 
adiposity levels. A recent Mendelian Randomisation study supported this hypothesis by 
showing that genetic disposition to high BMI and WC was associated with an increased 
probability of being a smoker or a former smoker (107). 
Socioeconomic status and its proxy, education, also contribute to obesity. One systematic 
review shows that there is an inverse association between educational attainment and obesity 
in high-income countries while middle- and low-income countries are more likely to show a 
null or positive association (108). Regarding income, another proxy for socioeconomic status, 
a meta-analysis based on studies from the US, the UK, and Canada showed that low income 
was associated with obesity. At the same time, obesity was associated with low income, 
suggesting the role of reverse causality through stigma and discrimination (109). A recent 
Mendelian Randomisation study also supported this reverse causality: people with a genetic 
disposition to high BMI and short stature had low income, low education, and low job class 
(110). 
Alcohol is another factor which might affect adiposity level. The link between alcohol 
consumption and adiposity seems extremely complicated, and results from observational 
studies are inconsistent. However, results from contemporary cross-sectional studies suggest 
that while moderate alcohol intake is not associated with obesity, this is not the case for 
heavy drinking and binge drinking which do increase the risk of obesity (111). A recent study 
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showed a negative genetic correlation between genes related to alcohol consumption and high 
BMI, high WC, and obesity (112). 
2.3 The association between adiposity and CVD 
2.3.1  The association between adiposity and CVD: evidence from observational studies 
Numerous observational prospective studies support the effect of adiposity on CVD. I briefly 
summarise recent evidence of association of general or abdominal adiposity with hard CVD 
endpoints, mainly from large pooled analysis or meta-analysis. 
Regarding BMI, previous observational studies have consistently shown that general obesity 
based on BMI categories is associated with CVD. For example,  a recent pooled analysis of 
163 cohorts with 2.43 million participants showed that an increase in BMI of 5 kg/m2 among 
those aged 55-64 years was associated with higher relative risks for ischemic heart disease 
(1.44 95%CI: 1.40-1.48) and diabetes (2.32 95%CI:2.04-2.63)(113).  
Abdominal adiposity, when assessed by simple anthropometric measures such as WC, WHR, 
and WHtR, is consistently associated with CVD events in observational studies. However, it 
is still controversial whether abdominal adiposity is more strongly associated with CVD 
events than general adiposity assessed using BMI. Some argue that abdominal adiposity is no 
different from general adiposity in terms of CVD risk. For example, the Emerging Risk 
Factors Collaboration analysed data from 221,934 individuals from 58 cohort studies which 
showed that increases in all three adiposity indexes, BMI, WC, and WHR, were significantly 
associated with high hazard ratios for CVD. However, the authors concluded that the 
predictive ability for CVD is similar for the different adiposity indices (114).  
On the other hand, some observational studies suggest abdominal adiposity may be more 
strongly associated with CVD than general adiposity. For instance, the INTERHEART study, 
a multinational case-control study of 15,152 myocardial infarction cases, showed that 
abdominal adiposity assessed by WHR was a stronger predictor of myocardial infarction than 
general adiposity (115). Furthermore, another multinational case-control study, 
INTERSTROKE, found that high WHR had a stronger association with the occurrence of all 
stroke and ischemic stroke than high BMI (116). Interestingly, the same study showed that 
the association between WHR and stroke was strongest in Western Europe, North America, 
and Australia while it was weakest in Eastern and Central Europe. Moreover, a recent 
prospective study among 479,610 individuals from the UK Biobank showed that abdominal 
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adiposity, especially WHR, was more strongly associated with future myocardial infarction 
than BMI, especially among women (117). 
2.3.2  The association between adiposity and CVD: evidence from Mendelian 
Randomisation 
The conventional observational studies reviewed above have potential limitations such as 
residual confounding and reverse causation. This makes it difficult to infer causality between 
adiposity and CVD as well as comparing the strength of the association between different 
anthropometric measures. Mendelian Randomisation studies might help to overcome these 
limitations and contribute to a better understanding of the causal relationship between 
adiposity and CVD. Briefly, Mendelian Randomisation studies use the genetic variant as a 
proxy of exposure in observational studies to make causal inferences between exposure and 
outcomes (118). The genetic variant needs to satisfy the following three assumptions: 1) the 
genetic variant is associated with the exposure of interest; 2) the genetic variant is not 
associated with confounders; and 3) the genetic variant is associated with the outcome of 
interest only via exposure. Mendelian Randomisation studies using appropriate genetic 
variants are less susceptible to confounders and reverse causality, being considered as an 
analogue to a randomised controlled trial (119). 
Recently, several Mendelian Randomisation studies have investigated the causal link between 
adiposity and CVD. Earlier Mendelian Randomisation analysis showed inconsistent results 
(120-122). Although an association between heart failure and BMI was suggested, results 
regarding the association between BMI and ischemic heart diseases were inconclusive. These 
inconsistent findings may have been caused by scores based on a small number of single-
nucleotide polymorphisms (SNPs) and a relatively small number of CVD events. Recent 
Mendelian Randomisation studies tend to use scores based on a larger number of SNPs than 
earlier studies in an attempt to overcome weak instrument bias. Hagg et al. investigated the 
association between a genetic score derived from 32 SNPs related to BMI and cardiovascular 
outcomes in up to 22,193 individuals from nine prospective studies and assessed the causal 
association between obesity and several CVDs (123): 3062 coronary heart disease (CHD) 
cases, 1652 heart failure cases, and 1500 ischemic stroke cases were included. Their findings 
suggested a causal link between adiposity and ischemic stroke for the first time. Furthermore, 
it also replicated the causal association between adiposity and heart failure, and a causal 
association between adiposity and CHD was suggested. 
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Mendelian Randomisation studies might not only provide additional information on the 
causal relationship between adiposity and CVD but also help us to understand whether 
abdominal adiposity is more strongly associated with CVD than general adiposity. Recently, 
two such studies have assessed the causal association between abdominal adiposity and CVD 
(124, 125). Emdin et al. investigated the association of genetic disposition to increase in 
WHR adjusted for BMI derived from 48 SNPs with CHD (124). The findings suggested the 
causal association of increased WHR with CHD and type 2 diabetes independent of BMI, 
indicating that fat distribution can explain these events beyond BMI. 
The largest Mendelian Randomisation study of this topic to date compared the association of 
three cardio-metabolic diseases (CHD, stroke, and type 2 diabetes) with a genetic score of 
BMI derived from 97 SNPs with that with a genetic score of WHR adjusted for BMI derived 
from 49 SNPs (125). This study used data from 14 cohort studies with 66,842 CHD cases and 
12,389 stroke cases. It found an association of CHD with both BMI and WHR adjusted for 
BMI. However, only the genetic disposition for high WHR adjusted for BMI was associated 
with stroke. This study also showed that IMT was more strongly associated with a genetic 
disposition to high WHR than with high BMI, although both were causally associated with 
increased IMT. 
In summary, evidence from contemporary Mendelian Randomisation studies supports: 1) the 
causal association between adiposity and CVD; and 2) a stronger association between 
abdominal adiposity and CVD than general adiposity. Mendelian Randomisation studies may 
contribute to further understanding the causal pathway between CVD and general and 
abdominal adiposity, including the role of mediators. However, it is important to recognise 
that this approach is not without its limitations.  
Here, the validity of the genetic variant is vital. The potential causes of the invalid genetic 
variant include the biological mechanism, the pattern of inheritance of the genetic variant, 
and population effect (119, 126, 127). The biological mechanism includes pleiotropy – a 
genetic variant associated with other risk factors in addition to the exposure on interest – and 
canalisation, the effect of the genetic variant being compensated through different pathways. 
The pattern of inheritance can also be problematic. For example, linkage disequilibrium, the 
distribution of variants being correlated due to the physical proximity, may cause the 
violation of the second or third assumption. Finally, population effects include population 
stratification and ascertainment effects. Population stratification occurs when the study 
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population is divided into subpopulations with a different frequency of the genetic variant 
and distribution of exposures. This can result in a spurious association. Ascertainment effects 
arise when the study population recruited has a different frequency of the genetic variant 
compared to the general population (119, 126, 127). While these violations of assumptions 
lead to biased results, it is difficult to know whether the genetic variant is valid because the 
biological knowledge is not comprehensive. However, despite these limitations, Mendelian 
Randomisation analysis provides an important alternative approach to establishing how far an 
association may be causal. In combination with conventional observational evidence, this 
approach helps to provide a better evidence base concerning potential causality. 
2.3.3 Role of mediators 
Among CVD risk factors, three cardio-metabolic risk factors, blood pressure, cholesterol, and 
blood glucose, are considered to act as mediators between adiposity and CVD. Bioactive 
substances released from adipose tissue influence insulin resistance, diabetes, lipid levels, and 
blood pressure, accelerating atherosclerotic change in arteries, leading to the occurrence of 
CVD. However, it is still unclear to what extent the association between adiposity and CVD  
is explained by these indirect pathways and how much is independent of these three 
mediators. 
Several observational studies have investigated the role of mediators in the association 
between adiposity and CVD. The Global Burden of Metabolic Risk Factors for Chronic 
Diseases Collaboration analysed 1.8 million individuals from 97 prospective cohort studies 
and estimated how much the association between increased BMI and CVD was mediated by 
three metabolic risk factors: blood pressure, cholesterol, and glucose (128). The three risk 
factors explained 46% and 76% of the excess risk of BMI for CHD and stroke, respectively. 
In this analysis, blood pressure played the most important role among the three metabolic risk 
factors. 
Findings from smaller studies are broadly consistent with this result regarding the role of 
cardio-metabolic risk factors as mediators. However, the extent to which the association is 
mediated varies according to the study. One meta-analysis with 302,206 individuals showed 
that the additional adjustment for blood pressure and cholesterol explained 45% of the 
association between overweight and CVD with adjustment for age, sex, smoking, and 
physical activity (129). Another pooled analysis by Wormser et al. showed a larger 
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contribution of three cardio-metabolic risk factors, which explained 60% of the association 
between obesity and CHD and 70% with ischemic stroke (114).  
Mendelian Randomisation studies have also contributed to a better understanding. A study 
with 90,000 individuals and 13,945 ischemic heart disease cases investigated the role of 
mediation of these cardio-metabolic risk factors (130). The authors concluded that excess 
ischemic heart disease risk was partly mediated by non-fasting chylomicron remnant, low-
density lipoprotein cholesterol, and blood pressure.  
2.3.4 The association between adiposity and atherosclerosis  
Thus far, I have summarised recent evidence to support the association between 
general/abdominal adiposity and CVD events. Turning now to the main cause of CVD, 
atherosclerosis, how strong is the evidence of the association between atherosclerosis and 
adiposity? In the next chapter, I describe my systematic review of the literature to investigate 
the association between adiposity and carotid atherosclerosis, which will provide the context 
of my thesis. 
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3 Systematic literature review 
To fully justify my choice of PhD topic, it was necessary to investigate what is already 
known about the association of adiposity measures (my exposure) with carotid 
atherosclerosis assessed by ultrasound  (my outcome) in a general population of adults. To 
ascertain this, I conducted a systematic literature review, described in this section. Although 
the main focus of my own analysis is on carotid plaques, in this systematic review, I have 
also included studies where intima-media thickness (IMT) is the outcome. This is because the 
bulk of the literature that has looked at the association between adiposity and carotid 
atherosclerosis assessed using ultrasound has focussed on IMT as the primary outcome. 
Therefore, the inclusion of IMT as an outcome will make a review of this topic more 
comprehensive. 
3.1 Aim 
To conduct a systematic review of the literature that provides quantitative estimates of the 
direction and strength of the association of various measures of adiposity with carotid 
atherosclerosis, assessed by ultrasound, in adult general population samples. 
3.2  Conceptual issues 
 Before describing the literature review in detail, I will address a number of important 
conceptual issues that have influenced how I conducted the review. 
3.2.1  Causal Diagram  
 I constructed a causal diagram of the possible association between adiposity and carotid 
atherosclerosis to make explicit my assumptions about the causal relationships between 
variables related to adiposity. First, I included traditional CVD risk factors as described in 
2.1.1 (age, sex, smoking, blood pressure, cholesterol, glucose), which can explain most CVD 
risk and are also associated with adiposity. Physical activity, diet, and the use of alcohol were 
excluded as the relevant data were not available for my main analysis when I obtained the 
dataset. Less well-established CVD risk factors were then considered. As for emerging CVD 
risk factors, a comprehensive review of meta-analyses and a systematic review were 
published recently, which investigated whether they can improve risk assessment beyond 
traditional CVD risk factors (43). A family history of CVD, high-sensitivity C-reactive 
protein and ankle-brachial index were identified as promising new CVD risk factors. I did not 
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include these either because they were highly clinical examinations which were not available 
for my analysis or because of the possibility of misclassification. 
Finally, I considered the determinants of obesity as described in chapter 2.2.5 and included 
education because it affects both adiposity and CVD. 
Blood pressure, cholesterol, and glucose were expected to be on the causal pathway between 
adiposity and carotid atherosclerosis and are thus considered as mediators. Other factors were 
considered confounders. One potential pattern of association is shown in Figure 3-1. 
 
Figure 3-1 Simplified causal diagram: One potential pattern of association between adiposity and 
carotid markers 
3.2.2  Adjustment 
To ensure the study results in the systematic review were comparable, I divided studies into 
three groups: those that adjusted for confounders (at least age and sex), those that adjusted for 
at least one potential causal mediator (such as blood pressure or cholesterol), and those with a 
crude association. Confounders and mediators here refer to those used in my main analysis.  
3.2.3  IMT assessment (carotid segment, calculation) and the definition of carotid plaque 
Studies varied according to the anatomical site of IMT assessment. The simple anatomy of 
the carotid artery is shown below (Figure 3-2). Guidelines recommend assessing IMT at the 
common carotid artery (CCA), where it is easy to capture an ultrasound image, and the value 
is more reliable (41, 131). Because atherosclerotic changes are more likely to occur at the 
carotid bulb and internal carotid artery (ICA), comparison between IMT assessed at the CCA 
and at other segments is not valid. However, some studies have assessed IMT at non-CCA 
segments or used composite IMT derived from several carotid segments. Thus, to reduce 
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heterogeneity across studies, I summarised the association between adiposity and IMT after 
removing studies using non-CCA segments or composite IMT. 
Studies also varied widely in terms of the definition of carotid plaque. As noted previously, 
the Mannheim consensus defines a plaque as a focal structure that encroaches into the arterial 
lumen of at least 0.5 mm or 50% of the surrounding IMT value or demonstrates a thickness > 
1.5 mm as measured from the media-adventitia interface to the intima-lumen interface (41). 
However, I summarised the association between adiposity and carotid plaque regardless of 
the definition of plaque. 
 
Figure 3-2 Carotid artery segment 
3.2.4  Studies excluding subjects with a history of CVD, hypertension, hyperlipidemia, 
and diabetes 
 Many studies have excluded people with existing diagnoses of CVD and cardio-metabolic 
diseases because the authors were principally interested in the clinical question of the value 
of IMT/ burden of carotid plaque as a predictor of CVD risks in an asymptomatic population 
without known CVD risks. However, from my perspective of wishing to estimate the 
association between adiposity and IMT/carotid plaque, these exclusions may have led to bias. 
Thus, I excluded these studies for the reasons described below:  
a. Causal pathway: Pre-existing hypertension, hyperlipidemia, and diabetes are on the 
causal pathway between adiposity and IMT/carotid plaque, so removing participants 
with these ailments can result in underestimation of the association. Furthermore, 
these conditions are common in an adult population. If participants with cardio-
metabolic diseases are excluded, the sample may not be representative of a general 
population. 
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b. Collider bias: Excluding participants with existing CVD can introduce collider bias 
(132). CVD is a common effect of both obesity and carotid atherosclerotic changes. 
Excluding subjects with CVD means conditioning on CVD status as a collider, which 
may bias the true association between adiposity and IMT/carotid plaque in the 
population as a whole.  
3.3 Systematic review method 
 I searched Embase, Pubmed, and Global Health for relevant publications. I combined 20 
search terms related to adiposity and eight search terms related to carotid atherosclerosis 
(Appendix A1). 
Studies were included if all the following criteria were met: (1) the direction, correlation or 
magnitude of the association between adiposity and IMT or carotid plaque was reported; (2) 
the study was based on a community/population-based sample; (3) the sample included an 
adult population; and the adult population was analysed separately.  
Studies were excluded if one of the following criteria was met: (1) the full-text was not 
available in English; (2) the paper was a conference abstract; (3) the study only included or 
presented analyses for subjects without a history of CVD, hypertension, hyperlipidemia, or 
diabetes; (4) the study subjects were hospital or clinic-based patients; (5) subjects were 
included because they had a diagnosis of a specific condition (other than obesity); (6) the 
association between adulthood adiposity and adulthood IMT or plaque status was not 
reported. 
The following information was abstracted for each study that included full-text review: 
author, year, country, study design, sample size, age, sex, the measure of adiposity used in the 
analysis, the method of measuring IMT and carotid plaque, the association between adiposity 
and IMT/plaque and the statistical method. The data extraction sheet and quality assessment 
sheet are presented in Appendixes A2 and A3. 
3.4 Results summary 
I screened 2644 articles, and 69 studies were included. The study selection process is 
summarised in Figure 3-3. 
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Figure 3-3 Flowchart of study selection process 
Study characteristics: IMT was used as an outcome in 69 studies (n=96632), whereas both 
IMT and carotid plaque were outcomes in 10 studies (n=16032). About 36% of samples were 
derived from Western European countries, while 1% were from Central and Eastern Europe 
and the former Soviet Union (CEE/FSU). There were no Russian studies. There was 
considerable variation in the IMT assessment method and carotid plaque definition. Among 
adiposity measures, BMI was the most frequently used (85.5%), followed by WC (53.6%) 
and WHR (30.4%). Body composition was assessed in 11 studies using bioelectric impedance 
analysis (BIA), dual-energy X-ray absorptiometry (DXA), CT, or MRI. The definition of 
carotid plaque differed from study to study, and only one study followed the definition 
recommended by the Mannheim consensus. 
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Findings: Table 3-1, Table 3-2, and Table 3-3 summarise the association between BMI and 
IMT assessed at CCA according to the statistical and adjustment methods. Figure 3-4 shows a 
forest plot for regression coefficients of studies that only use similar IMT assessments. 
Overall, BMI was positively associated with IMT in most studies, regardless of adjustment 
and statistical method. WC and WHR showed similar trends, but less consistently. Fat mass 
seems to be associated with IMT, but the number of studies was limited, and conclusions 
were difficult to draw. 
Table 3-4 and Table 3-5 summarise the association between adiposity and carotid plaque. 
Results for this association were mixed. Because most results were adjusted for multiple 
mediators, and no result was adjusted for appropriate confounders, it is difficult to estimate 
the un-mediated association between adiposity and carotid plaque. Furthermore, differences 
in plaque definition and statistical methods between studies make the interpretation 
complicated. Most studies used plaque presence (Yes/No) as an outcome, while two studies 
used quantitative measures: total plaque area and plaque height (133, 134). 
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Table 3-1 Association between BMI and IMT adjusted for confounders 
Author Number of participants β (95%CI) IMT(µm) 
per BMI unit* 
IMT 
measurement 
site 
IMT 
assessment 
Adjustment 
Chow 2008 (135) India (303)  2.6 (1.2, 3.9) Both CCA mean Age, sex 
Australia (1111) 1.8 (1.1, 2.6) 
Macharia 2014 (136) 
 
491 4 (1.5, 6.5) Both CCA mean Age, sex 
Masley 2015 (137) 
 
592 4.2 (2.5, 5.9) Both CCA mean Age, sex  
 
Pitha 2013 (138) 699 2.2 (1.0, 3.4) Both CCA mean Age (all female 
samples) 
Youn 2011 (139) 
 
1716 7.4 (5.4, 9.4) 
 
Either CCA, mean Age, sex 
 
Raitakari 2003 (140) 2229 2.5 (1.62, 3.38) Left CCA max Age, sex 
Ferreira 2004 (141) 336 2.8** Not clear not clear Sex and height (all 
same age) 
CCA: common carotid artery, IMT: carotid intima-media thickness *Units are converted to IMT (µm) per BMI unit regardless of units used in original papers.  
When only p-value was reported, 95% confidence interval was calculated. **Only regression coefficient reported in the original article. 
1. Studies included in this table are those which measured IMT at CCA and provided a regression coefficient adjusted only for confounders.  
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Table 3-2 Association between BMI and IMT adjusted for mediators 
Author Number of 
participants 
β (95%CI): IMT(µm) 
per BMI unit* 
IMT 
measurement 
site 
IMT 
assessment 
method 
Adjustment 
Breton 2011 (142) 768 1.4 (0.3, 2.4) Right CCA mean Age, sex, ethnicity, SBP 
Ceponiene 2015 
(143) 
Male 168 2.0 (-2.0, 6.0) Both CCA mean Childhood SBP, BMI, sexual maturity score. 
Adulthood SBP, HDL, LDL. Smoking, 
education level 
Female 
212 
2.0 (-1.0, 5.0) 
Czernichow 2005 
(144) 
1014 2.8 (1.4, 4.2) Both CCA  Age, sex, MAP, smoking, DM, HL, height, 
heart rate 
Macharia 2014 
(145) 
 
491 3.0 (0.5, 5.5) Both CCA mean Age, sex, DM 
Masley 2015 (137) 
 
592 3.75 (1.6, 5.9) Both CCA mean Age, sex, SBP, DBP, waist, %BF, BMI, 
TC/HDL ratio, Tri/HDL ratio, glucose, 
fitness markers, Fish, Fibre, Zing 
Youn 2011 (139) 
 
1716  
5.2 (3.0, 7.2) 
Either CCA mean Age, sex, SBP, DBP, triglycerides, HDL, 
LDL, hs-CRP, DM, smoking 
Oren 2013 (146) 524 2.5 (1.7, 3.2) Both CCA mean or 
mean-max 
Age, sex, 
Su 2012 (147) 2690 2.42 (0.32, 4.51) Both CCA max Age, sex, SBP, medication history 
(hypertension, DM), fasting glucose, 
smoking, alcohol, HDL, LDL, LVH on ECG 
*Units are converted to IMT (µm) per BMI unit regardless of units used in original papers. When only p-value was reported, 95% confidence interval was calculated. 
BMI: body mass index, CCA: common carotid artery, IMT: carotid intima-media thickness, DBP: diastolic blood pressure, DM: diabetes, ECG: electrocardiogram, 
HDL: high density lipoprotein, LDL: low density lipoprotein, LVH: left ventricular hyperplasia, MAP: mean arterial pressure, SBP: systolic blood pressure 
1. Studies included in this table are those which measured IMT at CCA and provided a regression coefficient adjusted for at least one mediator 
  
Yume Imahori  
53 
 
Table 3-3 Association between BMI and IMT (correlation coefficient) 
  n r effect p-value   statistical method      
Azarpazhooh 2014 
        
431 0.12 + <0.05  Pearson correlation 
Besir 2011 2230 0.208 + <0.001  Partial correlation analysis r  
Bradshaw 2007 602 0.17 + <0.001  Spearman correlation 
Chang 2007 280 0.202 + 0.001  Partial correlations  
Ferreires 1999 (men) 536 0.28 + <0.001  Spearman correlation   
Ferreires 1999 (women) 477 0.22 + <0.001  Spearman correlation   
Hung 1999 1111 0.21 + <0.0001  Spearman correlation 
Huynh 2013 (men) 1150 0.097 + <0.01  Spearman correlation   
Huynh 2013 (women) 1178 0.082 + <0.01  Spearman correlation   
Kim 2008 160 0.203 + <0.05  Pearson correlation   
Koshkinen 2009 1809 0.19 + <0.0001  Pearson correlation  
Lu 2012 (men) 74 0.436 + <0.001  Pearson correlation  
Scuteri 2012 6148 0.373 + <0.0001  Pearson correlation 
Sipila 2009 (men) 607 0.045 + 0.267  Pearson correlation  
Sipila 2009 (women) 746 0.171 + <0.001  Pearson correlation  
Takami 2001 849 0.138 + 0.0001  Spearman correlation  
Yang 2014 472 0.125 + <0.01  Spearman correlation 
Wright 2001 (men) 233 0.19 + <0.05  Standardised regression coefficients  
Wright 2001 (women) 293 0.14 + <0.05        
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1. Association between BMI and IMT adjusted for confounders (upper) 
2. Association between BMI and IMT adjusted for mediators (lower) 
 
       *Studies included in this figure are those which assessed IMT at CCA 
Figure 3-4 Forest Plot: Association between BMI and IMT according to adjustment 
1
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Table 3-4 Association between adiposity and carotid plaque: studies using logistic regressions with odds ratios 
Author Date Age (range or 
mean±SD) 
Number of 
participants 
Carotid plaque 
variable  used 
in analysis 
Prevalence of 
plaque presence  
(%) 
Adiposity 
measure 
OR1(crude) OR2 (adjusted for 
confounders or 
mediators or both) 
Adjustment 
Bonithon-Kopp 
1996 (148) 
59-71, 
N=1282 
 
Plaque presence 
 
male25.6% 
female 16.5% 
at ICA or bulb 
BMI per unit - 1.01(0.97-1.05) sex, age, 
hypertension, 
hypercholesterolemia, 
diabetes, and ever 
smoking 
Chaubey 2010 
(149) 
 
56-77, 
N=792 
 
Plaque presence  
 
men; both CCA 
32%, only left 
11.5%, only right 
12% 
Women: both CCA 
30%, only left 
12.5%, right 13.9% 
WHR per0.1 - Left CCA 
1.33 (1.04-1.71) 
 
HbA1c, smoking 
status, low-density 
lipoprotein cholesterol 
levels, hypertension, 
sex, and age 
Right CCA 
1.28 (1.00-1.64) 
 
Czernichow 2005 
(144) 
59.4±4.7, 
N=1014 
 
Plaque presence 
 
32.0% Per BMI 
tertile 
 
- T1 ref 
T2 1.33 (0.94–
1.89) 
T3 1.27 (0.89–
1.83) 
age, gender, mean 
arterial pressure, 
smoking status, 
diabetes, 
hypercholesterolemia, 
height and heart rate Per FM tertile 
 
T1 ref 
T2 1.34 (0.94–
1.93) 
T3 1.12 (0.74–
1.70) 
Per FFM 
tertile 
 
T1 ref 
T2 1.14 (0.77–
1.68) 
T3 1.06 (0.65–
1.74) 
Per %BF 
tertile 
T1 ref 
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 T2 1.31 (0.93–
1.86) 
T3 1.33 (0.93–
1.90) 
Per WC  
tertile 
 
T1 ref 
T2 1.33 (0.93–
1.90)  
T3 1.19 (0.82–
1.73) 
Per HC tertile 
 
T1 ref 
T2 1.13 (0.80–
1.61) 
T3 0.86 (0.59–
1.25) 
Per WHR 
tertile 
T1 ref 
T2 0.91 (0.64–
1.31) 
T3 1.35 (0.94–
1.91)) 
Debette 2008 
(150) 
65-85, 
N=6265 
 
Plaque presence 
 
41.5, 44.9, 50.2, 
51.2% according to 
WC quartile 
Per CC 
quartile 
 
- Q1 reference 
Q2 1.00 (0.86–
1.17) 
Q3 0.91 (0.78–
1.06) 
Q4 0.79 (0.68–
0.93) 
age, gender, smoking 
habits, alcohol 
consumption, systolic 
blood pressure, 
antihypertensive 
treatment, high-
density lipoprotein 
cholesterol, low-
density lipoprotein 
cholesterol, 
triglycerides (log-
transformed value), 
lipid-lowering drugs, 
diabetes, history of 
vascular disease. 
WC per 
quartile 
 
Q1 reference 
Q2 1.03 (0.88–
1.20) 
Q3 1.13 (0.97–
1.32) 
Q4 1.01(0.85–
1.19) 
WHR per 
quartile 
Q1 reference 
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BMI; 
body 
mass index, CC; calf circumference, FM; fat mass, FFM; fat-free mass, %BF; percent body fat, WC; waist circumference, HC; hip circumference, OR: odds 
ratio, Q; quartile, WHR; waist-hip-ratio 
Q2 1.16 (1.00–
1.36) 
Q3 1.15 (0.98–
1.35) 
Q4 1.15 (0.98–
1.35) 
Hung 1999 (151) 27-77, 
N=1111 
Plaque presence 
 
27.4%,24.5%,25.9% 
according to ACE 
genotype 
WHR (>0.91) 
binary 
- 2.1 (1.3-3.3) age, systolic blood 
pressure, pack-years 
of smoking, 
low-density 
lipoprotein cholesterol 
level, waist/hip ratio, 
and history of 
antihypertensive 
treatment 
Khalil 2013 (152) 33-38, 
N=600 
Plaque presence  BMI per z 
score 
 
 1.14 (0.95 -
1.36) 
 
 - Age, sex 
WC per z 
score 
1.27 (1.06-
1.52) 
Terzis 2012 (153) 40.5 ± 1.1, 
N=106 
Current plaque 
presence 
 
 
22% Current BMI 
per unit 
 
 1.14 (1.04–
1.25) 
 
1.153 (1.031–
1.289) 
OR1: none 
age, gender, BMI 
change, waist, BMI, 
change from normal 
weight since 
adolescence to over-
weight status in 
adulthood, systolic 
and diastolic blood 
pressure, and smoking 
Current WC 
per unit 
1.04 (1.009–
1.07) 
plaque 
thickness 
 
  
2.54(1.22) vs 
2.60(1.00),NS 
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Table 3-5 Association between adiposity and carotid plaque: studies in which effect estimates were not presented 
BMI; body mass index, CC; calf circumference, FM; fat mass, FFM; fat-free mass, %BF; percent body fat, WC; waist circumference, HC; hip circumference, Q; quartile, 
WHR; waist-to-hip ratio 
Author Date Age (range 
ormean±SD) 
Number of 
participants 
Carotid plaque 
variable  used 
in analysis 
Prevalence of 
plaque presence  
(%) 
Adiposity 
measure 
Findings Adjustment 
Herder 2012 
(133) 
Baseline 
men 
55.8 (9.08) 
Baseline 
women 
56.6 (10.2) 
N=2743 
Total plaque 
area follow-
up, total 
plaque area 
change, 
(linear 
regression) 
 BMI  smoking habits, prevalent 
diabetes, angina pectoris, 
previous myocardial 
infarction, stroke, and 
current use of 
antihypertensive- and lipid-
lowering drugs at baseline 
Bradshaw 2007 
(154) 
18-74, 
N=602 
Plaque 
presence 
>40% BMI binary: 
high vs low 
High BMI group:  81% had carotid plaque  
Low BMI group: 78% had carotid plaque 
Difference: not significant 
 
WHR 
binary: high 
vs low 
High WHR group: 91% had carotid plaque 
Low WHR group:  78% had carotid plaque   
Difference: 2p<0.001 
Holewijn 2010 
(134) 
50-70, 
N=1517 
Plaque 
presence 
Men 40.7% - 
46.8%, 
Women 26.7% -
34.8 
Lowest and 
highest 
quartile of 
WC 
Prevalence of carotid plaque was 
significantly different between the top WC 
quintile and the bottom quintile (top vs 
bottom: men +3.3% NS, women +9.3 % 
NS) 
 
Age 
Plaque 
thickness 
 
 
Plaque thickness was higher in the top WC 
quintile than the bottom quintile in women 
by 16.6% while it was not significantly 
different among men 
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3.5 Gaps in knowledge and conclusion 
This systematic review had three major findings. First, a number of studies investigated the 
association between BMI and IMT. The results were generally consistent with a positive 
association between BMI and IMT, regardless of adjustment and statistical methods. 
Secondly, measures of abdominal adiposity such as WC and WHR were less commonly-used 
than BMI. The association between abdominal adiposity measures and IMT broadly showed 
similar patterns to BMI, although the results were less consistent than BMI. Finally, the 
association between adiposity and carotid plaque showed mixed results.  
This systematic review identified five gaps in the existing knowledge. Firstly, although the 
association between adiposity and IMT was broadly consistent, no population-based studies 
with standard IMT assessment investigated the association between adiposity and IMT using 
appropriate confounder adjustment (age, sex, smoking). Second, only 11 studies investigated 
body composition among the exposure variables. Third, evidence regarding the association 
between adiposity and carotid plaque was scarce (10 studies) although carotid plaque is 
expected to predict CVD risk better than IMT. Only two studies used quantitative plaque 
assessment, which may perform better than the binary plaque variable (presence: Yes/No) as 
it provides continuous information. Fourth, the IMT assessment method and plaque definition 
differed widely across studies, making comparison of results difficult. Finally, no Russian 
studies were found, and studies from CEE/FSU regions were scarce. More research in this 
area is needed in order to investigate the association of IMT/carotid plaque with a range of 
measures of adiposity further in Russia and elsewhere. 
Given the relative paucity of evidence about the association of adiposity with carotid plaque 
compared to the association with IMT, I concluded that a focus on the carotid plaque as my 
primary outcome in this thesis would address a gap in the existing evidence. Furthermore, 
this review has highlighted the importance of appropriate adjustment. In particular, as most of 
the studies investigating the association between simple anthropometric measures and carotid 
plaque adjusted for various mediators and confounders altogether, it was difficult to 
determine the unmediated association between these simple adiposity measures and carotid 
plaque. This provides an additional rationale for looking at the association between simple 
adiposity measures and carotid plaque with an appropriate adjustment in the current study. 
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4 Study setting and design 
This chapter describes the setting and study designs and methods of the Know Your Heart 
study (KYH) and the Tromsø Study, the two data sources which I use in this thesis. The first 
section describes the Know Your Heart study, followed by the Tromsø Study. Finally, the 
rationale for comparing the two studies is provided. 
4.1 Know Your Heart study 
4.1.1 Study setting 
Novosibirsk and Arkhangelsk are cities in the Russian Federation. Novosibirsk is the third-
most populous city in Russia, with a population of nearly 1,500,000. It is situated in south-
western Siberia. Arkhangelsk is a smaller city located in northern European Russia, 1100 km 
to the north of Moscow. It has a population of about 350,000. These two cities were chosen 
because large-scale epidemiological studies had been conducted there previously (155, 156), 
and it was expected that they would have the capacity for comprehensive epidemiological 
studies to be carried out. The location of the two cities is shown on the map below (Figure 4-
1). The location of Tromsø, where the Tromsø Study was conducted, is also shown on the 
map. The protocols of the main examinations of KYH were designed to align with the 
Tromsø Study seventh survey so that the two studies would be comparable. Details of this are 
provided in a later section. 
 
Figure 4-1 Location of Arkhangelsk, Novosibirsk, and Tromsø 
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4.1.2  Study design 
KYH is a part of the International Project of Cardiovascular Disease in Russia (IPCDR). The 
objective of IPCDR is to understand why Russia has one of the highest CVD mortality rates 
in the world (2). Briefly, IPCDR is a comprehensive project consisting of the following four 
themes. The first is to investigate the differences in coding of cause of death between Russia 
and other countries, and how the differences in coding affect CVD mortality rates; the second 
is to create an updated trend of CVD mortality rates in Russia; the third is to investigate the 
potential role of the health care system and treatment in Russia; the last theme is to conduct a 
cross-sectional study to investigate the contemporary distribution of various behavioural and 
medical risk factors for CVD. This thesis will use data from this cross-sectional study (known 
as the Know Your Heart study: KYH).  
Details of the rationale and design of the KYH study have been provided elsewhere (2).  One 
of the main aims of this cross-sectional study was to compare the findings with those from 
another European country with low CVD risk to facilitate the understanding of the causes of 
high CVD mortality in Russia. In particular, the study was designed to be comparable with 
the seventh survey of the Tromsø Study (Tromsø 7), the population study from a low CVD 
risk country, Norway. To allow a reasonable comparison, the protocols for the main medical 
examinations in KYH, such as carotid and cardiac ultrasound examinations, were designed to 
align with those of Tromsø 7 which was conducted over the same period.  
The data collection in KYH comprised two stages: a baseline interview in the home and a 
medical examination at a polyclinic. Figure 4-2  shows a simplified study design. Briefly, 
4500 men and women aged 35-69 years were recruited from four districts in each city, the 
two largest city centre districts and two suburban districts, between November 2015 and 
December 2017. The four districts were selected to represent a range of socio-demographic 
and mortality levels. A random sample stratified by age and gender was derived from the list 
of the Territorial Health Insurance Funds in each district.  
Recruitment was conducted by Levada, a survey company. Trained interviewers from Levada 
visited the addresses on the list of a randomised sample and identified residents with the 
appropriate age and gender. If the participant was not available at the first visit, the 
interviewers visited on at least two more occasions, including weekends. If the person agreed 
to participate in the survey, and oral informed consent was obtained, the interview was 
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conducted to collect data including CVD risk factors, potential confounders, and potential 
mediators. 
At the end of the interview, the person was invited to attend a comprehensive health 
examination at a polyclinic at a later date. If participants accepted the invitation, an 
appointment was made. Data collection at the polyclinic included an interview on medical 
history and medication, anthropometric measurements, vital signs, spirometry, and cardiac 
and carotid ultrasound. Blood, urine, and faecal samples were also collected. Blood samples 
were frozen and transferred to Moscow for analysis.  
 
 
Figure 4-2 Design overview of Know Your Heart study 
5089 individuals were recruited for the baseline interview. A total of 4542 individuals 
attended a medical examination at a polyclinic, of these 2381 (52.4%) were from 
Arkhangelsk, and 2161 (47.6%) were from Novosibirsk. Fewer males were included than 
females with 41.5% and 42.0% in Arkhangelsk and Novosibirsk respectively. 
The overall response rate was markedly different between the two cities. Three types of 
response percentages were calculated using three types of the denominator. The type 1 
response percentage was the most conservative: all the addresses approached were used as 
the denominator, even if an address was invalid. The type 2 response percentage excluded 
invalid addresses or those at which no one in the household was of the appropriate age or sex 
from the denominator. Addresses were usually found to be invalid because the original list 
was outdated or inaccurate. Finally, the type 3 response percentage restricted the denominator 
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to addresses with an eligible participant of the appropriate age and sex. This third type 
reflects a willingness to participate. 
Table 4-1below summarises the three types of response percentages by sex and city. More 
detailed data have been made available elsewhere (2). Overall, the response percentages were 
much higher in Arkhangelsk than in Novosibirsk. Although the reason for the low response 
rate in Novosibirsk is unclear, it is possible that since it is a much larger city than 
Arkhangelsk, people might be more suspicious of being contacted by strangers. The response 
rate was particularly low among men at the lower end of the age distribution. Among those 
who completed a baseline interview, 96% and 83% subsequently attended the medical 
examination at the polyclinic in Arkhangelsk and Novosibirsk, respectively. Younger males 
with lower educational attainment were less likely to attend the medical examination, 
whereas those with a medical history of CVD risk factors were more likely to attend. 
Table 4-1 Response percentages by sex and city 
 Arkhangelsk Novosibirsk 
 Men Women Total Men  Women Total 
Type 1 
response  
36.7% 51.0% 43.9%  17.0% 25.6% 20.9% 
Type 2 
response 
45.7% 60.1% 53.1% 22.1% 31.5% 26.5% 
Type 3 
response 
60.4% 75.2% 68.2% 35.4% 48.0% 41.1% 
Table modified from Cook et al. (2) 
4.2  Tromsø Study 
4.2.1  Study setting 
Tromsø is located in Northern Norway, ~400km north of the Arctic Circle. It is the ninth 
most populous city in Norway with a population of about 67,000.  In spite of its location 
within the Arctic Circle, the climate is relatively mild for its latitude due to the warming 
effect of the Gulf Stream. 
4.2.2 Study design 
The Tromsø Study is a population-based prospective cohort study started in 1974 to 
investigate causes of CVD mortality; it was eventually broadened to include other chronic 
diseases. An overview of its design has been published elsewhere (157). It consists of seven 
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surveys: Tromsø 1 (1974), Tromsø 2 (1979-80), Tromsø 3 (1986-87), Tromsø 4 (1994-95), 
Tromsø 5 (2001-02), Tromsø 6 (2007-08), and Tromsø 7 (2015-16). Details of the Tromsø 
Study are described elsewhere (157). Most of the participants are Caucasian. Tromsø surveys 
4-7 have two stages: following the first visit (visit 1), the pre-identified population was 
invited to a second visit (visit 2) with a more extensive examination. Carotid ultrasound 
examination was performed in visit 2 in Tromsø 4-7. 
Tromsø 4 was conducted in 1994-95; it was the largest survey, and all residents of the 
municipality of Tromsø aged over 25 years were invited based on the official population 
registry. Data were collected through a self-administered questionnaire, physical 
examination, and blood sample. Information on CVD risk factors, lifestyle, and medical 
history was obtained through a questionnaire. Furthermore, everyone aged 55-74 years and a 
5-10% random sample of other age groups were eligible for visit 2 where extensive studies, 
including carotid ultrasound examination, were conducted. All participants who underwent 
carotid examination were invited to Tromsø 5 visit 2 as well as Tromsø 6 visit 2 where 
participants underwent follow-up carotid examination. In summary, participants in Tromsø 4-
6 visit 2 mainly comprised Tromsø 4 visit 2 participants regardless of the sampling methods 
for visit 1 participants. The attendance rate was high at >75% for Tromsø 1-5 and 66% for 
Tromsø 6. 
The most recent Tromsø survey (Tromsø 7) was conducted in 2015-16. All residents aged 
over 40 years living in the municipality of Tromsø were invited. A total of 21,083 men and 
women attended (response rate 65%). A random sample including previous participants was 
invited to visit 2.  
4.2.3 Why compare the Tromsø Study with the Know Your Heart Study? 
The selection of the city in the two studies 
In this thesis, I compared the burden of adiposity, the burden of carotid atherosclerosis, and 
their associations in a general population in Russia with that in Norway, using data from 
KYH and Tromsø 7. The ultimate aim is to elucidate the reason for the excess CVD burden in 
Russia. To justify this comparison, it is necessary to show that CVD mortality in the two 
Russian cities was not significantly different from that in the whole of Russia and that in 
Tromsø was not significantly different from the whole of Norway. The CVD mortality rate in 
each city compared to the whole nation is discussed below. 
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KYH  
Table 4-2 below compares CVD and all-cause mortality rates for the whole of Russia, 
Arkhangelsk, Novosibirsk, Tromsø, and the whole of Norway between 2012 and 2016. The 
mortality rate from all circulatory diseases in Novosibirsk was slightly lower than the 
national average for both sexes while that in Arkhangelsk was higher than the national 
average.  Regarding mortality from ischemic heart disease, both cities showed a higher rate 
than the national average. Nevertheless, the mortality rate from all circulatory diseases and 
ischaemic heart disease in both cities was relatively similar to the national average, which 
was markedly higher than the Norwegian national average and that of Tromsø.  
To check whether Novosibirsk and Arkhangelsk are considered as typical Russian cities, age 
distribution and educational attainments were compared between Novosibirsk, Arkhangelsk, 
and the whole of Russia. The age and education distributions of Novosibirsk and 
Arkhangelsk were reasonably similar to those of the total Russian urban population, although 
the prevalence of higher education was slightly higher in Novosibirsk than the national 
average (2). It can be said that the two cities are not very different from typical Russian cities. 
Table 4-2 Mortality rates by sex and cause for population aged 35-69 (2012-16) 
 
Table taken from Cook et al. (2) 
Tromsø Study 
Regarding Tromsø, Table 4-2 above shows that the mortality rate from all circulatory 
diseases and ischemic heart disease in Tromsø was lower than that for the whole of Norway 
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during this period. However, the mortality rate in Tromsø in this table is based on a relatively 
small number of deaths (2).  
Figure 4-3 shows the CVD mortality rate by Norwegian regions between 2000 and 2012. 
Historically the CVD mortality rate in northern Norway, where Tromsø is located, was higher 
than the national rate (158). However, CVD mortality rates from different regions in Norway 
have converged over the last decade. The difference in CVD mortality rate between Northern 
Norway and the whole nation is now small. Thus, it is safe to say that the CVD mortality rate 
in Tromsø is reasonably similar to the whole of Norway and considerably lower than that in 
Russia. Therefore, I concluded that the selection of two Russian cities and Tromsø was 
appropriate for comparison of the CVD burden in a general population between Russia and 
Norway. 
 
Graph taken from public health report from the Norwegian Institute of Public Health (158) 
Figure 4-3 Age-adjusted mortality from cardiovascular disease by different Norwegian regions 
(2000-2012) 
 
Comparison between KYH and Tromsø Studies 
In the 1970s, Norway had a higher CVD burden than most Western European countries 
(159). However, the CVD mortality rate in Norway has declined in the past four decades and 
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is now similar to other Western European countries (158). The decrease in CVD risk factors, 
especially blood pressure and cholesterol levels, is likely to have contributed to this decline in 
CVD burden (158). However, like other countries, an increase in other CVD risk factors such 
as general and abdominal obesity and type 2 diabetes is a concerning trend in Norway (89). 
Because Norway once suffered a high CVD burden, like Russia, followed by a sharp decline 
in CVD mortality, comparison between Norway and Russia in terms of the distribution of 
CVD risk factors might allow us to identify CVD risk factors which explain the higher CVD 
burden in Russia and provide insight into effective intervention.  
In addition to the similar protocols for medical examinations in KYH and Tromsø 7, there are 
several factors that enable us to compare the two studies. First, due to its geographical 
proximity to Russia, Tromsø has a relatively similar climate to the two Russian cities. 
Furthermore, the ethnic composition is also similar to the Russian cities, which mainly 
consist of people with European ancestry. These factors help us to make a reasonable 
comparison of adiposity level, carotid plaque burden, and the impact of adiposity on carotid 
atherosclerosis between the two populations from two countries with very different CVD 
burdens. 
4.2.4 Ethical approval and confidentiality 
KYH 
Ethical approval for the study was obtained from the ethics committees of the London School 
of Hygiene & Tropical Medicine (approval number 8808 received 24/02/2015), Novosibirsk 
State Medical University (approval number 75 approval received 21/05/2015), the Institute of 
Preventative Medicine (no approval number; approval received 26/12/2014), Novosibirsk and 
the Northern State Medical University, Arkhangelsk (approval number 01/01-15 received 
27/01/2015). 
The KYH dataset I received was anonymised and did not include any information on personal 
identifiers (name, initials, postcode) which was consistent with the London School of 
Hygiene and Tropical Medicine guidelines for good research practice. 
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Tromsø Study 
Ethical approval was obtained from the Norwegian Data Inspectorate and the Regional 
Committee for Medical and Health Research Ethics. Written informed consent for using 
information in future research projects was introduced in the Tromsø Study fourth survey.  
Data access to Tromsø Study 4-7th surveys for this PhD project was requested and approved 
by the Data and Publication Committee at the Arctic University of Norway. The dataset I 
received was anonymised.  
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5 Main exposure, outcome and other variables 
This chapter summarises the main variables pertinent to my main analysis. The first section 
describes methods of measurement of the main anthropometric exposures, followed by 
consideration of potential measurement error. Then the method to measure the main outcome 
carotid plaque is explained followed by those for the main confounders and mediators. 
Finally, CVD risk factors which I considered including in my main model but ultimately 
omitted are described. 
5.1 Key exposures: adiposity measures 
5.1.1 Assessment of anthropometric measures in the two studies 
The key exposures in my main models were four simple anthropometric measures: body mass 
index (BMI), waist circumference (WC), waist-to-hip ratio (WHR), and waist-to-height ratio 
(WHtR). 
In the Know Your Heart study (KYH), height was measured using a Seca® 217 portable 
stadiometer (Seca Ltd) to the nearest millimetre. Weight was measured with a TANITA BC 
418 body composition analyser (TANITA, Europe GmbH) with participants barefoot and 
wearing one layer of thin clothing. WC was measured at the smallest part of the trunk using a 
tape measure to the nearest millimetre followed by measurement of the hip at the widest part. 
When it was difficult to locate the natural indent of the trunk, the measurement was 
conducted at the level of the umbilicus. The tape was kept horizontal during the 
measurement, which was repeated twice. The protocol for the assessment of anthropometric 
measures is found in Appendix A4. 
In the Tromsø Study, participants were measured in light clothing. Height was measured to 
the nearest centimetre in Tromsø 4 and to the nearest millimetre in Tromsø 5-7. Weight was 
measured to the nearest kilogram in Tromsø 4 and to the nearest 100 grams in Tromsø 5-7. 
WC was measured at the level of the umbilicus to the nearest centimetre using a tape 
measure. Hip circumference was measured at the widest part.  
It should be noted that the measurement of WC was made at different sites in the two studies: 
the smallest part of the trunk in KYH and the level of the umbilicus in Tromsø 7. Previous 
studies have shown that WC measured at different sites differs significantly, especially 
among women (160, 161). Therefore, I converted WC at the level of the umbilicus in Tromsø 
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7 to the minimal WC using the equation derived by Mason et al. (161). The mean value of 
WC before and after the conversion and the conversion equation used are presented in 
Appendix A5. This equation was derived from 542 healthy volunteers aged 20-67 years who 
were predominantly white. Considering the relatively similar age and ethnic structures to 
Tromsø 7 participants, using this equation was reasonable in the Tromsø 7 population. 
5.1.2 Measurement error 
Random measurement error in continuous exposure variables could cause regression dilution 
bias and underestimation of the regression coefficient between adiposity and carotid plaque 
burden in my analysis (162). Therefore, I used data from the repeat study of KYH and 
investigated the reproducibility of the anthropometric measures. The details of the repeat 
study are described elsewhere (2). Briefly, two hundred participants from each Russian city 
were invited back one year after the first examination to reduce the effect of seasonality. 
They were subsequently re-interviewed and underwent a second health check. The primary 
objective of this repeat study was to estimate the correction factors to correct for 
measurement error. Meanwhile, the secondary objective was to investigate the reproducibility 
of each measurement.  
I estimated the intra-class correlation coefficients (ICC) for height, WC, hip circumference, 
BMI, WHR, and WHtR. Table 5-1 shows the results. The ICCs for height was 0.99. 
However, the ICCs for other measurements were not as high as that for height. However, it 
should be noted that the repeat measurement was made one year after the first measurement, 
during which time, weight, WC, and hip circumference are highly likely to have undergone 
true changes, with the magnitude of true changes differing among the individuals. As an 
illustration of this, one American study followed 1,145 middle-aged adults aged between 50 
and 75 years. After one year, mean weight increased by 1.72 kg, while mean WC increased 
by 1.76  cm (163). Therefore, it is possible that the correction of regression dilution based on 
the ICCs from this result does not necessarily improve the estimates because the ICCs may 
partially reflect heterogeneity in the true changes among individuals, in which case correcting 
for this as measurement error may over-correct, introducing bias rather than removing it.   
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Table 5-1 Intra-class correlation coefficients (ICC) of various anthropometric measures: 
 Know Your Heart Study 
 
 Individual ICC 95% CI 
Height   
1st height measurement 0.99 0.99, 0.99 
2nd  height measurement 0.99 0.99, 0.99 
Mean height measurement 0.99 0.99, 0.99 
Weight   
Tanita weight 0.97 0.97, 0.98 
Weight 0.97 0.97, 0.98 
Waist circumference   
1st waist measurement 0.93 0.92, 0.95 
2nd waist measurement 0.94 0.92, 0.95 
Mean waist measurement 0.94 0.92, 0.95 
Hip circumference   
1st hip measurement 0.93 0.91, 0.94 
2nd hip measurement 0.88 0.86, 0.90 
Mean hip measurement 0.92 0.91, 0.94 
Adiposity measures   
BMI 0.97 0.96, 0.97 
WHR 0.91 0.89, 0.92 
WHtR 0.94 0.92, 0.95 
 
Then I conducted a literature review of existing studies investigating the reproducibility of 
anthropometric measurements. One literature review showed excellent intra- and inter-
observer reliability of height and weight (164). As a result, BMI is unlikely to be materially 
affected by measurement error. However, in the same literature review, WC and hip 
measurement showed lower inter-observer reliability, although intra-observer reliability was 
excellent (164). However, this result is based on old studies conducted more than 20 years 
ago. Recent studies have shown higher inter-observer reliability.  For example, Mason et al. 
investigated the inter-observer reliability of WC measurement at four different measurement 
sites (161). The intraclass correlation coefficient (ICC) of WC at the level of the umbilicus 
and minimal waist in women was 0.96 and 0.98, respectively. For men, the ICC for WC at 
the level of the umbilicus and minimal waist was even better with 0.98 and 0.99, respectively. 
Similarly, Chen et al. reported excellent intra-observer and inter-observer ICC for both WC 
and WHR (intra-observer ICC: WC 0.987, WHR 0.970, inter-observer ICC: WC 0.988,  
WHR0.969) (165). Although this reproducibility from contemporary studies presents higher 
ICCs than the present study, it is very likely that ICCs in KYH are affected by heterogeneity 
in the true biological changes among individuals. 
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Training has been shown to improve the reliability of anthropometric measurement (166). 
Intra- and inter-observer reliability of several anthropometric measures was investigated in a 
study involving 12 physicians whose knowledge of appropriate measurement technique was 
poor. Without training, inter-observer reliability of the assessment by these physicians was 
unsatisfactory regarding WC (the coefficient of reliability 0.92), hip circumference (0.70), 
and WHR (0.51) although that of BMI was excellent. However, after a one-hour training 
session, inter-observer reliability showed substantial improvement (WC 0.97, hip 
circumference 0.92, WHR 0.89). In both the KYH and Tromsø 7 studies, appropriate training 
was delivered to improve the reliability of anthropometric measurements, and the detailed 
method was explained in the protocol.  
In summary, the reproducibility of anthropometric measures in KYH seems acceptable, and 
the corrections of regression dilution using ICCs obtained might be problematic due to the 
true biological change between first and second measurements.  Furthermore, intra- and inter-
observer reliability of anthropometric measures, including WC and WHR, in contemporary 
studies seems very good. In addition, examiners in KYH and Tromsø 7 were provided with 
appropriate training in advance of the measurement process. Therefore, I did not conduct 
corrections for the effects of measurement error on the assumption that our reproducibility is 
comparable to that from recent studies. However, the association between carotid plaque and 
adiposity may be underestimated.  
5.2  Key outcomes: carotid plaque  
5.2.1  Assessment of carotid plaque in the two studies 
Key outcomes in this thesis are two carotid plaque variables assessed using ultrasound: the 
presence of carotid plaques and carotid plaque score based on the presence of plaques in each 
carotid segment. In Chapters 6 and 7 using the Tromsø Study, total plaque area (TPA) is used 
as well. 
Carotid ultrasound examination was performed using a comparable protocol in KYH and 
Tromsø 7. The protocol can be found in Appendix A6. Both carotid arteries were scanned for 
carotid plaques using Vivid q (GE Health care) with a linear 6~13 MHz transducer in KYH 
and Vivid 7 (GE Health care) with a linear 12 MHz transducer in Tromsø 7. Carotid plaque 
was defined as a focal structure encroaching into the arterial lumen at least 0.5 mm or 50% of 
the surrounding intima-media thickness (IMT) value, or demonstrates a thickness > 1.5 mm 
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as measured from the media-adventitia interface to the intima-lumen interface based on the 
Mannheim consensus in both studies (41). Images were stored, digitalised, and converted to 
Digital Imaging and Communications in Medicine (DICOM) digital records for offline 
reading. 
There was a minor difference in the reading process for carotid plaque between the two 
studies. In Tromsø 7, the presence of carotid plaques and the plaque score, based on the 
presence of plaques in each carotid segment, were determined during the ultrasound 
examination by experienced sonographers. The longitudinal still image of every plaque was 
digitally documented using DICOM files for the offline reading of TPA. In KYH, offline 
readings were made by a team of experienced cardiologists to determine the presence of 
plaques and the actual number of plaques based on cine-loop of the carotid artery and still 
images of plaques using EchoPAC software (v. 113, GE-Vingmed AS, Norten, Norway). 
However, it is unlikely that this difference between the online and offline reading of the 
presence and number of plaques causes a meaningful difference since the assessment was 
made by experienced ultrasonographers /physicians in both studies. Another difference was 
how carotid plaques were counted, which is described in detail in the next section. 
5.2.2 Measurement error 
Random measurement error in the carotid ultrasound variables will not bias the regression 
coefficients between carotid variables and adiposity because they are outcome variables, but 
will affect the precision. Regarding the Tromsø Study, reasonable reproducibility of carotid 
plaque measurement has been previously reported (167). Briefly, they investigated the inter- 
and intra-observer agreements on plaque detection using the Tromsø Study fourth (1994-95) 
and fifth surveys (2001-02). Inter-observer agreement in plaque detection was good with 
kappa values of 0.72 and 0.67 in the fourth survey and the fifth survey, respectively. The 
intra-observer agreement was excellent (kappa values: 0.76 in the fourth survey, 0.80 in the 
fifth survey). Reproducibility of TPA was also investigated. The inter-observer 
reproducibility of TPA was satisfactory with a mean arithmetic difference -1.0 (95% CI: -1.4, 
-0.6) although the difference between the two observers tended to increase as TPA increased. 
The Tromsø Study used a consistent protocol of carotid examination in all the surveys. 
Overall, it is expected that my main outcomes, the presence of plaques and plaque score, will 
have reasonable reproducibility. 
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The burden of plaque was assessed slightly differently between the two studies, which may 
result in systematic measurement error. In both studies, plaques were sought in each segment 
(common carotid artery (CCA), bifurcation, internal carotid artery (ICA)) of both carotid 
arteries, a total of six carotid segments). The Tromsø 7 protocol explicitly further divided 
each segment into far and near wall locations, giving a total of twelve sites. However, only 
one plaque could be counted at each site because of concerns about differentiating between a 
single large plaque and two discrete plaques. This means each individual in Tromsø 7 can 
contribute to the maximum plaque number of twelve (maximum of two plaques for each of 
the six segments). In KYH, however, the protocol did not involve recording the near or far 
wall location, and there was no restriction on how many plaques could be recorded for each 
of the six segments. This protocol difference could lead to an artefactually higher plaque 
burden in KYH than Tromsø 7. Appendix A7 shows the number of plaques in KYH and in 
Tromsø 7 originally recorded by each carotid segment.  
To ensure comparability of plaque burden in the two studies, I created a more comparable 
total plaque score using the following rule: when three plaques (the maximum seen) were 
recorded for any one of the six carotid segments in KYH this was converted to a score of two. 
Otherwise, the number of plaques for the six segments were converted to plaque score 
without changes. A total plaque score was then created by adding the plaque score from each 
carotid segment in KYH and Tromsø 7, giving a maximum plaque score of twelve.  However, 
because KYH did not provide information on wall side location, the plaque scores were not 
completely comparable between the two studies. For example, if there were two plaques at 
the right bifurcation in KYH, it was not possible to determine if the appropriate score should 
be one (if both plaques were on the same wall side) or two (if on different sides). 
To reduce the risk of the overestimation of plaque score in KYH, I also conducted a 
sensitivity analysis by using a simpler plaque score, which was independent of information 
about wall side. A score of one was assigned for the presence of one or more plaques in each 
of the six carotid segments (CCA, bifurcation, ICA of each carotid artery). This resulted in a 
consistent approach for both studies, with a maximum possible score of six for each 
individual. As reported in Chapter 9, the results of this sensitivity analysis were substantively 
the same as found using the full plaque score with a maximum of twelve. 
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5.3 Other CVD risk factors 
5.3.1  Main confounders (age, sex, smoking, educational attainment) 
Age, sex, smoking, and educational attainment were considered a priori as main confounders 
throughout all my analyses. Information on age, smoking (current smoker, ex-smoker, never-
smoker) and educational attainment was obtained through face-to-face interview in KYH and 
self-administered questionnaires in Tromsø 7. The education variable in KYH was a 
categorical variable with seven levels (1: incomplete secondary, 2: complete secondary, 3: 
professional school, 4: professional school and secondary, 5: specialised secondary, 6: 
incomplete higher education, 7: higher education). Tromsø 7 had three levels (1: primary 
education, 2: secondary education, 3: tertiary education). Due to differences in the education 
system between Western European countries and Russia, it was difficult to convert the 
educational variable in KYH to the categorical variable with three levels that could be 
compared with Tromsø 7. Therefore, the education variables in the two studies were 
converted to the binary variables (higher education: Yes/No). The  KYH questionnaire is 
available online (https://wellcomeopenresearch.org/articles/3-67) as supplementary material 
in Cook et al.(2). The Tromsø Study questionnaire is available on the Arctic University of 
Norway website (http://tromsoundersokelsen.uit.no/tromso/). 
5.3.2  Main mediators (SBP, cholesterol level, glucose/HbA1c) 
As can be justified from my literature review in Chapter 3, systolic blood pressure (SBP), 
cholesterol level, glucose (or glycosylated haemoglobin (HbA1c)) were considered as main 
mediators throughout my analyses. In KYH, SBP was measured three times, seated, using 
OMRON 705 IT automatic blood pressure monitors (OMRON Healthcare). Non-fasting 
venous blood samples were frozen within 2 hours of collection and stored at -20 degrees. 
Within three weeks, they were transferred to -80-degree freezers and eventually shipped to 
the laboratory in Moscow where all samples were analysed based on a standardised method.  
In the Tromsø Study, SBP was recorded three times with Dinamap (CARESCAPE V100 
Monitor, GE Healthcare). Both Dinamap and OMRON (used in KYH) have been validated to 
British Hypertension Society standards. Non-fasting venous blood samples were obtained, 
and fresh serum was analysed at the University Hospital laboratories.  
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5.3.3 CVD risk factors not included in the main model (physical activity, alcohol) 
Two variables I considered including in the main model but ultimately omitted were physical 
activity and alcohol consumption. I did not include physical activity in the main model 
because the assessment methods differed markedly between the two studies. In KYH, the 
total physical activity index and Cambridge physical activity index were derived based on a 
detailed questionnaire regarding recreational and occupational physical activity. However, in 
Tromsø 7, recreational physical activity was categorised using a simple question (Describe 
your exercise and physical exertion in leisure time over the last year. 1: reading, watching 
TV/screen or other sedentary activity?, 2: Walking, cycling, or other forms of exercise at 
least 4 hours a week? (including walking or cycling to place of work, Sunday-walking, etc.), 
3: Participation in recreational sports, heavy gardening, snow shovelling, etc at least 4 hours a 
week?, 4: Participation in hard training or sports competitions, regularly several times a 
week?).  
Furthermore, although physical activity is a very important CVD risk factor, regarding the 
association between adiposity and carotid atherosclerosis, it cannot be simply considered as a 
confounder: physical activity is more likely to be located upstream of this association, with 
adiposity behaving as a mediator. Since physical activity is not on the causal pathway 
between adiposity and carotid atherosclerosis, it is not considered as a mediator either. For 
this reason, it seems reasonable to exclude it from my main model, although I used it in one 
analysis using the Tromsø Study (Chapter 7). 
Alcohol consumption is considered an important CVD risk factor in Russia (168-170). 
However, when I obtained the dataset, comparable alcohol variables in the two studies were 
still unavailable. The available alcohol variable in KYH was a categorical variable with six 
levels based on ethanol consumption per year which was derived from questions about 
frequency and usual volume of consumption of beer, wine, and spirits (not drinker, >0 <2 
litre/year, 2-4 litre/year, 4-9 litre/year, 10-19 litre/year, 20+ litre/year). On the other hand, 
Tromsø 7 had a categorical variable with five levels (How often do you usually drink 
alcohol? 1: never, 2: monthly or less frequently, 3: 2-4 times a month, 4: 2-3 times a week, 5: 
4 or more times a week).  
Furthermore, it is unclear whether alcohol should be considered as a confounder in the 
association between adiposity and carotid atherosclerosis; alcohol may affect adiposity as 
described in Chapter 2. However, whether either the volume of alcohol consumption or 
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pattern of drinking is associated with carotid atherosclerosis is unclear. In addition, alcohol 
consumption is not on the causal pathway between adiposity and carotid atherosclerosis, and 
thus cannot be considered as a mediator of this association.  
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6 The contribution of obesity to carotid atherosclerotic plaque 
burden in a general population sample in Norway: The 
Tromsø Study (Paper 1) 
6.1 Introduction 
Following two chapters (Chapters 6 and 7) use the Tromsø Study fourth (1994-95) and fifth 
(2001-02) surveys, and Chapters 8 and 9 use both the Know Your Heart Study and the 
Tromsø Study seventh survey.   
In this chapter, I describe my investigation of the cross-sectional associations between 
general and abdominal adiposity and carotid plaque burden (the presence of carotid plaques, 
total plaque area (TPA)) using four anthropometric adiposity measures (body mass index 
(BMI), waist circumference (WC), waist-to-hip ratio (WHR), waist-to-height ratio (WHtR)) 
in a general population in Norway. I used data from the Tromsø Study fifth survey. 
As described in my systematic literature review (Chapter 3), in contrast to extensive evidence 
on the associations between adiposity and CVD, there is little evidence on the associations 
between adiposity and carotid plaque, even in high-income Western countries. The limited 
evidence available does not adjust for confounders separately from mediators. Therefore, it is 
unclear whether this pathway is similar to that between adiposity and CVD, or whether it is 
similarly mediated by cardio-metabolic CVD risk factors. For this reason, in advance of my 
main analysis, a comparison between the Know Your Heart Study and the Tromsø Study 
seventh survey, I conducted an exploratory analysis using a previous survey from the Tromsø 
Study, and examined whether a potential causal pathway (Figure 3-1 in Chapter 3) is a 
reasonable assumption. 
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Background and aims: Few studies have investigated the association of different measures of adiposity
with carotid plaque. We aimed to investigate and compare the associations of four measures of adiposity:
body mass index (BMI), waist circumference (WC), waist-to-hip ratio (WHR), and waist-to-height ratio
(WHtR) with the presence of carotid plaque and total plaque area (TPA) in the right carotid artery.
Methods: We included 4906 individuals aged 31e88 years who participated in a population-based study
with ultrasonography of the right carotid artery. Adiposity measures were converted to sex-speciﬁc SD
units to allow comparison of effect sizes. TPA was log transformed due to its skewed distribution. Logistic
and linear regression models were used respectively to investigate the association of each adiposity
measure with the presence of plaque and with log-transformed TPA. Estimates were adjusted for po-
tential confounders and mediators such as blood pressure and lipids.
Results: After adjustment for age, sex, smoking, and education level, there was strong evidence of an
association between all adiposity measures and log-transformed TPA, whereas only WHR was weakly
associated with presence of plaque. WHR showed the largest adjusted effect size for both log-
transformed TPA (beta 0.055, 95%CI 0.028e0.081) and the presence of plaque (OR 1.07, 95%CI 1.01
e1.15). Adjustment for mediators led to appreciable attenuation of observed effects.
Conclusions: Adiposity is more consistently associated with extent of plaque burden than with whether
an individual does or does not have any plaque. There was evidence that established biomarkers mediate
much of this association. Abdominal adiposity appears to show the strongest effect.
© 2018 Elsevier B.V. All rights reserved.
1. Introduction
Obesity is a global epidemic, affecting an increasing proportion
of the world's population [1]. In 2014, approximately 40% of adults
worldwide were estimated to be overweight, and 13% obese [2].
This trend is alarming because it might be expected to result in a
steep increase in non-communicable diseases, particularly cardio-
vascular disease (CVD) which is the leading cause of death world-
wide. Obesity contributes to CVD through a variety of pathways
including hypertension, hyperlipidemia, and diabetes [3]. A better
understanding of the pathways through which obesity affects CVD
risk may contribute to developing interventions to mitigate the
effect of this modiﬁable risk. Furthermore, it is known that to
achieve sufﬁcient weight-loss and to sustain it for a long-term is
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relatively difﬁcult while the control of hypertension, hyperlipid-
emia, and diabetes are well-established [4,5].
Many studies have investigated the association between various
adiposity measures and subclinical carotid atherosclerosis [6].
However, most of these have focussed on carotid intima-media
thickness (IMT). Studies using carotid plaque as an outcome are
scarce, and most of them use the binary indicator of presence or
absence of plaque [7e15]. Although studies have consistently
shown that increased IMT predicts future CVD events, increased
IMT does not necessarily reﬂect atherosclerotic changes of the ca-
rotid artery and can be caused by other mechanisms [16]. In
contrast, the presence of carotid plaque is characteristic of a later
stage of atherosclerosis and thus, not surprisingly, predicts future
CVD events better than IMT [17]. Beyond this, a quantitative mea-
sure of carotid plaque burden, such as total plaque area (TPA), has
also been shown to be strongly predictive of future CVD events
[18,19].
A small number of studies have investigated the association of
body mass index (BMI) with quantitative measures of carotid pla-
que burden, although they failed to demonstrate a signiﬁcant as-
sociation [13,20]. However, BMI has limitations as a measure of
adiposity [21]. It neither differentiates between fat and lean mass
nor does it reﬂect body fat distribution. Accumulating evidence
suggests that abdominal obesity may be correlated with CVD risks
more strongly than general obesity, reﬂecting a more important
role of visceral adipose tissues in the development of CVD [22].
Waist circumference (WC), waist-to-hip ratio (WHR), and waist-to-
height ratio (WHtR) are easily evaluated in a routine clinical setting
and reﬂect abdominal obesity better than BMI. To our knowledge,
associations of plaque burden with these alternative measures of
adiposity have not been investigated.
The aim of our study was to evaluate the associations between
four adiposity measures (BMI, WC, WHR, WHtR) and plaque pres-
ence (yes/no) as well as TPA in a population-based sample. In
addition, we investigated the extent to which established CVD risk
factors mediated any such associations. We used the Norwegian
Tromsø Study which is one of few population-based studies that
have quantitative plaque measures as well as multiple measures of
adiposity.
2. Materials and methods
2.1. Participants
Subjects in this analysis participated in the ﬁfth survey of the
Tromsø Study (Tromsø 5) conducted in 2001-02. The Tromsø Study
is a large population-based study with repeated health surveys
conducted in the municipality of Tromsø, Norway, which started in
1974. Details of the Tromsø Study have been published previously
[23].
The study consisted of two parts: a ﬁrst visit that collected data
via questionnaires, interviews, physical examinations and biolog-
ical samples, and a second visit at which more extensive clinical
examinations were conducted, including carotid ultrasonography.
A total of 10353 people aged 30e89 years were invited to the ﬁrst
visit, and 8130 people attended [23]. A subset of 6969 participants
among thosewho attended the ﬁrst visit were invited to the second
visit, of whom 5952 attended. The Regional Committee for
Research Ethics approved the study, and The Norwegian Data
Inspectorate licensed the data.
2.2. First visit measurements
Height, weight, waist and hip circumference were measured
using standard methods. Blood pressure was measured using
Dinamap Vital Signs Monitor 1846l. After a 2-min rest, three
measurements were taken with 1-min intervals, with the partici-
pant in a sitting position. The mean of the two ﬁnal readings was
used in the analysis. Smoking habit, length of education (years), and
medical history (hypertension, diabetes, CVD) were collected from
self-administered questionnaires. A non-fasting blood sample was
obtained. Serum total cholesterol and triglycerides were analyzed
with enzymatic colorimetric methods. Serum high-density lipo-
protein (HDL) cholesterol was measured after separating apoB
containing lipoproteins by using heparin and manganese chloride
[24]. Low-density lipoprotein (LDL) cholesterol was calculated us-
ing the Friedewald equation.
2.3. Ultrasound examination
By design, the carotid plaque examinations excluded those who
had not had a carotid ultrasound examination in the Tromsø 4
study (1994-95). This meant that of those who attended the second
visit (N¼ 5952), carotid ultrasound examinations in Tromsø 5 were
conducted on only 5453 participants, of whom data was available
for analysis for 5423.
Carotid plaque was assessed by recording ultrasonographic
images of the right carotid artery using an Acuson Xp10 128 ART
ultrasound scanner equipped with a linear array 5e7MHz trans-
ducer. Participants were in a supine position during the
examination.
The plaque was deﬁned as a localized protrusion of the vessel
wall into the lumen of at least 50% compared with the adjacent
intima-media thickness. The near and far wall of the common ca-
rotid artery, bifurcation, and internal carotid artery were examined
to seek plaques, and a scorewas calculated based on the presence of
plaque in each location up to a maximum of six. For each plaque
identiﬁed, a longitudinal still plaque image was recorded. Subse-
quent ofﬂine reading was undertaken tomeasure plaque area using
a semi-automatic border detection software Arterial Measurement
System (AMS) that involved the operator outlining each plaque
[25]. For those with more than one plaque, all plaque areas were
added together to calculate TPA. Details of the ultrasound exami-
nation have been described in a previous publication [26].
2.4. Statistical methods
Characteristics of the study population were summarised using
means with standard deviations (SD) or medians with the inter-
quartile range for continuous variables, or numbers and percent-
ages for categorical variables.
The distribution of TPA was highly skewed and zero-inﬂated,
which led us to use a combination of two models. A logistic
regression model was used with presence of plaque (yes/no) as an
outcome to explore the association of adiposity with having at least
one plaque. Secondly, log-transformed TPA was used as the
outcome in a linear regression model to explore the association
between adiposity and plaque burden excluding those with no
recorded plaque. TPA was log-transformed to improve the
approximation to the normal distribution. These two models in
conjunction are equivalent to using a hurdle model [27], with the
logistic regression modelling the distribution of zero plaque versus
at least one plaque, and the linear regression modelling the dis-
tribution of the non-zero measures.
For both outcomes, we investigated the association with four
different measures of adiposity: BMI, WC, WHR, WHtR. To directly
compare the strength of association of each adiposity measure,
taking account of the different distributions inmen andwomen, we
calculated sex-speciﬁc standardized adiposity scores by subtracting
the sex-speciﬁc mean of each adiposity measure from the observed
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value and then dividing by the sex-speciﬁc SDs. We ﬁtted a
sequence of threemodels to each of the adiposity measures in turn.
Model 1 was adjusted for age as a continuous variable and sex.
Model 2 was further adjusted for potential behavioural con-
founders; smoking (a categorical variable of three levels: current
smoker, ex-smoker, never-smoker), and years of education (as a
continuous variable). Model 3 was additionally adjusted for po-
tential biological mediators of the association between adiposity
and plaque as follows; systolic blood pressure (SBP), HDL-
cholesterol, LDL-cholesterol and glycated hemoglobin (HbA1c), all
as continuous variables. These analyses were restricted to partici-
pants with all four adiposity measures and all covariates recorded
to compare effect sizes.
Previous research on adiposity in relation to cIMT has suggested
that there may be different associations seen in men and women
[28]. We therefore checked for interactions with sex in the asso-
ciations of adiposity with TPA, by adding interaction terms for all
three models.
Statistical analyses were performed using Stata statistical soft-
ware (version 14: Stata Corp) [29].
3. Results
Of the 5423 subjects for whom we had carotid ultrasound data,
we used the subset of 4906 who had complete data on all relevant
variables. Missing data on education (5%) and HbA1c (2%) were the
main reasons for subjects being dropped from the analyses. The
characteristics of the subset analysed were very similar to that of all
subjects who had undergone carotid ultrasound examination (data
not shown).
The prevalence of carotid plaque and median TPA are shown in
Table 1. The prevalence of having at least one plaque was 60%.
Table 2 shows the means of each adiposity measure by category of
plaque burden. There was a tendency for the adiposity means to
increase across categories of plaque burden except for BMI.
Table 3 shows the odds ratios for the presence of plaque for each
of the four adiposity measures. In models 1 and 2 only WHR
showed some evidence of an association with presence of plaque.
This was attenuated and became non-signiﬁcant on adjustment for
mediators in model 3.
Table 4 shows the associations of log-TPA with each adiposity
measure. There was evidence of positive associations with all four
measures in model 2 after adjustment for potential confounders,
with WHR showing the strongest effect. All associations were
attenuated on further adjustment for potential mediators, with
WHR remaining the only one showing (weak) evidence of an as-
sociation. Tests for interactions between adiposity and sex and
adiposity and age on log-TPA were non-signiﬁcant (data not
shown).
Table 1
Participant characteristics of study population. The Tromsø Study 2001-2002.
Participants included in the analysisa (n¼ 4906) Participants included in the analysis with plaqueb(n¼ 2906)
Age (years) median (IQR) 66 (60e72) 68 (63e74)
Sex (% of women) 2722 (55.5) 1450 (49.9)
Current smoker (%) 1249 (25.5) 794 (27.3)
Ex-smoker (%) 1999 (40.8) 1234 (42.5)
Education (year) 9.9 (3.6) 9.4 (3.3)
SBP (mmHg) 143.0 (21.6) 147.3 (21.5)
Anthropometry measures
Height (cm) 167.4 (9.3) 167.3 (9.5)
Weight (kg) 75.2 (13.9) 75.1 (13.8)
BMI (kg/m2) 26.8 (4.2) 26.8 (4.1)
WC (cm) 90.3 (12.2) 91.1 (12.0)
WHR 0.89 (0.09) 0.90 (0.09)
WHtR 0.54 (0.07) 0.55 (0.07)
Blood sample
HDL cholesterol (mmol/l) median(IQR) 1.43(1.19e1.72) 1.42 (1.18e1.70)
LDL cholesterol (mmol/l) 4.11 (1.07) 4.16 (1.09)
Triglycerides (mmol/l) median (IQR) 1.34 (0.96e1.90) 1.39 (1.00e1.94)
HbA1C (%) 5.50 (0.80) 5.58 (0.83)
Comorbidities (self-report)
Diabetes (%) 222 (4.6) 152 (5.4)
Myocardial infarction (%) 378 (7.9) 311 (11.0)
Angina pectoris (%) 501 (10.5) 398 (14.1)
Stroke (%) 191 (4.0) 148 (5.2)
Current medication (self-report)
Anti hypertensive drug (%) 1194 (24.9) 869 (31.7)
Lipid lowering drug (%) 708 (15.0) 541 (19.5)
Carotid variable
Plaque presence (%) 2906 (59.2%) 2906 (100%)
Number of plaque (%)
1 1372 (28.0) 1372 (47.2)
2 931 (19.0) 931 (32.0)
3 427 (8.7) 427 (14.7)
4 134 (2.7) 134 (4.6)
5 36 (0.7) 36 (1.2)
6 6 (0.1) 6 (0.2)
TPA (mm2) 17.6 (10.0e31.3)
Data are mean values with standard deviations for continuous variables except for age, triglycerides, HDL cholesterol, and TPA which is shown with median and interquartile
range.
BMI: body mass index, WC: waist circumference, WHR: waist-to-hip ratio, WHtR: waist-to-hight ratio, HDL: high-density lipoprotein, LDL: low-density lipoprotein, HbA1c:
glycated haemoglobin, TPA: total plaque area.
a Participants are restricted to those with all main variables and non-missing TPA variable.
b Participants are restricted to those with all main variables and at least one plaque.
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4. Discussion
To our knowledge, this is the ﬁrst study to investigate the
burden of carotid plaque andmultiple adiposity measures in a large
population-based study. Our study had three major ﬁndings. First,
all adiposity measures were associated with log-TPA, but the evi-
dence for an association with plaque presence was weak except for
WHR. Second, the associations between adiposity and carotid pla-
que appeared to be at least partially mediated by traditional CVD
risk factors. Thirdly, our main measure of central obesity (WHR)
showed the strongest and most consistent association with plaque
presence and burden.
Previous studies investigating the association between
adiposity and the presence of plaque are scarce, and the results are
inconsistent [7e12] in part reﬂecting differences in statistical
methods and the extent to which adjustments were made sepa-
rately for potential confounders and mediators. Czernichow et al.
showed that BMI, WC, and WHR were not associated with carotid
plaque occurrence after adjustment for traditional CVD risk factors
in 1014 healthy adults [9]. Several other studies however had re-
sults that were broadly consistent with our analyses. A French study
with 6265 participants aged 65-years and older showed that fre-
quency of carotid plaque increased as WC and WHR increased, but
the association became non-signiﬁcant after the adjustment for
traditional CVD risk factors [10]. On the other hand, WHR had
signiﬁcant associations with the presence of plaque in two cross-
sectional studies. Chaubey et al. showed that the odds of having
plaque increased by approximately 30% as WHR increased by 0.1
after adjustment for traditional CVD risk factors [8]. Finally, an
Australian population study showed that those with WHR larger
than 0.91 had two-fold increased odds for having plaque compared
to those with smaller WHR [11].
The particularly weak association between BMI and the burden
of carotid plaque in our analysis after adjustment for traditional
CVD risk factors is in line with the only two previous study results
[13,20]. Herder et al. showed that baseline BMI was not associated
with future TPA nor change in TPA in a 13-year follow-up study [13].
Selwaness investigated determinants of plaque burden assessed
using MRI, and BMI was not signiﬁcantly associated with the
burden of plaque [20]. We were unable to ﬁnd any other studies
that had examined plaque burden in relation to any of our three
other measures of adiposity.
The fact that our study has found evidence for adiposity being
related to extent of plaque burden rather than the presence/
absence of plaque per se is intriguing. This may indicate that
adiposity contributes to the process of the development of existing
plaque more than the process of plaque initiation. However,
because TPA is a continuous measure and contains more informa-
tion than the binary plaque (present/absent) variable this may
make an association easier to detect.
Table 2
The association between adiposity and TPA quartiles (crude). The Tromsø Study 2001-2002.
Total numbera BMI (kg/m2) WC (cm) WHR WHtR
Persons without plaques 2000 26.8 (4.3) 89.0 (12.5) 0.87 (0.09) 0.53 (0.07)
Persons with plaques
TPA quartile 1 (lowest) 727 26.7(4.2) 89.3 (11.9) 0.88 (0.09) 0.54 (0.07)
TPA quartile 2 726 27.1 (4.3) 91.2 (12.3) 0.89 (0.09) 0.55 (0.07)
TPA quartile 3 727 26.6 (3.9) 90.8(11.7) 0.90 (0.09) 0.54 (0.07)
TPA quartile 4 726 26.7 (4.0) 93.2 (11.7) 0.92 (0.08) 0.55 (0.07)
Data are mean values with standard deviations.
BMI: body mass index, WC: waist circumference, WHR: waist-to-hip ratio, WHtR: waist-to-hight ratio, TPA: total plaque area.
a Only the participants with all adiposity variables and covariates are used in this table.
Table 3
The association between sex-speciﬁc standardized adiposity scores and the presence of plaque (Yes/No) using logistic regression: this analysis is restricted to participants with
non-missing presence of plaque variable and all variables in the model (n¼ 4906). The Tromsø Study 2001-2002.
Model 1 OR (95%CI) p-value Model 2 OR (95%CI) p-value Model 3 OR (95%CI) p-value
st BMI 0.98 (0.92, 1.04) 0.45 1.03 (0.96, 1.09) 0.45 0.95 (0.88, 1.01) 0.11
st WC 0.98 (0.92, 1.05) 0.58 1.01 (0.95, 1.08) 0.79 0.92 (0.86, 0.99) 0.03
st WHR 1.08 (1.01, 1.15) 0.02 1.07 (1.01, 1.15) 0.03 1.01 (0.94, 1.08) 0.87
st WHtR 1.02 (0.96, 1.08) 0.57 1.04 (0.98, 1.11) 0.21 0.96 (0.90, 1.03) 0.28
St BMI:standardized body mass index, st WC: standardized waist circumference, st WHR: standardized waist-to-hip ration, st WHtR: standardized waist-to-height ratio, OR:
odds ratio, 95% CI: 95% conﬁdence interval, SD: standard deviation.
Model 1: adjusted for age and sex, Model 2: adjust for variables in Model 1 plus other confounders (smoking and education), Model 3: adjusted for variables in Model 2 and
mediators (systolic blood pressure, HDL cholesterol, LDL-cholesterol, glycated hemoglobin).
Table 4
The association between sex-speciﬁc standardized adiposity scores and log-transformed TPA using linear regression: this analysis is restricted to participants with plaque and
all variables in the model (n¼ 2906). The Tromsø Study 2001-2002.
Model 1 b (95%CI) p-value Model 2 b (95%CI) p-value Model 3 b (95%CI) p-value
st BMI 0.012 (0.015, 0.039) 0.38 0.032 (0.004, 0.059) 0.02 0.002 (0.026, 0.031) 0.87
st WC 0.031 (0.005, 0.058) 0.02 0.042 (0.015, 0.068) 0.002 0.012 (0.017, 0.040) 0.42
st WHR 0.056 (0.029, 0.083) <0.001 0.055 (0.028, 0.081) <0.001 0.030 (0.002, 0.058) 0.04
st WHtR 0.038 (0.011, 0.065) 0.005 0.046 (0.019, 0.073) 0.001 0.017 (0.012, 0.045) 0.26
St BMI: standardized body mass index, st WC: standardized waist circumference, st WHR: standardized waist-to-hip ratio, st WHtR: standardized waist-to-height ratio, b:
regression coefﬁcient, 95% CI: 95% conﬁdence interval, SD: standard deviation.
Model 1: adjusted for age and sex, Model 2: adjust for variables in Model 1 plus other confounders (smoking and education), Model 3: adjusted for variables in Model 2 and
mediators (systolic blood pressure, HDL cholesterol, LDL-cholesterol, glycated hemoglobin).
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Several studies investigated the association between multiple
adipositymeasures and IMTand compared the effect size. However,
their results are inconsistent. After adjustment for traditional CVD
risk factors, some studies showed abdominal obesity was more
strongly associated with IMT [30,31] while in one study BMI
showed the largest effect size [9]. In another study, BMI and WC
showed the same effect size [32]. It seems which anthropometry
measure is the most strongly associated with IMT is still
inconclusive.
The potential importance of our ﬁnding that TPA is associated
with adiposity is underlined by the fact that it has been found to be
predictive of CVD events. Spence et al. investigated 1686 patients
from an atherosclerosis prevention clinic and showed that those in
the top TPA quartile had nearly three times the odds of stroke and
myocardial infarction compared to those in the ﬁrst TPA quartile
after 5-year follow up [18]. The Tromsø Study compared the asso-
ciations between myocardial infarction and stroke with IMT and
TPA. TPAwas a strong predictor of future myocardial infarction and
stroke, while IMT at the common carotid artery was not associated
with future events [19,34]. Sillesen et al. showed that plaque
burden was more strongly associated with coronary artery calcium
score than IMT [35].
One of our most striking results is that the association of
adiposity with the burden of carotid plaque is strongly attenuated
by adjustment for biological factors that are plausible mediators of
this association. Because our study is cross-sectional it is not
possible to describe this as deﬁnitive evidence of mediation, but it
is consistent with such an interpretation. Looking at the larger
literature on mediators of the association between obesity and CVD
events, a recent pooled-analysis using 97 cohort studies showed
that half of the risk of coronary heart diseases and stroke was
mediated by blood pressure, cholesterol, and glucose [36]. A more
recent report from the ARIC study suggested that the association of
obesity with coronary heart disease was fully explained by tradi-
tional mediators [37]. These results taken overall suggest that strict
control of traditional CVD risk factors including lipids and blood
pressure could substantially mitigate the harmful effect of obesity
on carotid atherosclerosis.
When comparing the effect sizes of four different adiposity
measures, WHR showed the largest effect size with a signiﬁcant
association with log-TPA followed byWHtR. While these estimated
effects have wide and overlapping conﬁdence intervals and thus
any differences need to be treated cautiously, our results do suggest
that central (visceral) obesity may play a more important role than
obesity as measured by BMI. Visceral adipose tissue is known to
pose a greater risk for CVDwith its stronger associationwith insulin
resistance and dyslipidemia than total fat and subcutaneous adi-
pose tissue [38,39]. It has also been suggested that the visceral
adipose tissue contributes to the progress of atherosclerotic change
[40].
Our study has some limitations. Firstly, the cross-sectional
design does not allow conclusions concerning causality. Secondly,
TPA is essentially a 2-dimensional proxy for the volume of a 3-
dimensional plaque structure. While this may result in measure-
ment error relative to a better assessment of plaque volume, using
3-dimensional ultrasound or MRI for example, this is unlikely to
bias the strength of association with plaque size as long as this is a
random measurement error in the outcome variable [47]. Thirdly,
we only had data available for the right carotid artery. However, this
is unlikely to have generated bias as there is no reason to believe
that the strength of association between adiposity and plaque will
differ between right and left carotid. Fourthly, the prevalence of
plaque was relatively high in our population. This may be because
participants were relatively old and the study was conducted in
2001-02 when the CVD event rate in the population was
appreciably higher [48]. To this extent, whether the strength of
association we report here is generalizable to contemporary pop-
ulations is a matter for further investigation. Finally, a particular
strength of our study is that the data are from a large population-
based study with a high response rate.
In summary, our results suggest that adiposity measures
reﬂecting abdominal obesity such as WHR may be more closely
associated with plaque burden than the traditional measure of BMI,
and that these effects may be mediated by established biological
risk factors such as blood pressure and lipids. Although further
studies are needed to investigate the usefulness of these adiposity
measures as predictors for an individual in a clinical setting
assessment of these measures may help to identify a high-risk
group with advanced carotid plaque. Further research is desirable
to investigate the prospective association between adiposity and
carotid plaque burden. It has been suggested that TPA could capture
the progress of atherosclerosis more sensitively than IMT because
longitudinal plaque growth is faster than its growth toward the
lumen [13,51]. This would make TPA suitable for prospective
studies.
4.1. Conclusion
Adiposity is more consistently associated with extent of plaque
burden than with whether an individual does or does not have any
plaque. Abdominal adiposity appears to show the strongest effects.
There was evidence that established biomarkers mediate much of
this association. It would be useful to examine the prospective ef-
fect of abdominal obesity on the progress of carotid atherosclerosis
in a cohort study.
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6.3 Summary 
 There was strong evidence of an association between adiposity and carotid plaque
burden (TPA) after adjustment for potential confounders (sex, smoking, education).
 The associations between adiposity and carotid plaque burden appeared to be
mediated by cardio-metabolic CVD risk factors to a large extent.
 Abdominal adiposity seemed more strongly associated with plaque burden than
general adiposity. In particular, waist-to-hip ratio showed the largest effect size
among four adiposity measures.
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7 How does obesity in adults affect the progression of carotid 
atherosclerosis in the general population?   (Paper 2) 
7.1 Introduction 
In this chapter, I present a prospective association between four anthropometric adiposity 
measures and the progression of carotid atherosclerosis (new plaque formation, number of 
plaques, total plaque area (TAP)) in a general population in Norway. Data from the Tromsø 
Study fourth (1994-95), fifth (2001-02), and sixth (2007-08) surveys were used in this 
analysis. 
In the previous chapter, based on the Tromsø Study fifth survey, I reported evidence of an 
association between adiposity, especially abdominal adiposity, and carotid plaque burden, 
which was largely mediated by cardio-metabolic CVD risk factors. In this chapter, I will 
extend this analysis to strengthen the findings observed in the previous chapter.  
7.2  Submitted paper 
89
SECTION D - Multi-authored work 
For multi-authored work, give full details of 
your role in the research included in the 
paper and in the preparation of the paper. 
(Attach a further sheet if necessary) 
SECTION E . 
Student Signature y lt1rv'\ e_,,,
Date )' 
I 
Supeovisor Signature 
Date 
Improving health worldwide 
f'/Cllv 
I conceptualized, conducted the analyses, wrote the first 
draft, coordinated all comments by co-authors, and was 
primarily responsible for the final draft .. 
), )Y\f\ � tJ v ; 
20 1 1 
Page 2 of 2 www.lshtm.ac.uk 
90
Yume Imahori 
91 
Title: How does obesity in adults affect the progression of carotid atherosclerosis in the 
general population?   
Running title: Obesity and the progression of carotid atherosclerosis 
Authors names  
Yume Imahori a , Ellisiv B. Mathiesen b  , Katy E. Morgan c , Chris Frost c , Alun D. Hughes d, 
Laila A. Hopstock e , Stein Harald Johnsen b ,  Nina Emaus f , David A. Leon a,e
Departments and institutions 
aDepartment of Non-communicable Disease Epidemiology, Faculty of Epidemiology and 
Population Health, London School of Hygiene & Tropical Medicine,WC1E 7HT, UK;  
bDepartment of Clinical Medicine, UiT The Arctic University of Norway, Tromsø and  
Department of Neurology, University Hospital of North Norway, 9037,Tromsø; Norway; 
c Department of Medical Statistics, London School of Hygiene & Tropical Medicine, WC1E 
7HT, UK; 
d Department of Population Science & Experimental Medicine, & MRC Unit for Lifelong 
Health and Ageing, University College London, WC1E 6BT, UK; 
e Department of Community Medicine, Faculty of Health Sciences, UiT The Arctic 
University of Norway, Tromsø, 9037, Norway; 
f Department of Health and Care Sciences, Faculty of Health Sciences, UiT the Arctic 
University of Norway, Tromsø ,9037, Norway 
Keywords: obesity, abdominal obesity, atherosclerosis, carotid plaque, epidemiology 
Contact info:  
Yume Imahori, MD 
Department of Non-communicable Disease Epidemiology, Faculty of Epidemiology and 
Population Health, London School of Hygiene & Tropical Medicine, Keppel Street, London 
WC1E 7HT, UK 
Tel: +44(0)7597647944 Email: yume.imahori@lshtm.ac.uk 
Competing interests statement: The costs of provision of the data analysed in this paper 
were met by the International Project on Cardiovascular Disease in Russia that was funded 
from several sources: the Welcome Trust (Strategic Award 100217); Arctic University of 
Norway, UiT The Arctic University of Norway in Tromsø, Norwegian Institute of Public 
Health; the Norwegian Ministries of Health and Foreign Affairs 
Disclosure: The authors declared no conflict of interest 
Author contributions: YI undertook the analyses and drafting of the manuscript. KM and 
CF advised on statistical methods and analysis. CF, DAL, EM, AH provided ongoing 
Yume Imahori 
92 
guidance during drafting. All authors commented on drafts of the paper and approved the 
final manuscript 
Yume Imahori 
93 
Abstract 
Background/Objectives: Few reports are available on the contribution of general and 
abdominal obesity to the progression of carotid atherosclerosis in late adulthood. This study 
investigated the impact of four simple anthropometric measures of general and abdominal 
obesity on the progression of carotid atherosclerosis and to what extent the association 
between adiposity and the progression of plaque burden is mediated by metabolic markers. 
Methods: 4345 adults (median age 60) from the population-based Tromsø Study were 
followed over 7 years from the first carotid ultrasound screening to the next. The progression 
of carotid atherosclerosis was measured in three ways: incidence of plaques in previously 
plaque-free participants, change in the number of plaques, and total plaque area (TPA). We 
used generalized linear models to investigate the association between each adiposity measure 
(body mass index (BMI), waist circumference (WC), waist-to-hip ratio (WHR) and waist-to-
height ratio (WHtR)) and each outcome. Models were adjusted for potential confounders 
(age, sex, smoking, education, physical activity). The pathways through which any 
associations observed might operate were investigated by further adjusting for physiological 
metabolic mediators (blood pressure, blood lipids and HbA1c). 
Results: There was little evidence that adiposity was related to the formation of new plaques 
during follow-up. However, abdominal adiposity was associated with TPA progression. 
WHtR showed the largest effect size (mean change in TPA per 1 SD increase in WHtR of 
0.665 mm2, 95% confidence interval 0.198, 1.133) while BMI showed the smallest. Effect 
sizes were substantially reduced after the adjustment for potential mediators. 
Conclusions: Abdominal obesity seems more strongly associated with the progression of 
carotid atherosclerosis than general obesity. These associations appear largely mediated by 
known physiological -metabolic markers.   
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Introduction 
Obesity is a global epidemic. In 2016, 39% of adults worldwide were estimated to be 
overweight, and 13% obese (99). The global prevalence of obesity has almost tripled over the 
last 30 years and continues to increase (99). This trend is of substantial concern, as obesity is 
associated with an increase in cardiometabolic disorders and cardiovascular disease (CVD), 
the leading cause of death worldwide.  Paradoxically, over this period, the burden of CVDs has 
been decreasing in industrialised countries (21, 22). However, the current increase in obesity 
could offset or reverse the downward trend of CVD mortality in spite of the decrease in the 
prevalence of other traditional CVD risk factors such as smoking and hypertension (22). A 
recent analysis of US data has suggested that if BMI had not increased, life expectancy in 2011 
at age 40 would be 0.9 years higher than was actually the case (171), which in part would be 
due to a slowdown in the rate of decline of CVD mortality (172). 
Atherosclerosis is a major cause of CVD. Carotid atherosclerosis is easily and non-invasively 
detected using the ultrasound. Carotid intima-media thickness (IMT) consistently predicts 
future CVD events, but carotid plaque outperforms IMT regarding its predictive ability of 
future CVD (14). Most previous studies on the association between obesity and carotid 
atherosclerosis in adults have been cross-sectional. Relatively few studies have attempted to 
look at this relationship prospectively. One population study investigated the association 
between lifetime BMI and carotid intima-media thickness (IMT) in late adulthood and showed 
that reduction in BMI category was associated with a decrease in IMT (173). Several others 
have investigated determinants of carotid plaque progression including obesity as one of the 
potential factors (133, 174-176).  
If there is evidence of obesity influencing progression, this is of direct relevance to clinical 
management in adulthood. Also, compared to general obesity (the exposure in most previous 
studies), abdominal obesity might play a more important role in progression because of its 
stronger association with cardio-metabolic diseases (177). 
In an earlier investigation of cross-sectional data from the population-based Tromsø Study, we 
have shown that abdominal obesity was more closely associated with carotid plaque burden 
assessed by total plaque area (TPA) than general obesity (178). We also found that 
physiological cardio-metabolic risk factors such as hyperlipidemia, glucose intolerance, and 
hypertension mediated much of this association. The aim of the current analysis is to extend 
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these investigations to determine whether progression of carotid plaque burden over a 7-year 
period is related to different measures of obesity in the Tromsø Study, and how far any 
indication of such an association is mediated by the same set of cardio-metabolic risk factors.  
Method  
Study design and participants 
The Tromsø Study (157) is an on-going population-based prospective cohort study based on 
the population of the municipality of Tromsø in North Norway, consisting of seven surveys 
from 1974-2016 (Tromsø 1-7).  
Baseline (1994-95): The Tromsø Study the fourth survey (the 4th survey) conducted in 1994-
95 is the largest survey so far inviting everyone aged 25 years and above living in the Tromsø 
municipality. Among the 4th survey participants, all those aged 55-74, plus sampling fractions 
between 5 and 10% from other age groups, were eligible for a second visit with extensive 
clinical examinations including carotid ultrasound, with 76% (n=6727) attending.  (179). All 
the 4th survey second visit participants were invited to the 5th (2001) and 6th (2007-08) survey 
for the follow-up ultrasound examination. 
7-year follow-up at the 5th Survey (2001): All 4th survey second visit participants, except
those who died (n=499) or moved from Tromsø (n=372), were invited to the 5th survey
ultrasound examination  (n=5856), with 83% attending (n=4858), i.e., 72% of the participants
from the 4th survey second visit were rescanned. After excluding participants without valid
written consent (n=29) and with missing data on the main covariates (n=484), 4345
participants were included in the current analysis of the7-year  follow-up (1994-2001) data.
14-year follow-up at the 6th Survey (2007-08): All the 4th survey second visit participants
except those who died (n=1515) or moved from Tromsø (n=468) were also invited to the 6th
survey ultrasound examination (n=4744), with 63% attending (n=2975), i.e., 44% of the
participants from the 4th survey were rescanned. After excluding those who withdrew their
consent (n=1) or had missing covariates (n=289), 2685 participants with complete repeated
measurements were eligible for the current analysis of 14-years follow-ups (1994-2008) data.
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The Regional Committee for Research Ethics and The Norwegian Data Inspectorate have 
approved the Tromsø Study study. All participants included in the present study have given 
written informed consent. 
Measurement of obesity and other CVD risk factors: the baseline 4th survey (1994-95) 
Height and weight were measured with light clothing and without shoes using standard 
methods. Waist circumference (WC) was measured at the level of the umbilicus while hip 
circumference was measured at the widest part of the thigh to the nearest 0.5 cm. BMI was 
calculated by dividing body weight by height squared. Waist-to-hip-ratio (WHR) and waist-to-
height-ration (WHtR) were calculated by dividing WC by hip and height, respectively. 
Categorical adiposity variables were created with three BMI levels (normal: BMI<25 kg/m2, 
overweight: 25<=BMI<30 kg/m2, obesity: 30 kg/m2≤MI), two WC levels (abdominal obesity: 
men>102 cm, women>88 cm), and two WHR levels (abdominal obesity: men>=0.9, 
women>=0.85) according to WHO cut-off points (180). 
Information on current smoking (yes/no), education level (primary education, vocational/high 
school, university/college), physical activity (hours spent on leisure physical activity 
(sweating/out of breath) per week in leisure time: none, less than 1, 1-2, 3 or more) and medical 
history (myocardial infarction, angina pectoris, stroke, diabetes) were obtained by self-
administered questionnaires. Non-fasting serum total cholesterol, triglycerides, and high-
density lipoprotein cholesterol (HDL-C) were determined using standardised methods. Low-
density lipoprotein cholesterol (LDL-C) was calculated using the Friedewald equation. HbA1c 
was measured using the Cobas Mira instrument. Blood pressure was measured seated three 
times with one-minute interval between readings after 1 min seated rest using an automatic 
device (Dinamap Vital Signs Monitor 1846; Critikon Inc., Tampa, FL, USA). The average of 
the last two blood pressure measurements was used in the analysis.  
Ultrasound examination: the 4th -6th survey (1994-2008) 
The right carotid artery was scanned in the far and near wall of the common carotid artery, 
bifurcation, and internal carotid artery to seek for carotid plaques using an Acuson Xp 10 128 
ART ultrasound scanner equipped with a 7.5 MHz linear-array transducer in the 4th and 5th 
surveys, and a GE Vivid 7 scanner with a linear 12 MHz transducer in the 6th survey, as 
previously described (167, 181). The same protocol was used at all surveys.  Carotid plaque 
was defined as a focal structure encroaching into the arterial lumen at least 0.5 mm or 50% of 
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the surrounding intima-media thickness (IMT) value or IMT >1.5 mm as measured from the 
media-adventitia interface to the intima-lumen interface. Cine loops and still images of each 
carotid plaque in the longitudinal plane were stored and digitalised for offline analysis. All 
plaque images were outlined manually to assess plaque areas using the Adobe Photoshop 
imaging-procession programme (ver. 7.0.1). When there were multiple plaques, all plaque 
areas were summarised to calculate total plaque area (TPA). Inter-equipment variability and 
intra-reader and inter-reader re-reproducibility of plaque detection and measurement of 
plaque area were acceptable (167, 181).  
Statistical analysis 
Primary analysis: changes from the baseline 4th survey to the 5th survey (1994-2001): 
Baseline characteristics were summarized as means with standard deviations (SD) (or medians 
with the inter-quartile range if markedly non-normally distributed) for continuous variables, 
and counts and frequencies (percentages) for categorical variables. 
We used three outcomes to assess the progression of carotid atherosclerosis: new plaque 
formation (binary yes/no) in those without plaque at baseline, change in the number of plaques 
from baseline to follow-up, and change in TPA over the same period.  
We converted each adiposity measure at baseline to sex-specific standardised adiposity scores 
by subtracting the sex-specific mean of each measure from the observed value and then 
dividing by the sex-specific SD.  
The association between new plaque formation and each adiposity measure was examined 
using a series of logistic regression models. The effect of each adiposity measure on the change 
in the number of plaques/TPA was estimated using analogous linear regression models. Due to 
concerns over normality assumptions, bias-corrected and accelerated bootstrap confidence 
intervals (CI) were estimated from 10000 bootstrap resamples for all linear regression models. 
However, the differences between these and standard CIs tended to be relatively small, and 
since bootstrapping precludes reporting of p-values, we present standard CIs in the results 
section.  
Separately for each outcome variable and each adiposity measure, we fitted a sequence of three 
models. We selected potential confounders and mediators a priori based on evidence of the 
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association between obesity and CVD.   Model 1 was adjusted for age (categorical 5-year 
interval) and sex. Model 2 was further adjusted for the other potential behavioural and socio-
demographic confounders: smoking, physical activity, and education, this being our main 
model for estimating the association between adiposity and the progression of atherosclerosis. 
To assess the extent to which any observed associations in model 2 might be mediated by 
physiological cardio-metabolic risk factors, model 3 further adjusted for the following potential 
mediators systolic blood pressure, HDL-C, LDL-C, and glycated haemoglobin as continuous 
variables, and antihypertensive- and lipid-lowering drug use and existing diabetes as binary 
variables.  
All the above models were refitted separately adding interactions with age and sex. None of 
the interactions was statistically significant (results not reported). STATA version 14 (Stata 
Corp) was used for all analysis. 
Secondary analyses: changes from the baseline 4th survey to the 6th survey (1994-2008): 
We conducted parallel analyses to those above using the 6th survey follow-up data (2008). In 
planning this study, we had intended to focus equally on this analysis. However, having 
undertaken the analysis, the sample size was appreciably smaller after 14-year follow-up, and 
effect estimates markedly less precise than those from our 5th survey analysis. Therefore, we 
focus our presentation on the 5th survey analysis. As our initial intention was to include analyses 
from the 6th survey data and to avoid publication bias, analyses involving the 6th survey after 
14-year follow-up are reported only in supplementary tables, although the results were largely
uninformative.
Results  
Baseline characteristics 
Table 1 shows participant characteristics at baseline. The median age of participants was 60 
years (interquartile range 55-66), and 51% were women. Compared to the 4th survey second 
visit participants who did not attend the 5th  or 6th survey, the attending population was 
younger with a more favourable CVD risk profile (Tables S1-2). Adiposity measures were 
approximately normally distributed. According to the BMI classification, 44.4% and 13.4% 
of the participants were categorised as overweight and obesity, respectively. Increased WC 
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(men>=102 cm, women>=88 cm) was observed in 28.3% of the participants while 42.7% had 
increased WHR (men>=0.9, women>=0.85). Lipid-lowering drug use prevalence was 2.6%. 
At baseline, 46.2% of participants had at least one plaque. The median TPA in subjects with 
plaques was 15.7 mm2 in men and 12.7 mm2 in women.  
Carotid plaque burden at 7-year follow-up 
Table 2 shows carotid plaque burden at the 5th survey by category of adiposity 7 years earlier 
at the 4th survey.  At the 7-year follow-up, 62.2% of the participants had at least one plaque. 
Among the 2337 participants without plaque at the baseline 4th survey, 40% developed at 
least one new plaque. Median TPA increased from 0 mm2 at baseline to 8.9 mm2. Participants 
who belong to higher adiposity category were more likely to have higher plaque burden and 
more progression of plaque burden compared to those in lower categories. 
New plaque formation among participants without plaque at baseline (baseline – the 5th 
survey) 
Table 3 shows the odds ratios for developing at least one plaque at 7-year follow up among 
the 2337 participants without plaque at baseline per 1 SD increase in each adiposity index. 
After adjustment for confounders (model 2), all estimated odds ratios were small and non-
significant.  
Progression of plaque number (baseline – the 5th survey) 
Table 4 shows the estimated changes in the number of plaques per 1 SD increase in each 
adiposity measure at baseline. After adjustment for confounders (model 2), no adiposity 
measure except for WHR was significantly associated with changes in the number of plaques. 
 Progression of TPA (baseline – the 5th survey) 
Table 5 shows the estimated changes in TPA per 1 SD increase in each adiposity measure at 
baseline. After adjustment for confounders (model 2), there were statistically significant 
associations between the progression in TPA and all adiposity measures except for BMI. 
WHtR showed the largest regression coefficient, followed by WHR, and BMI showed the 
smallest. After further adjustment for potential mediators (model 3), all effect sizes decreased 
substantially, and all became non-significant.  
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14-year follow-up (baseline - the 6th survey)
Analogous tables to those above for the 6th survey follow-up data are shown in Tables S3-5. 
These analyses included markedly fewer people than those for the 5th survey follow-up and 
effect estimates were consequently considerably less precise with wide CIs.  
Discussion 
In this 7-year follow-up of a population-based sample of women and men in late adulthood, 
we found that abdominal obesity was more strongly associated with progression of carotid 
plaque burden than general obesity. New plaque formation among participants without plaque 
at baseline was however not associated with any adiposity measures. Furthermore, all 
significant associations observed were in part mediated by cardio-metabolic risk factors.  
The progression of carotid plaque burden and obesity 
Our results suggest that abdominal obesity in late adulthood might contribute to the 
progression of carotid plaque burden with larger effect estimates than general obesity, 
imposing an excess risk on the progression of atherosclerosis. This finding concurs with our 
previous findings from a cross-sectional analysis, although considerable overlap of CIs 
prevents us from drawing definitive conclusions (178).  
Several previous studies have investigated the effect of general obesity on the progression of 
carotid atherosclerosis (133, 174, 175). Herder et al. investigated the determinants of the 
progression of IMT and TPA after 13 years follow-up; in this study, BMI at baseline did not 
predict progression of either (133). Similarly, van der Meer et al. showed that BMI was not 
associated with an increase in plaque number over an average follow-up of 6.5 years (174). 
Molino-Lova et al. showed that overweight/obesity according to BMI category was not 
associated with the new formation of plaque in 486 elderly participants without plaque at 
baseline over a 3 year follow-up period (175). All these findings agree with the relatively 
weak association between BMI and the progression of atherosclerosis in our analysis. 
On the other hand, not much has been done to clarify the influence of abdominal obesity on 
the progression of carotid atherosclerosis. One prospective study (n=1894) with 4-year 
follow-up showed that an increase in WC was one of the determinants of the new formation 
of plaque among 462 participants without plaque at baseline after adjustment for age, sex, 
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and follow-up time while BMI was not (176). However, neither was a determinant of the 
progression of TPA. In the Rotterdam Study, the determinants of the progression of the 
number of plaques were analyzed in 3409 participants after the 6.5-year follow-up. An 
increase in WHR was associated with an increase in the number of plaques after adjustment 
for traditional CVD risk factors. Again, BMI was not associated with increases in the number 
of plaques (174).  Although a direct comparison of their findings with ours is difficult due to 
differences in statistical methods and adjustments, the potentially stronger effect of 
abdominal obesity compared to general obesity is consistent with our results. 
Other prospective studies 
The objectives of the studies mentioned above were to investigate the determinants of the 
progression of atherosclerosis (133, 174, 176) or the association between other main 
exposures than obesity and atherosclerosis (175). When restricted to studies directly 
investigating the association between obesity and atherosclerosis, there is some evidence that 
IMT in adulthood may partly reflect childhood obesity (141, 143, 182-185). However, the 
question of whether or not the development or progression of carotid plaque in adult life is 
related to obesity in early life has not been investigated.  
General and abdominal obesity 
Most previous studies have used BMI to assess obesity. However, it does not provide 
information about the fat distribution. Abdominal obesity, reflecting excess visceral adipose 
tissue, has a stronger association with insulin resistance and dyslipidemia than general 
obesity (177). Regarding whether abdominal obesity is more strongly associated with CVD 
than general obesity, evidence from observational studies is inconsistent. The Emerging Risk 
Factors Collaboration analysed 221,934 individuals from 58 cohorts and found that BMI, 
WC, and WHR were all associated with CVD risk, and the authors concluded that their effect 
sizes were similar (63). 
On the other hand, some studies suggest a stronger effect of abdominal obesity than general 
obesity. The INTERHEART Study, a large multicentre case-control study with 12,461 
myocardial infarction cases, suggested that increased WHR was more strongly associated 
with the occurrence of myocardial infarction than BMI (115). Further, the recent 
INTERSTROKE Study showed a stronger association of WHR than BMI with stroke (116). 
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Recently, two large Mendelian randomisation studies have shed light on the effect of 
abdominal obesity on CVD (124, 125). Dale et al. analysed data from 14 prospective studies 
with 66,842 coronary heart disease cases and 12,389 ischemic stroke cases, and compared 
associations of genetic risk scores for BMI and WHR adjusted for BMI with various cardio-
metabolic risks. The results showed that WHR might have a stronger effect on coronary heart 
disease and stroke than BMI. In particular, only WHR was associated with increased risk of 
ischemic stroke (125). Another study with 111,986 participants from UK Biobank showed 
that a genetic disposition to higher WHR adjusted for BMI was associated with type 2 
diabetes and coronary heart disease, supporting causal relationships (124). These findings 
emphasise the important role of abdominal obesity. Using BMI may lead to underestimation 
of the true risk of obesity for CVD. 
TPA and the number of plaques 
In the present study, associations were more statistically significant in the analyses using 
TPA as an outcome than those using the number of plaques. It is expected that continuous 
plaque variables such as TPA and total plaque volume (TPV) can capture the small change in 
plaque over time more easily than a simple categorical plaque variable, requiring smaller 
sample sizes and potentially shorter follow-up time to detect significant changes. Further, it 
has been suggested that TPA is likely to be more sensitive to the progression of 
atherosclerosis than the more commonly studied outcome of IMT because plaque grows 
along the axis of the artery 2.4 times faster than it changes in thickness (44). One study with 
349 atherosclerotic patients compared the predictive ability of future CVD events among 
TPV, TPA, and IMT after 5-year follow-up (186). Progression of TPV was significantly 
associated with CVD events after the adjustment for traditional CVD risk factors. Although 
the predictive ability of TPA was inferior to TPV, TPA performed better than IMT. While 
TPV is more sensitive to the progression with its three-dimensional information, TPA would 
be sensitive enough to detect the progression of plaque burden within a reasonable timeframe, 
which makes TPA an attractive outcome in large population-based studies. 
The formation of new plaque among participants without plaque at baseline 
New plaque formation was not associated with any adiposity measures. Considering that our 
sample were in late adulthood, having no plaque at baseline might mean that participants are 
to some extent resistant to atherosclerotic changes due to genetic or other reasons. This might 
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contribute to the slower progression of carotid atherosclerosis and make it difficult to detect 
changes in this population. Another potential explanation is lack of power: by restricting the 
analysis to participants without plaque at baseline, the sample size was almost halved.  
Besides, like the number of plaques variable, binary plaque variable provides less statistical 
information on the progression of plaque burden than a continuous plaque variable capturing 
size such as TPA.  
The contribution of mediators: 
All effect sizes of observed associations between obesity and the progression of plaque 
burden in the main analysis were substantially reduced after the adjustment for cardio-
metabolic risk factors in model 3, and no associations remained significant. This finding is 
supported by previous studies where strong determinants of the progression of carotid plaque 
burden included systolic blood pressure and total cholesterol (133, 174). Our finding 
validates that the pathway from obesity to carotid atherosclerosis is at least in part through 
cardio-metabolic risk factors. 
Recent studies with CVD mortality as an outcome also showed the risk of obesity for 
atherosclerotic CVD is largely or fully mediated by these cardio-metabolic risk factors (128, 
187). These findings suggest that the strict control of cardio-metabolic risk factors might in 
part attenuate the risk of obesity on the progression of atherosclerosis. Interventions to bring 
long-term and sustained weight loss through lifestyle change have not been uniformly 
successful (31, 188). On the other hand, the effective treatment of cardio-metabolic risk 
factors is established, the strict control of which might reduce the indirect effect of obesity on 
atherosclerosis. Nevertheless, the treatment of obesity is vital to block any direct pathway to 
the progression of atherosclerosis and to control cardio-metabolic risk factors better (76). 
Because our main objective was to investigate the association between obesity and plaque 
burden with and without the adjustment for mediators as a whole, this did not require 
partitioning of the contribution of a specific mediator to the overall effect.    
Study strengths and limitations 
Our major strength is a large sample size with a relatively long follow-up period, which 
allowed us a reasonable estimation of the association between the progression of carotid 
atherosclerosis and obesity. Further, theTromsø Study is one of the few prospective studies 
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with repeated carotid plaque measurements. The use of the quantitative plaque variable TPA 
is another advantage.  
Our main limitation is a loss to follow-up. This might reduce the power of the study to detect 
associations between adiposity and the progression of carotid plaque burden. Further, 
selection bias may be introduced. Thus, the association should be interpreted with caution, as 
should generalisability to the whole population. Another limitation is the possibility of 
residual confounding. For example, we did not include the statin use in the model because the 
statin use was not common at the baseline. 
Furthermore, we did not consider subsequent changes in CVD risk factors and medications. 
Moreover, the abdominal obesity index that we used is a crude measure of abdominal adipose 
tissue. However, it is easily available in a real-world clinical setting. Further study using the 
reliable measurement of visceral adipose tissue would be informative. Finally, only the right 
carotid artery was assessed. 
Conclusion 
Abdominal obesity, especially WHtR and WHR, seems to be more strongly associated with 
the progression of carotid atherosclerosis than general obesity. These associations are largely 
mediated by established cardio-metabolic risk factors. 
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Table1. Participant characteristics at baseline (Tromsø Study the 4th survey: analysis restricted 
to participants with all covariates and outcomes at both 4th and 5th survey: n=4345) 
Variable Total (4345) Men (2114) Women (2231) 
Age (years) median(IQR) 60 (55-66) 60 (55-65) 61 (56-67) 
Female (%) 2231 (51.4) 
Anthropometric measures 
Height (cm) 168.5 (9.4) 175.6 (6.7) 161.8 (6.2) 
Weight (kg) 74.0 (13.0) 80.6 (11.5) 67.8 (11.2) 
BMI (kg/m2) 26.0 (3.7) 26.1 (3.2) 25.9 (4.2) 
WC (cm) 89.7 (11.0) 95.0 (9.0) 84.7 (10.5) 
WHR 0.87 (0.08) 0.92 (0.06) 0.82 (0.06) 
WHtR 0.53 (0.06) 0.54 (0.05) 0.52 (0.07) 
Categorical obesitya 
Normal (BMI<25 kg/m2) (%) 1836 (42.3) 803 (38.0) 1033 (46.3) 
Overweight (25<=BMI<30 
kg/m2)(%) 
1930 (44.4) 1087 (51.4) 843 (37.8) 
Obesity (BMI>=30 kg/m2) 
(%) 
579 (13.3) 224 (10.6) 355 (15.9) 
Abdominal obesity (WC: 
m>102 cm, w>88 cm) (%)
1226 (28.2) 449 (21.2) 777 (34.8) 
Abdominal obesity  
(WHR (%) m>0.9 f>0.85) 
1850 (42.6) 1245 (58.9) 605 (27.1) 
Potential confounders 
Smoker (%) 1290 (29.7) 657 (31.1) 633 (28.4) 
Physical activity (h/week) b 
 None 2666 (61.4) 1077 (51.0) 1589 (71.2) 
 Less than 1 673 (15.5) 381 (18.0) 292 (13.1) 
1-2 670 (15.4) 421 (19.9) 249 (11.2) 
 3 or more 336 (7.7) 235 (11.1) 101 (4.5) 
Education (%) 
Primary education 2229 (51.3) 910 (43.1) 1319 (59.1) 
Vocational/high school 1328 (30.6) 738 (34.9) 590 (26.5) 
University/college 788 (18.1) 466 (22.0) 322 (14.4) 
Potential mediators 
Systolic blood pressure 
(mmHg) 
143.4 (21.5) 143.6 (19.4) 143.2 (23.2) 
Total cholesterol (mmol/l) 6.69 (1.27) 6.51 (1.18) 6.85 (1.32) 
Triglycerides (mmol/l) 1.51 (0.88) 1.62 (0.96) 1.41 (0.79) 
HDL cholesterol (mmol/l) 1.52 (0.44) 1.37 (0.39) 1.66 (0.44) 
LDL cholesterol (mmol/l) 4.48 (1.17) 4.40 (1.09) 4.55 (1.22) 
HbA1c (%) 5.44 (0.63) 5.42 (0.57) 5.47 (0.68) 
Medical history/medication 
 Myocardial infarction 
 (%) 
197 (4.5) 156 (7.4) 41 (1.8) 
 Angina pectoris (%) 335 (7.7) 198 (9.4) 137 (6.1) 
 Stroke (%) 83 (1.9) 42 (2.0) 41 (1.8) 
 Diabetes (%) 96 (2.2) 46 (2.2) 50 (2.2) 
 Lipid lowering drug 
 use (%) 
114 (2.6) 64 (3.0) 50 (2.2) 
 Blood pressure  
 lowering drug use (%) 
515 (11.9) 248 (11.7) 267 (12.0) 
TPA at T4 (mm2) 
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median (IQR) 
 TPA Q1 0-0 0-0 0-0
 TPA Q2 0-0 0-4.0 0-0
 TPA Q3 0-12.9 4.0-16.2 0-10.4
 TPA Q4 12.9-135.1 16.2-135.1 10.4-121.2 
Number of plaques at T4 
(%) 
 0 2337 (53.8) 1027 (48.6) 1310 (58.7) 
 1 1268 (29.2) 655 (31.0) 613 (27.5) 
 2 534 (12.3) 295 (14.0) 239 (10.7) 
 3 147 (3.4) 95 (4.5) 52 (2.3) 
 4 49 (1.1) 35 (1.7) 14 (0.6) 
 5 9 (0.2) 7 (0.3) 2 (0.1) 
 6 1 (0.02) 1 (0.04) 
BMI: body mass index, WC: waist circumference, WHR: waist-to-hip ratio, WHtR: waist-to-height ratio, HDL: high-density 
lipoprotein, LDL: low-density lipoprotein, HbA1c: glycated haemoglobin, TPA: total plaque area 
aIncreased waist circumference (>102 cm for men, >88 cm for women) and increased WHR (>=0.9 for men, >=0.85 for 
women) are categorized according to WHO cut-off points (180). bHours spent on hard physical activity (sweating/out of 
breath) in leisure time. 
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Table2. Carotid plaque at the 5th survey (2001) according to adiposity category at the baseline 4th survey (1994-95) (n=4345) 
Total 
population 
BMI categoriesa WC categoriesa WHR categoriesa 
Carotid 
variable n/N (%) 
Normal 
n/N (%) 
Overweight 
n/N (%) 
Obesity 
n/N (%) 
Abdominal obesity Abdominal obesity 
No    n/N (%) Yes    n/N (%) No    n/N (%) Yes   n/N (%) 
At least one 
plaque at T5 
2704/4345 
(62.2) 
1078/1836 
 (58.7) 
1250/1930 
(64.8) 
376/579 
(64.9) 
1901/3119 
(61.0) 
803/1226 
 (65.5) 
1414/2495 
(56.7) 
1290/1850 
(69.7) 
New plaques 
at T5b 
938/2337 
 (40.1) 
374/1021 
 (36.6) 
450/1028 
(43.8) 
114/288 
(39.6) 
660/1703 
 (38.8) 
278/634 
(43.9) 
521/1454 
 (35.8) 
417/883 
(47.2) 
Number of 
plaques at T5 
0 1641 (37.8) 758 (41.3) 680 (35.2) 203 (35.1) 1218 (39.1) 423 (34.5) 1081 (43.3) 560 (30.3) 
1 1230 (28.3) 478 (26.0) 578 (30.0) 174 (30.1) 861 (27.6) 369 (30.1) 675 (27.1) 555 (30.0) 
2 869 (20.0) 361 (19.7) 378 (19.6) 130 (22.5) 614 (19.7) 255 (20.8) 463 (18.6) 406 (22.0) 
+3 605 (13.9) 239 (13.0) 294 (15.2) 72 (12.4) 426 (13.7) 179 (14.6) 276 (11.1) 329 (17.8) 
Change in 
number of 
plaques from 
T4 to T5 
Increased 442 (10.2) 181 (9.9) 198 (10.3) 63 (10.9) 304 (9.8) 138 (11.3) 243 (9.7) 199 (10.8) 
No change 2191 (50.4) 960 (52.3) 943 (48.9) 288 (49.7) 1612 (51.7) 579 (47.2) 1349 (54.1) 842 (45.5) 
Decreased 1712 (39.4) 695 (37.9) 789 (40.9) 228 (39.4) 1203 (38.6) 509 (41.5) 903 (36.2) 809 (43.7) 
Median (IQR) 
TPA at T5 
(mm2) 
8.9 (1-22.6) 7.5 (0-20.7) 9.7 (0-24.6) 10.9 (0-24.3) 8.3 (0-21.7) 10.4 (0-24.4) 6.6 (0-18.8) 12.5 (0-28.8) 
Change in 
TPA from T4 
to T5 (mm2) 
0 (0-12.1) 0 (0-10.6) 1.6 (0-13.1) 0.7 (0-12.1) 0 (0-11.5) 1.7 (0-13.5) 0 (0-9.3) 3.7 (0-15.2) 
Data are count and percentage for binary plaque and median and IQR for number of plaques and TPA. BMI: body mass index, T4: Tromsø Study the fourth survey, T5: Tromsø Study the fifth 
survey, TPA: total plaque area 
WC: waist circumference, WHR: waist-to-hip ratio, WHtR: waist-to-height ratio, TPA: total plaque area 
aBMI categories: normal <25.0 kg/m2, overweight 25.0-29.9 kg/m2, obesity >30 kg/m2 ,  abdominal obesity WC: >102 cm for men, >88 cm for women, WHR: >=0.9 for men, >=0.85 for 
women (categorized according to WHO cut-off points, b New plaques at T5: The number of participants who developed at least one plaque among participants without plaque at T4
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Table3. Odds ratios of having plaque at the 5th survey (2001) among participants without plaque at the baseline 4th survey (1994-95), by adiposity at 
the 4th survey (incident plaque when plaque is absent at the 4th survey) (n=2337)
Model 1 OR (95%CI) p-value Model 2 OR (95%CI) p-value Model 3 OR (95%CI) p-value
BMI (per 1 SD) 0.98 (0.89, 1.08) 0.75 1.03 (0.93, 1.13) 0.60 0.94 (0.85, 1.05) 0.29 
WC (per 1 SD) 1.01 (0.92, 1.11) 0.87 1.04 (0.94, 1.15) 0.44 0.96 (0.86, 1.07) 0.49 
WHR (per 1 SD) 1.06 (0.96, 1.16) 0.24 1.06 (0.97, 1.17) 0.20 1.01 (0.92, 1.12) 0.77 
WHtR (per 1 SD) 1.04 (0.94, 1.14) 0.49 1.07 (0.96, 1.18) 0.21 0.98 (0.87, 1.09) 0.68 
BMI: body mass index, WC: waist circumference, WHR: waist-to-hip ratio, WHtR: waist-to-height ratio, OR: odds ratio, 95% CI: 95% confidence interval, SD: standard deviation, Model 1: 
adjusted for age and sex, Model 2: adjust for variables in Model 1 plus other confounders (smoking, physical activity and education), Model 3: adjusted for variables in Model 2 and mediators 
(systolic blood pressure, HDL cholesterol, LDL cholesterol, glycated hemoglobin, diabetes, lipid and blood pressure lowering drug) 
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Table 4. The association between the change in the number of plaques between the baseline 4th survey (1994-95) and the 5th survey (2001) and a 1 SD 
increase in baseline adiposity (n=4345)
Model 1 β (95%CI) p-value Model 2 β (95%CI) p-value Model 3 β (95%CI) p-value
BMI  (per 1 SD) -0.016 (-0.047, 0.015) 0.32 0.004 (-0.028, 0.035) 0.82 -0.011 (-0.046, 0.023) 0.51 
WC (per 1SD) 0.001 (-0.030, 0.032) 0.97 0.014 (-0.017, 0.045) 0.38 0.002 (-0.031, 0.036) 0.89 
WHR (per 1 SD) 0.029 (-0.002, 0.060) 0.07 0.032 (0.001, 0.064) 0.04 0.028 (-0.005, 0.061) 0.09 
WHtR (per 1 SD) 0.010 (-0.021, 0.042) 0.52 0.024 (-0.008, 0.056) 0.14 0.013 (-0.021, 0.048) 0.45 
BMI: body mass index, WC: waist circumference, WHR: waist-to-hip ratio, WHtR: waist-to-height ratio, OR: odds ratio, 95% CI: 95% confidence interval, SD: standard deviation, Model 1: 
adjusted for age and sex, Model 2: adjust for variables in Model 1 plus other confounders (smoking, physical activity and education), Model 3: adjusted for variables in Model 2 and mediators 
(systolic blood pressure, HDL cholesterol, non-HDL cholesterol, glycated hemoglobin, diabetes, lipid and blood pressure lowering drug) 
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Table 5. The association between change in total plaque area (mm2) between the baseline 4th survey (1994-95) and the 5th survey (2001) and a 1 SD 
increase in baseline adiposity (n=4302)
Model 1 β (95%CI) p-value Model 2 β (95%CI) p-value Model 3 β (95%CI) p-value
BMI (per 1 SD) 0.184 (-0.298, 0.666) 0.45 0.412 (-0.077, 0.902) 0.10 0.005 (-0.525, 0.534) 0.99 
WC (per 1 SD) 0.468 (-0.014, 0.949) 0.06 0.608 (0.122, 1.094) 0.01 0.261 (-0.260, 0.782) 0.33 
WHR (per 1 SD) 0.698 (0.211, 1.185) 0.005 0.697 (0.209, 1.186) 0.005 0.471 (-0.038, 0.980) 0.07 
WHtR (per 1 SD) 0.614 (0.122, 1.106) 0.01 0.750 (0.252, 1.249) 0.003 0.397 (-0.138, 0.932) 0.15 
BMI: body mass index, WC: waist circumference, WHR: waist-to-hip ratio, WHtR: waist-to-height ratio, OR: odds ratio, 95% CI: 95% confidence interval, SD: standard deviation, Model 1: 
adjusted for age and sex, Model 2: adjust for variables in Model 1 plus other confounders (smoking, physical activity and education), Model 3: adjusted for variables in Model 2 and mediators 
(systolic blood pressure, HDL cholesterol, non-HDL cholesterol, glycated hemoglobin, diabetes, lipid and blood pressure lowering drug) 
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Table S1: Participant characteristics at the baseline 4th survey (1994-95) in those scanned at the 5th survey (2001) vs those not scanned at the 5th 
survey  
Continuous variable at the 
4th survey 
The 5th survey carotid 
scanned 
The 5th  survey carotid 
missing 
Adjusted for age, sex 
β (95%CI) 
p-value
Number 4829 1748 
Age (median) (year) 60 (55-66) 65 (58-70) -0.49 (-0.59, -0.39) <0.001 
Height (cm) 168.4 (9.4) 167.9 (9.6) 0.54 (0.19, 0.89) 0.003 
Weight (kg) 74.0 (13.1) 73.6 (14.5) 0.41 (-0.25, 1.06) 0.23 
BMI (kg/m2) 26.0 (3.8) 26.0 (4.5) -0.02 (-0.24, 0.19) 0.83 
WC (cm) 89.8 (11.1) 91.1 (12.3) -0.56 (-1.12, -0.01) <0.05 
WHR 0.87 (0.08) 0.88 (0.09) -0.008 (-0.012, -0.005) <0.001 
WHtR 0.53 (0.06) 0.54 (0.07) -0.005 (-0.009, -0.002) 0.002 
SBP (mmHg) 143.7 (21.6) 149.5 (24.5) -2.79 (-3.93, -1.65) <0.001 
Total cholesterol (mmol/l) 6.70 (1.27) 6.72 (1.38) -0.03 (-0.09, 0.04) 0.43 
Triglycerides (mmol/l) 1.52 (0.89) 1.65 (1.06) -0.13 (-0.18, -0.07) <0.001 
HDL cholesterol (mmol/l) 1.52 (0.44) 1.49 (0.46) 0.03 (0.00, 0.05) 0.03 
LDL cholesterol (mmol/l) 4.48 (1.17) 4.49 (1.27) 0.00 (-0.06, 0.06) 0.98 
HbA1c (%) 5.4 (0.6) 5.6 (0.8) -0.08 (-0.12, -0.04) <0.001 
TPA (median) 0 (0-13.1) 7.9 (0-22.9) -4.01 (-4.93, -3.09) <0.001 
Categorical variable at the 
4th survey 
Female (%) 2490 (51.6%) 829 (47.4%) 0.79 (0.71, 0.89) <0.001 
Plaque (1+ vs 0) 2229 (46.2%) 1031 (59.0%) 0.69 (0.61, 0.77) <0.001 
Current Smokers (vs non-
smokers) 
1456 (30.2%) 703 (40.2%) 0.57 (0.51, 0.64) <0.001 
Medical history 
Myocardial infarction 220 (4.6%) 187 (10.8%) 0.48 (0.39, 0.60) <0.001 
Angina pectoris 377 (7.8%) 237 (13.6%) 0.68 (0.57, 0.82) <0.001 
Stroke 100 (2.1%) 81 (4.7%) 0.56 (0.41, 0.76) <0.001 
Diabetes 114 (2.4%) 95 (5.5%) 0.52 (0.39, 0.69) <0.001 
BMI: body mass index, CI: confidence interval, HbA1c: glycated haemoglobin, HDL: high-density lipoprotein, LDL: low-density lipoprotein, OR: odds ratio, SBP: systolic 
blood pressure, TPA: total plaque area, WC: waist circumference, WHR: waist-to-hip ratio, WHtR: waist-to-height ratio, OR: odds ratio,  
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Table S2: Participant characteristics at the baseline 4th survey (1994-95): scanned at the 6th survey (2007-08) vs those who scanned at the 6th survey 
Variable at the 4th survey The 6th survey carotid 
scanned 
The 6th survey carotid 
missing 
Adjusted for age, sex 
 β (95%CI) 
p-value
Number 2974 3714 
Age (median) (year) 58 (53-63) 65 (59-70) -1.30 (-1.39, -1.21) <0.001 
Height (cm) 168.9 (9.3) 167.7 (9.6) 0.48 (0.14, 0.82) 0.005 
Weight (kg) 74.1 (12.7) 73.7 (14.1) 0.05 (-0.58, 0.67) 0.89 
BMI (kg/m2) 25.9 (3.5) 26.2 (4.3) -0.13 (-0.34, 0.08) 0.22 
WC (cm) 89.0 (10.7) 91.1 (12.0) -0.97 (-1.50, -0.44) <0.001 
WHR 0.86 (0.08) 0.88 (0.08) -0.009 (-0.013, -0.006) <0.001 
WHtR 0.53 (0.06) 0.54 (0.07) -0.007 (-0.011, -0.004) <0.001 
SBP (mmHg) 139.6 (20.0) 149.6 (23.4) -4.23 (-5.32, -3.13) <0.001 
Total cholesterol (mmol/l) 6.58 (1.24) 6.81 (1.33) -0.10 (-0.16, -0.03) 0.003 
Triglycerides (mmol/l) 1.49 (0.86) 1.61 (1.00) -0.11 (-0.16, -0.06) <0.001 
HDL cholesterol (mmol/l) 1.51 (0.43) 1.51 (0.45) 0.02 (-0.01, 0.04) 0.14 
LDL cholesterol (mmol/l) 4.39 (1.15) 4.56 (1.22) -0.07 (-0.13, -0.01) 0.02 
HbA1c (%) 5.4 (0.4) 5.6 (0.8) -0.10 (-0.14, -0.06) <0.001 
TPA (median) 0 (0-9.6) 7.2 (0-20.5) -3.62 (-4.50, -2.73) <0.001 
Categorical variable at the 4th 
survey 
Female (%) 1532 (51.5%) 1849 (49.8%) 0.80 (0.72, 0.89) <0.001 
Plaque (1+ vs 0) 1149 (38.6%) 2172 (58.5%) 0.67 (0.60, 0.75) <0.001 
Smokers 833 (28.0%) 1361 (36.7%) 0.48 (0.43, 0.54) <0.001 
Medical history 
Myocardial infarction 99 (3.3%) 315 (8.5%) 0.54 (0.42, 0.69) <0.001 
Angina pectris 153 (5.2%) 470 (12.7%) 0.59 (0.48, 0.72) <0.001 
Stroke 30 (1.0%) 153 (4.1%) 0.34 (0.22, 0.51) <0.001 
Diabetes 43 (1.5%) 170 (4.6%) 0.45 (0.31, 0.65) <0.001 
BMI: body mass index, CI: confidence interval, HbA1c: glycated haemoglobin, HDL: high-density lipoprotein, LDL: low-density lipoprotein, OR: odds ratio, SBP: systolic 
blood pressure, TPA: total plaque area, WC: waist circumference, WHR: waist-to-hip ratio, WHtR: waist-to-height ratio, OR: odds ratio 
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Table S3. Odds ratios of having plaque at the 6th survey (2007-08) among participants without plaque at the baseline 4th survey (1994-95), by 
adiposity at the 4th survey (incident plaque when plaque is absent at the 4th survey) (n=1639) 
Model 1 OR (95%CI) p-value Model 2 OR (95%CI) p-value Model 3 OR (95%CI) p-value
st BMI 1.05 (0.93, 1.18) 0.43 1.09 (0.96, 1.23) 0.18 0.99 (0.86, 1.13) 0.88 
st WC 1.06 (0.94, 1.20) 0.31 1.08 (0.96, 1.22) 0.19 1.00 (0.88, 1.15) 0.95 
st WHR 1.08 (0.97, 1.21) 0.17 1.08 (0.96, 1.21) 0.18 1.03 (0.91, 1.16) 0.67 
st WHtR 1.10 (0.97, 1.24) 0.13 1.12 (0.99, 1.27) 0.08 1.02 (0.89, 1.17) 0.82 
BMI: body mass index, WC: waist circumference, WHR: waist-to-hip ratio, WHtR: waist-to-height ratio, OR: odds ratio, 95% CI: 95% confidence interval, SD: standard deviation, Model 1: 
adjusted for age and sex, Model 2: adjusted for variables in Model 1 plus other confounders (smoking, physical activity and education), Model 3: adjusted for variables in Model 2 and mediators 
(systolic blood pressure, HDL cholesterol, non-HDL cholesterol, glycated hemoglobin, diabetes, lipid and blood pressure lowering drugs) 
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Table S4. The association between the change in the number of plaques between the baseline 4th survey (1994-95) and the 6th survey (2007-08)and a 1 
SD increase in baseline adiposity (n=2685)
Model 1 β  (95%CI) p-value Model 2 β (95%CI) p-value Model 3 β (95%CI) p-value
st BMI 0.005 (-0.036, 0.047) 0.81 0.019 (-0.023, 0.061) 0.39 0.014 (-0.031, 0.059) 0.55 
st WC 0.004 (-0.038, 0.045) 0.86 0.012 (-0.030, 0.054) 0.59 0.008 (-0.037, 0.053) 0.74 
st WHR 0.008 (-0.032, 0.048) 0.70 0.009 (-0.032, 0.049) 0.67 0.007 (-0.036, 0.049) 0.76 
st WHtR 0.012 (-0.030, 0.055) 0.58 0.020 (-0.023, 0.063) 0.37 0.016 (-0.031, 0.062) 0.51 
BMI:body mass index, WC: waist circumference, WHR: waist-to-hip ratio, WHtR: waist-to-height ratio, OR: odds ratio, 95% CI: 95% confidence interval, SD: standard deviation, Model 1: 
adjusted for age and sex, Model 2: adjusted for variables in Model 1 plus other confounders (smoking, physical activity and education), Model 3: adjusted for variables in Model 2 and mediators 
(systolic blood pressure, HDL cholesterol, non-HDL cholesterol, glycated hemoglobin, diabetes, lipid and blood pressure lowering drugs) 
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Table S5. The association between change in total plaque area (mm2) between the baseline 4th survey (1994-95) and the 6th survey (2007-08) and a 1 
SD increase in baseline adiposity  (n=1515)
In the 6th survey, participants without plaque are categorised as TPA missing data. Consequently, this analysis includes a smaller number of participants than 
that using change in the number of plaques between the 4th survey and the 6th survey 
Model 1 β  (95%CI) p-value Model 2 β (95%CI) p-value Model 3 β (95%CI) p-value
st BMI -1.009 (-2.172, 0.155) 0.09 -0.694 (-1.877, 0.489) 0.25 -0.971 (-2.233, 0.290) 0.13 
st WC -0.479 (-1.662, 0.704) 0.43 -0.269 (-1.464, 0.926) 0.66 -0.529 (-1.802, 0.743) 0.42 
st WHR -0.168 (-1.278, 0.943) 0.77 -0.122 (-1.235, 0.990) 0.83 -0.294 (-1.448, 0.859) 0.62 
st WHtR -0.801 (-2.010, 0.408) 0.19 -0.593 (-1.819, 0.633) 0.34 -0.895 (-2.193, 0.402) 0.18 
BMI:body mass index, WC: waist circumference, WHR: waist-to-hip ratio, WHtR: waist-to-height ratio, OR: odds ratio, 95% CI: 95% confidence interval, SD: standard deviation, Model 1: 
adjusted for age and sex, Model 2: adjusted for variables in Model 1 plus other confounders (smoking, physical activity and education), Model 3: adjusted for variables in Model 2 and mediators 
(systolic blood pressure, HDL cholesterol, non-HDL cholesterol, glycated hemoglobin, diabetes, lipid and blood pressure lowering drugs) 
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7.3 Potential further directions of analysis 
This paper focused on answering the clinically relevant question of whether adiposity level at 
baseline predicts the subsequent progression of carotid plaque burden. However, further 
analysis may focus on answering the slightly different question of whether any change in 
adiposity during the follow-up period is associated with a change in plaque burden. The use 
of change in adiposity will address rather an etiological question of whether an increase or a 
decrease in adiposity level – regardless of the baseline – is associated with the progression of 
plaque burden. While this is an interesting question, it is not the same as that addressed in this 
paper. It should also be noted that the interpretation of an association between the changes in 
two given variables is complex. Specifically, if the two variables are associated with each 
other at baseline, and if the change in each is associated with the baseline level (for example 
through regression to the mean), then this will induce an association between the two 
observed changes that is merely a consequence of these associations rather than representing 
a true relationship between the respective changes.  
All four adiposity scores were approximately normally distributed in men and women in both 
populations, with means that differed markedly particularly for women, but with similar 
standard deviations. To make comparisons between the two populations, standard deviation 
scores were created using the means and the standard deviations in the Norway data. 
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7.4 Summary 
 Findings from this prospective study with 7-year follow-up were generally consistent
with findings from the previous cross-sectional analysis.
 There was little evidence of an association of adiposity with the new formation of
plaque or a change in the number of plaques.
 There was evidence of an association between change in total plaque area and all
adiposity measures, except BMI.
 These associations are largely mediated by cardio-metabolic CVD risk factors.
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8 Comparison of adiposity in the Know Your Heart and Tromsø 
7 studies 
So far, I have investigated the association between carotid plaque and adiposity using data 
from the Tromsø Study. In the following two chapters, I report on comparisons based on data 
from two population-based studies: the Russian Know Your Heart Study (KYH) and the 
Tromsø Study seventh survey (Tromsø 7). I will present the anthropometric measures of 
adiposity and the prevalence of general and abdominal obesity in each study and compare 
them to understand the distribution of my main exposure adiposity in the two studies. 
First, I describe the methods followed by participant characteristics in KYH and Tromsø 7. 
Finally, anthropometric measures of adiposity and the prevalence of obesity are presented, 
and the two studies are compared. 
8.1 Method 
8.1.1  Study population 
Data sources reported in this chapter are KYH and the Tromsø 7 first visit. As described in 
chapter 4.2.2, Tromsø 7 comprises two stages: all residents over 40 years in Tromsø were 
invited to a first visit (visit 1) and a random sample, including participants in the previous 
survey, was invited to a second visit where more extensive clinical examinations including 
the carotid ultrasound were conducted. For this reason, in this analysis, all visit 1 participants 
were included, regardless of attendance at the carotid examination, to accurately determine 
the distribution of obesity in this population.  
Tromsø 7 includes participants aged over 40 years while KYH includes participants aged 
between 39 and 69 years. To make the two studies comparable, participants included in the 
analysis were restricted to those aged 40-69 years. In total, 4640 and 17649 participants were 
included in KYH and Tromsø 7, respectively. 
8.1.2  Adiposity and other variables 
As described in Chapter 5, all the anthropometric measurement methods were comparable 
across the two studies except for waist circumference (WC): in Tromsø 7, WC was measured 
at the level of the umbilicus, while it was assessed at the minimal point of the trunk in KYH. 
Therefore, WC in Tromsø 7 was converted to the minimum WC using the conversion 
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equation, and waist-to-hip ratio (WHR) and waist-to-height ratio (WHtR) in Tromsø 7 were 
calculated using this converted WC (161). The mean values of the original and converted WC 
in Tromsø 7, by age group and sex, are presented in Appendix A5. 
As described in detail in Chapter 5, three variables potentially related to adiposity and 
cardiovascular disease (CVD), education, physical activity, and available alcohol variables, 
were measured differently in the two studies, making comparison challenging. Thus, these 
data were presented as original variables in each study. 
8.1.3 Statistical methods 
Adiposity measures in each country 
Since there are marked sex differences in the amount of fat and fat distribution, all results are 
presented according to sex. Anthropometric measures in each study were summarised using 
mean (SD), and the prevalence of obesity was summarised using numbers and percentages 
according to sex. 
Comparison of anthropometric measures and the prevalence of obesity 
To perform a statistical comparison of anthropometric measures of adiposity and the 
prevalence of obesity in two studies, the pooled data from the KYH dataset and the Tromsø 7 
visit 1 dataset were analysed. Two types of outcome were used: four continuous adiposity 
measures of adiposity (BMI, WC, WHR, WHtR) and three binary variables of obesity using 
BMI, WC, and WHR cut-off points (BMI>=30 kg/m2: Yes/No, WC men>102 cm women>88 
cm: Yes/No, WHR men>=0.9 women>=0.85: Yes/No), respectively. The binary variable 
formed using the BMI as a cut-off is a proxy for general obesity, while those using WC and 
WHR cut-off are indicators of abdominal obesity. The study (KYH or Tromsø 7) was used as 
the main exposure.  
Body size in terms of, for example, height may be positively correlated with the selected 
adiposity measures. For example, a tall individual may have a larger WC than a short 
individual even if their adiposity level is similar. If adiposity level is strongly correlated with 
height, it is possible that the difference in height between the two populations, if any, leads to 
differences in the selected four adiposity measures between the two studies, even when the 
adiposity level is similar. Therefore, I examined to what extent height was correlated with 
each of the adiposity measures using Pearson’s correlation coefficient. Furthermore, I 
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examined correlation coefficients among the four adiposity measures and investigated to 
what extent general adiposity (BMI) is associated with abdominal adiposity (WC, WHR, 
WHtR). 
The association between each anthropometric measure and study was examined using the 
separate linear regression models for each sex. The model was adjusted for categorical age 
(5-year intervals) bearing in mind the possibility that the association is not linear. Interactions 
between sex and study, and between age and study were investigated by adding interaction 
terms to models for the full dataset with age, sex, and study as predictor variables. An 
analogous set of logistic regression models was used to investigate associations between each 
binary obesity variable and study.  
8.2 Results 
8.2.1 Participant characteristics in the two studies 
Table 8-1 shows participant characteristics of the KHY and Tromsø 7 visit 1 participants. It 
should be noted that the values in this table are not age-standardised. Caution is needed when 
comparing the two studies. 
KYH participants 
 In KYH, the mean age was 55.6 years, and 57.1% were women. The largest age group was 
60-69 years. There was a big difference in the prevalence of current smoking by sex, with
36.7% of men and 16.0% of women being current smokers. Overall, 35.5% had completed
higher education. The alcohol drinking pattern differed between men and women: men were
more likely to consume more litres of alcohol per year than women. Regarding cardio-
metabolic CVD risk factors, men had higher systolic blood pressure (SBP) than women while
women had higher total cholesterol, high-density lipoprotein (HDL) and low-density
lipoprotein (LDL) cholesterol.
Tromsø 7 visit 1 participants 
Among Tromsø 7 visit 1 participants aged 40-69 years, the mean age was 53.7 years, and 
52.7% were women. The participants were slightly younger than the KYH participants. The 
largest age group was 40-49 years. Unlike KYH, the prevalence of current smokers was 
similar between men (14.3%) and women (15.5%). 52.8% had completed higher education, 
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which was higher than KYH. Men tended to drink alcohol more frequently than women, but 
drinking patterns were relatively similar between sexes. Regarding cardio-metabolic CVD 
risk factors, as was seen in KYH, men showed higher SBP than women. However,  SBP of 
both men and women in Tromsø 7 was lower than KYH. In Tromsø 7, HDL cholesterol was 
higher in women than men, while LDL cholesterol was slightly higher in men.
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Table 8-1 Participant characteristics in the two studies (KYH and Tromsø 7 visit 1) 
Know Your Heart Study Tromsø Study the seventh survey visit 1 
Variable Total Men Women Variable (if 
different to 
KYH) 
Total Men Women 
N=4640 N=1994 N=2646 N=17649 N=8349 N=9300 
Age (year) 55.6 (8.7) 55.7 (8.6) 55.4 (8.8) 53.7 (8.4) 53.8 (8.5) 53.6 (8.4) 
Categorical age 
40-49 1346 (29.0) 560 (28.1) 786 (29.7) 6433 (36.5) 3055 (36.6) 3378 (36.3) 
50-59 1498 (32.3) 635 (31.9) 863 (32.6) 6036 (34.2) 2791 (33.4) 3245 (34.9) 
60-69 1796 (38.7) 799 (40.1) 997 (37.7) 5180 (29.4) 2503 (30.0) 2677 (28.8) 
Sex (female) 2646 (57.0) 9300 (52.7) 
Smoking 
Never-smoker 2081 (50.3) 443 (25.5) 1638 (68.2) 7416 (42.3) 3654 (44.1) 3762 (40.8) 
Ex-smoker 1036 (25.0) 655 (37.7) 381 (15.9) 7488 (42.7) 3447 (41.6) 4041 (43.8) 
Current smoker 1023 (24.7) 639 (36.8) 384 (16.0) 2615 (14.9) 1188 (14.3) 1427 (15.5) 
Education* Education* 
Incomplete secondary 186 (4.0) 115 (5.8) 71 (2.7) Lower than 
secondary 
3312 (19.0) 1627 (19.7) 1685 (18.3) 
Complete secondary 507 (10.9) 275 (13.8) 232 (8.8) Upper 
secondary 
4942 (28.3) 2546 (30.8) 2396 (26.0) 
Professional no 
secondary 
173 (3.7) 82 (4.1) 91 (3.4) Tertiary 9221 (52.8) 4093 (49.5) 5128 (55.7) 
Professional & 
secondary 
382 (8.2) 176 (8.8) 206 (7.8) 
Specialised secondary 1620 (34.9) 609 (30.5) 1011 (38.2) 
Incomplete higher 124 (2.7) 69 (3.5) 55 (2.1) 
Higher 1648 (35.5) 668 (33.5) 980 (37.0) 
Physical activity** Physical 
activity** 
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Inactive 268 (5.9) 102 (5.2) 166 (6.4) Sedentary 2415 (14.0) 1249 (15.2) 1166 (12.8) 
Moderately inactive 523 (11.5) 237 (12.1) 286 (11.0) Light 10005 (57.8) 4076 (49.6) 5929 (65.2) 
Moderately active 2600 (57.0) 1031 (52.6) 1569 (60.4) Moderate 4285 (24.8) 2529 (30.8) 1756 (19.3) 
Active 1168 (25.6) 589 (30.1) 579 (22.3) Heavy 603 (3.5) 359 (4.4) 244 (2.7) 
Alcohol*** Alcohol*** 
Not alcohol drinker 991 (21.4) 357 (18.0) 634 (24.0) Never 1117 (6.4) 426 (5.1) 691 (7.5) 
>0 <2 (little/year) 2214 (47.8) 557 (28.0) 1657 (62,7) Monthly 4138 (23.5) 1610 (19.4) 2528 (27.3) 
2-4     (little/year) 604 (13.1) 391 (19.7) 213 (8.1) 2-4/month 6952 (39.6) 3436 (41.3) 3516 (38.0) 
5-9     (little/year) 422 (9.1) 323 (16.3) 99 (3.8) 2-3/week 4385 (25.0) 2288 (27.5) 2097 (22.7) 
10-19 (little/year) 249 (5.4) 219 (11.0) 30 (1.1) 4+/week 985 (5.6) 558 (6.7) 427 (4.6) 
20+    (little/year) 149 (3.2) 140 (7.1) 9 (0.3) 
Cardio-metabolic 
risk factors 
Systolic blood 
pressure (mmHg) 
133.7 (20.2) 138.7 (19.8) 130.2 (19.8) 126.9 (18.3) 130.8 (17.1) 123.4 (18.7) 
Total cholesterol 
(mmol/l) 
5.6 (1.2) 5.4 (1.1) 5.7 (1.2) 5.5 (1.0) 5.5 (1.0) 5.5 (1.0) 
Triglycerides 
(mmol/l) 
1.6 (1.2) 1.7 (1.4) 1.5 (1.1) 1.5 (1.0) 1.8 (1.1) 1.3 (0.8) 
HDL cholesterol 
(mmol/l) 
1.4 (0.4) 1.3 (0.3) 1.5 (0.4) 1.6 (0.5) 1.4 (0.4) 1.7 (0.5) 
LDL cholesterol 
(mmol/l) 
3.8 (0.9) 3.7 (0.9) 3.8 (1.0) 3.6 (1.0) 3.7 (1.0) 3.6 (1.0) 
Medical 
history/medication 
Myocardial 
infarction 
154 (4.8) 105 (7.8) 49 (2.6) 376 (2.2) 314 (3.9) 62 (0.7) 
Angina pectoris 381 (12.0) 182 (13.5) 199 (10.8) 249 (1.4) 180 (2.2) 66 (0.7) 
Heart failure (-) (-) (-) 182 (1.1) 129 (1.6) 53 (0.6) 
Stroke 113 (3.5) 59 (4.4) 54 (2.9) 309 (1.8) 182 (2.2) 127 (1.4) 
Hypertension 2283 (62.2) 928 (60.1) 1355 (63.8) 4141 (23.9) 2149 (26.2) 1992 (21.9) 
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Diabetes 315 (8.5) 110 (7.0) 205 (9.6) 704 (4.1) 393 (4.8) 311 (3.4) 
Anti-hypertensive 
medication┼ 
1886 (82.7) 738 (79.7) 1148 (84.7) 2951 (16.9) 1601 (19.4) 1350 (14.6) 
Lipid-lowering 
medication 
1881 (10.8) 1068 (13.0) 813 ( 
BMI: body mass index, HDL: high-density lipoprotein, KYH: Know Your Heart Study, LDL: low-density lipoprotein, PA: physical activity, Tromsø 7: 
Tromsø Study seventh survey, WC: waist circumference, WHR: waist-to-hip ratio, WHtR: waist-to-height ratio 
**Physical activity: Physical activity in KYH is based on total physical activity index. Physical activity in Tromsø 7 is based on a simple questionnaire (1. 
Reading, watching TV/screen or other sedentary activity? 2. Walking, cycling, or other forms of exercise at least 4 hours a week? (including walking or 
cycling to the place of work, Sunday-walking, etc.), 3. Participation in recreational sports, heavy gardening, snow shovelling etc at least 4 hours a week, 4. 
Participation in hard training or sports competitions, regularly several times a week? 
***Alcohol consumption in KYH is ethanol consumption per year calculated based on questions  of frequency and usual volume of beer, wine, and spirits 
while in Tromsø 7 it is based on the following question (How often do you usually drink alcohol? 1: Never, 2: Monthly or less, 3:2-4 times a month, 4: 2-3 
times a week, 5: 4 or more times a week) 
┼ In KYH, the denominator is participants with hypertension while in Tromsø 7 it is all participants 
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8.2.2 Anthropometric measures and the prevalence of obesity in the two studies 
Correlations of anthropometric measures 
Table 8-2 below shows the correlation coefficients for the four adiposity measures with each 
other and with height in participants aged 40-69 years in KYH and Tromsø 7 visit 1. The 
height showed only weak correlations with all adiposity measures. WHtR showed relatively 
stronger correlations than other three adiposity measures.  
Regarding the correlations for the four adiposity measures with each other, three abdominal 
adiposity measures (WC, WHR, WHtR) showed strong correlations with each other. While 
correlations of BMI with WC or WHtR were quite strong, its correlation with WHR was 
relatively weak. 
Table 8-2 Correlations of anthropometric measurement (participants aged between 40-69 years in 
Know Your Heart and Tromsø 7 visit 1) 
 BMI WC WHR WHtR Height 
KYH men      
BMI 1     
WC 0.92 1    
WHR 0.66 0.82 1   
WHtR 0.92 0.95 0.83 1  
Height 0.01 0.15 -0.04 -0.15 1 
KYH 
women 
     
BMI 1     
WC 0.90 1    
WHR 0.50 0.74 1   
WHtR 0.91 0.97 0.75 1  
Height -0.17 -0.05 -0.19 -0.29 1 
Tromsø 7 
men 
     
BMI 1     
WC 0.88 1    
WHR 0.60 0.79 1   
WHtR 0.88 0.94 0.82 1  
Height -0.05 0.11 -0.13 -0.23 1 
Tromsø 7 
women 
     
BMI 1     
WC 0.88 1    
WHR 0.47 0.74 1   
WHtR 0.88 0.96 0.75 1  
Height -0.11 0.04 -0.12 -0.23 1 
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Sex-difference in the study 
Table 8-3 shows anthropometric measures, the prevalence of obesity in KYH and Tromsø 7 
visit1, and age-adjusted comparison between the two studies. For KYH, anthropometric 
measures were generally slightly higher in men than women, but BMI was higher in women. 
The prevalence of general obesity and abdominal obesity using WC cut-off point was higher 
in women than in men while men had a higher prevalence of abdominal obesity using the 
WHR cut-off point. Conversely, in Tromsø 7, all anthropometric measures and the 
prevalence of obesity were higher in men than in women. 
Difference between the two studies 
In terms of the comparison between the two studies, KYH men were significantly shorter and 
lighter than Tromsø 7 men. However, the difference in BMI was not statistically significant 
between the two studies. Regarding abdominal variables, while WC was significantly lower 
in KYH men than Tromsø 7 men, WHR and WHtR were not significantly different between 
the two studies. There was no significant difference in the prevalence of general obesity using 
BMI cut-off or of abdominal obesity using WC and WHR cut-offs in men between KYH and 
Tromsø 7. Overall, the difference in adiposity level and the prevalence of obesity in men 
between the two studies was small. 
Women showed a contrasting result.  KYH women were significantly shorter and heavier 
than Tromsø 7 women. The general adiposity measure (BMI) and all three abdominal 
adiposity measures (WC, WHR, WHtR) were significantly higher in KYH women than 
Tromsø 7 women. The prevalence of general obesity in KYH was considerably higher than in 
Tromsø 7. The prevalence of abdominal obesity showed a substantial difference: odds ratio 
for abdominal obesity using the WC cut-off point in KYH compared to Tromsø 7 was 2.8 
(95%CI: 2.5-3.0) whereas that using the WHR cut-off point was 3.8 (95%CI: 3.5-4.2). 
In summary, the burden of general and abdominal adiposity did not seem materially different 
between KYH and Tromsø 7 for men whereas the burden of adiposity, especially abdominal 
adiposity, seemed much higher in KYH women than in Tromsø 7 women. There was strong 
evidence of interactions between country and sex in all linear regression models using all 
adiposity measures. Regarding age, there was evidence of interactions between country and 
age in all linear regression models except for that using WHR. The difference between the 
studies tended to become larger as age increased.  
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Table 8-3 Anthropometric measures and the prevalence of obesity in two studies 
KYH men Tromsø 7 
men 
Age-adjusted 
comparison 
(95%CI) 
KYH vs T7 
KYH 
women 
Tromsø 7 
women 
Age-adjusted 
comparison 
(95%CI) 
KYH vs T7 
Variable N=1994 N=8349 Mean difference 
(95%CI) 
N=2646 N=9300 Mean difference 
(95%CI) 
Age 55.7 53.8 (8.5) 55.4 (8.8) 53.6 (8.4) 
Anthropometric measures 
Height (cm) 174.7 (6.7) 178.3 (6.7) -3.3 (-3.7, -3.0) 161.1 (6.3) 165.0 (6.4) -3.6 (-3.8, -3.3)
Weight (kg) 84.7 (16.2) 88.9 (14.2) -3.8 (-4.6, -3.1) 75.1 (16.4) 72.9 (14.0) 2.2 (1.5, 2.8) 
BMI (kg/m2) 27.7 (4.8) 27.9 (4.0) -0.2 (-0.4, 0.0) 29.0 (6.3) 26.8 (4.9) 2.1 (1.8, 2.3) 
WC (cm) 97.2 (12.6) 98.3 (10.8) -1.5 (-2.0, -0.9) 90.7 (14.3) 82.1 (11.7) 8.1 (7.6, 8.7) 
WHR 0.95 (0.07) 0.94 (0.07) -0.03 (-0.00, 0.01) 0.85 (0.07) 0.79 (0.07) 0.05 (0.05, 0.06) 
WHtR 0.56 (0.07) 0.55 (0.06) 0.00 (-0.00, 0.01) 0.56 (0.09) 0.50 (0.07) 0.06 (0.06, 0.07) 
Prevalence of obesity 
Odds ratio 
(95%CI) 
Obesity (BMI≥30 
kg/m2)* 
469 (27.0) 2140  (25.7) 1.08 (0.96, 1.21) 928 (38.7) 2044 (22.0) 2.19 (1.99, 2.41) 
Abdominal obesity 
using WC cut-off** 
569 (32.7) 2779 (33.4) 0.92 (0.82, 1.03) 1285 (53.4) 2644 (28.5) 2.75 (2.51, 3.02) 
Abdominal obesity 
using WHR cut-off*** 
1320 (76.0) 6002 (72.2) 1.09 (0.96, 1.24) 1131 (47.1) 1696 (18.3) 3.81 (3.45, 4.20) 
BMI: body mass index, WC: waist circumference, WHtR: waist-to-height ratio, WHR: waist-to-hip ratio 
**prevalence of obesity: BMI cut-off >=30 kg/m2 
***prevalence of abdominal obesity: WC cut-off men>102 cm, women>88 cm, WHR cut-off men>=0.9, women>=0.85 
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8.3 Discussion 
There were two main findings in this analysis. First, regarding conventional CVD risk 
factors, KYH participants showed an unfavourable pattern compared to Tromsø 7 visit 1 
participants: men in KYH had a higher smoking prevalence than men in Tromsø 7, and both 
sexes in KYH had higher SBP. Second, the level of adiposity was only significantly different 
among women between the two studies: there was no significant difference in the burden of 
obesity in men between the two studies whereas the burden of both general and abdominal 
obesity in KYH women was considerably higher than that of Tromsø 7 women. 
Participants in KYH were characterised by high smoking prevalence in men and high SBP in 
both sexes, which generally agrees with existing evidence on the comparison of CVD risk 
factors between Russia and Western Europe (shown in Chapter 2) (1). However, taking only 
traditional CVD risk factors into consideration, the KYH population does not seem to be at 
extremely high-risk for CVD compared to the Tromsø 7 population. 
The higher prevalence of general obesity in KYH women is also consistent with previous 
findings. According to the CVD statistics report from the European Society of Cardiology, 
the prevalence of general obesity in Russian men was similar to or lower than that of Western 
European counterparts, while Russian women had a higher prevalence of general obesity than 
Western European women (20). Central and Eastern European countries are more likely to 
show higher obesity prevalence than Western European countries for both men and women 
(189). However, the obesity level in Russian women might be more problematic than other 
Central European countries. One large-scale population study, the HAPIEE Study, compared 
the prevalence of general obesity in Russia, Poland, and the Czech Republic (190). The 
prevalence of general obesity was highest in Russian women while Russian men had the 
lowest prevalence, with Russia showing the largest gender difference among the three 
countries. The authors suggested that this large gender difference might be attributable to the 
low Gross National Product in Russia. 
Evidence on the prevalence of abdominal obesity in the general population is limited 
compared to the prevalence of general obesity. Only two population studies in Russia provide 
information on the prevalence of abdominal obesity in a general population sample; these 
used a different measurement site of WC (65, 191). The SAGE first wave provided 
prevalence estimates of abdominal obesity using the WHR cut-off among the general 
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population aged 50+ (men: 50-59 years 69%, 60-69 years 69.2%, women: 50-59 years 
48.8%, 60-69-years 65.7%) (65). WC was assessed at the superior border of the iliac crest 
(192). A more recent Epidemiological Survey of cardiovascular diseases in different regions 
of the Russian Federation (ESSE-RF) ascertained the prevalence of abdominal obesity using 
the WC cut-off among 21,768 participants among aged 25-64 years. The prevalence was 
24.3% in men and 38.4% in women, which were lower than in KYH(191). 
More and more attention has been paid to abdominal obesity due to its stronger association 
with cardio-metabolic CVD risk factors. However, the protocol for WC measurement has not 
been standardised. One literature review reports 14 different measurement sites in previous 
publications (160). This difference in measurement site affects the WC value. In particular, 
the prevalence of abdominal obesity is affected by measurement site (160, 193). In the SAGE 
study mentioned above, although the prevalence of abdominal obesity was relatively similar 
to that in KYH, the prevalence in women was higher than KYH. This can be explained by the 
difference in the WC measurement site; the superior border of the iliac crest in SAGE and the 
minimal point of the trunk in KYH. In the ESSE-RF study, the prevalence of abdominal 
obesity in comparable age groups seemed higher than KYH, especially among women. This 
may also be caused by different WC measurement sites. This emphasises the difficulty in 
comparing the prevalence of abdominal obesity between studies and the importance of 
standardised WC measurement. Nevertheless, bearing in mind the comparison with the two 
other Russian studies, the high burden of abdominal obesity in women observed in KYH is 
unlikely to be overestimated. Although more data are available on abdominal obesity in 
Western Europe, unstandardized measurement protocols make it difficult to accumulate 
evidence to lead to a conclusion. 
Another concern when comparing the adiposity level between different populations relates to 
the residual influence of height. The KYH participants were significantly shorter than the 
Tromsø 7 participants. Here, the concern is that the difference in adiposity level between the 
two studies is partially explained by the difference in height and does not reflect a true 
difference in adiposity. However, the height was only weakly correlated with the four 
selected adiposity measures in this study, although the correlation with WHtR did appear to 
be slightly stronger than the other three measures. This relatively strong correlation between 
WHtR and height is consistent with the previous study (194). When comparing two 
Yume Imahori 
130 
populations with different heights, WHtR may be more susceptible to the residual effect of 
height. 
I used three simple adiposity measures (WC, WHR, WHtR) as a proxy of abdominal 
adiposity. As is shown in Table 8-2, while WC and WHtR showed strong correlations with 
BMI, WHR was relatively weakly associated with BMI. When BMI is combined with 
abdominal adiposity measures in adiposity studies, WHR may be a good option for 
complementary information. In addition, WHR may be a more important measure in terms of 
the association with CVD burden. In my previous analysis in Chapter 6, WHR appeared to be 
more strongly associated with carotid plaque burden than the other two adiposity measures 
(WC and WHtR). Meanwhile, as was discussed in Chapter 2, it is suggested that WHR may 
be more strongly associated with CVD events than BMI (124, 125). It would thus appear to 
be reasonable to choose WHR as a proxy of abdominal adiposity when the impact of 
adiposity on CVD burden is explored.  
To the best of my knowledge, this is the first study to compare the prevalence of abdominal 
obesity between Russia and Western European countries. Data used in my study were 
collected over the same period in both Tromsø 7 and KYH. Furthermore, the waist 
measurement in Tromsø 7 was converted appropriately, which allowed me to make a 
reasonable comparison of abdominal obesity between KYH and Tromsø 7. In our study, it 
was of concern that the difference in the prevalence of abdominal obesity in women in KYH 
compared with women in Tromsø 7 was even higher than the difference in general obesity.  
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9 To what extent does obesity explain differences in carotid 
burden in studies conducted in Norway and Russia? 
Comparison of two populations at very different risk of 
cardiovascular death (Paper 3) 
9.1 Introduction 
In this chapter, the association of general and abdominal adiposity (body mass index (BMI), 
waist circumference (WC), waist-to-hip ratio (WHR), waist-to-height ratio (WHtR)) with 
carotid plaque burden (the presence of carotid plaques, carotid plaque score) is examined and 
compared between the Know Your Heart study (KYH) in Russia  and the Tromsø Study 
seventh survey (Tromsø 7) in Norway. I then consider whether the difference in carotid 
plaque burden between the two studies, if any, can be explained by the burden of adiposity.  
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Abstract  
Large differences exist between Russia and Norway and other Western European countries in 
cardiovascular disease (CVD) mortality, the reasons for which are poorly understood. The 
presence and extent of carotid plaque provides a measure of atherosclerosis. There is 
evidence from studies of Western populations that obesity is associated with carotid plaque 
prevalence. We investigated whether this association was observed in a random sample of the 
general population of two Russian cities (Know Your Heart (KYH) Study N=3262) and 
compared its strength to that observed in a parallel study in Norway (Tromsø 7 study 
N=1800). We then investigated whether differences in adiposity between the two populations 
could explain differences in the burden of carotid plaque. Women in KYH had higher levels 
of general/abdominal adiposity than those in Tromsø 7. However, levels among men were 
similar. The associations of the presence of plaques (yes/no) with obesity were similar in the 
Norwegian and Russian studies with waist-to-hip ratio (WHR) showing the largest effect size 
(OR per SD in WHR 1.18 (95% CI 1.06, 1.31) for men; 1.15 (1.06, 1.25) for women). 
Associations were also observed between WHR and number of plaques. The prevalence of 
carotid plaques was higher in the Russian study than the Norwegian one (age-adjusted OR 
3.2 (2.6, 4.0) for men and 1.9 (1.6, 2.3) for women). However, adiposity failed to explain 
these differences in carotid plaque burden. We conclude that factors other than obesity 
underlie the large differences in the burden of CVD between Russia and Norway. 
 
Key words: Carotid atherosclerosis, Carotid plaque, Obesity, Russian Federation, Europe, 
Health inequality 
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Introduction 
The Russian population suffers from a much higher burden of cardiovascular disease (CVD) 
than Western European countries. In 2015, the CVD mortality rate in the Russian Federation 
was four times higher than in England and Wales or Norway (2). The differences in 
premature CVD mortality rates are even larger: in 2012-16, the CVD mortality rate for the 
Russian population aged 35-69 was eight times higher than that in Norway (2). These 
premature deaths contribute to low life expectancy in Russia. A major cause of CVD is 
atherosclerosis, the detection of which in its early stages is useful to stratify CVD risk in the 
population. Carotid plaque can be non-invasively identified using ultrasound and predicts 
future CVD events independently of conventional CVD risk factors (14). 
Increased obesity prevalence is a public health concern in both Russia and Western Europe. 
The negative impact of obesity on CVD is well established, although most of the evidence 
regarding this association is derived from high-income Western countries. Less is known 
about this association in non-Western countries, such as Russia, which may have a different 
distribution and structure of confounders (63, 195, 196).  
The reason behind the huge gap in the burden of CVD between Russia and Western Europe 
has not been well understood. Historically it has been contended that differences in 
conventional CVD risk factors such as smoking, blood pressure, and cholesterol levels do not 
seem to explain this difference (4, 5). Due to the disproportionally high CVD mortality rate in 
Russia, the European Society of Cardiology recommends that a different version of the 
Systematic Coronary Risk Evaluation (SCORE) for Western Europe be used for Russia and 
other central European countries to estimate CVD risk more appropriately (12, 197). To the 
best of our knowledge, the contribution of obesity to this gap in CVD burden has not been 
specifically reported.  
While some studies of the health impact of obesity in Russia have been conducted, most are 
restricted to using body mass index (BMI) which is a crude adiposity measure with important 
limitations. Abdominal obesity may be a more important risk factor with its stronger 
association with cardio-metabolic CVD risk factors. Understanding the distribution of both 
general and abdominal obesity, and quantifying their associations with atherosclerosis could 
strengthen the evidence base for improving strategies to reduce the burden of CVD in Russia. 
The aim of this study was to compare the association between general and abdominal obesity 
assessed by four simple anthropometric measures (BMI, waist circumference (WC), waist-to-
Yume Imahori  
137 
 
hip ratio (WHR), waist-to-height ratio (WHtR)) and ultrasound-assessed carotid plaque 
measures (the presence of plaques and plaque score) between Russia and Norway ,which is 
one of CVD low-risk European countries.  
Methods 
This study compares two population-based cross-sectional studies: the Know Your Heart 
Study (KYH) conducted in two cities in Russia and the seventh survey of the Tromsø Study 
(Tromsø 7) from Tromsø, Norway. The design of the two studies is comparable in terms of 
the main examinations. 
Study design and participants 
KYH is a population-based cross-sectional study of 4500 women and men aged 35-69 years 
conducted between 2015 and 2017 in two Russian cities: Novosibirsk and Arkhangelsk. The 
details of KYH have been described elsewhere (1). Briefly, participants were recruited from a 
random sample stratified by age and gender, derived from the list of the Territorial Health 
Insurance Funds., and trained interviewers visiting the addresses on the list identified 
residents with appropriate age and sex, and collected information on CVD risk factors and 
medical history. Participants were then invited to a comprehensive examination, including 
anthropometric measurement, blood sampling, and carotid ultrasound. Of potential 
participants initially approached, 68% and 41% in Arkhangelsk and Novosibirsk, 
respectively, agreed to be interviewed; of these, 89% attended the medical examination.  
Ethical approval for the study was obtained from the ethics committees of the London School 
of Hygiene & Tropical Medicine, the Novosibirsk State Medical University, the Institute of 
Internal and Preventative Medicine - Branch of Institute of Cytology and Genetics, the 
Siberian Branch of RAS (Novosibirsk), and the Northern State Medical University 
(Arkhangelsk). 
Data from participants in Tromsø 7 are used in this analysis. The Tromsø Study is an ongoing 
population-based study in Tromsø municipality, North Norway, and consists of seven surveys 
from 1974-2016 (Tromsø 1-7) (2). All residents in Tromsø aged 40 years and older were 
invited to participate in the study. A total of 21083 (response rate 65%) attended the first visit 
during which questionnaires were applied, a physical examination was carried out, and 
biological samples were taken. A random sample including previous participants were invited 
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to a second visit to undergo more comprehensive examinations. Of this sample, 4153 
participants were invited to a carotid ultrasound examination, and 2974 (71.6%) attended. 
Ethical approval was obtained from the Norwegian Data Inspectorate and the Regional 
Committee for Medical and Health Research Ethics.  
Participants aged between 40-69 years (n=5782) were eligible for the present study. We 
excluded participants with missing data on all adiposity measures (n=42), and potential 
confounders and mediators (n=678), leaving 3262 participants from KYH (57% women) and 
1800 from Tromsø 7 (55% women) for the analyses.  
Assessment of anthropometric measures and other CVD risk factors 
In both studies, anthropometric measures were assessed by trained staff using standard 
methods. Height and weight were measured without shoes in light clothing. Height was 
measured to the nearest millimetre using a Seca® 217 portable stadiometer (Seca limited) in 
KYH and an electronic stadiometer (DS-103, Dongsahn JENIX Co. Ltd) in Tromsø 7. 
Weight was measured to the nearest 100 g with a TANITA BC 418 body composition 
analyser (TANITA, Europe GmbH) in KYH and an electronic digital scale (DS-B02, 
Dongsahn JENIX Co.Ltd) in Tromsø 7. Body mass index (BMI) was calculated by dividing 
weight in kilograms by squared height in meters. Waist circumference (WC) was measured at 
a different site in the two studies: in KYH, WC was measured at the narrowest part of the 
trunk to the nearest millimetre using a tape measure, while in Tromsø 7 WC was measured at 
the level of the umbilicus. Hip circumference was measured at the widest part in both studies. 
To ensure WC was comparable between the two studies, WC in Tromsø 7 was converted to 
the narrowest waist using a conversion equation (161). Waist-to-hip ratio (WHR) and waist-
to-height ratio (WHtR) were calculated by dividing WC by hip circumference and height, 
respectively. A previous study has shown excellent intra- and inter-observer reliability of 
height and weight (164). Recent studies also show excellent intra- and inter-observer 
reliability for WC and WHR when they were measured by trained staff (161, 165). 
We selected potential confounders and mediators a priori, based on evidence of the 
association between obesity and CVD. Age, smoking, and education were considered as 
potential confounders while systolic blood pressure (SBP), HDL cholesterol, LDL 
cholesterol, glycosylated haemoglobin (HbA1c) and medical history of diabetes mellitus 
(DM) were considered as potential mediators. Information on age (defined as 5-year 
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categories), smoking (current smoker, ex-smoker, never-smoker), educational attainment 
(higher education: Yes/No), and medical history of DM (Yes/No) were collected through 
face-to-face interview in KYH and self-administered questionnaire in Tromsø 7.  
Systolic blood pressure (SBP) was measured three times in the sitting position using 
OMRON 705 IT automatic blood pressure monitors (OMRON Healthcare) in KYH and 
Dinamap (CARESCAPE V100 Monitor, GE Healthcare) in Tromsø 7. The mean of the 
second and third measurements was used in the analysis. Non-fasting venous blood samples 
were obtained. Fresh serum was analysed at the University Hospital laboratories in Tromsø 7. 
In KYH, serum was processed, frozen within 2 hours, and shipped to Moscow for central 
analysis (2). In both studies, HDL cholesterol, LDL cholesterol, and HbA1c were determined 
using comparable standard methods (2).  
 Ultrasound examination 
Both carotid arteries (common carotid artery (CCA), bifurcation, and internal carotid artery 
(ICA)) were scanned for carotid plaques using Vivid q (GE Health care) with 6~13 MHz 
linear transducers in KYH and Vivid 7 (GE Health care) with a linear 12 MHz transducer in 
Tromsø 7. The protocols of the examination procedure were aligned between the two studies. 
Carotid plaque was defined as a focal structure encroaching into the arterial lumen at least 0.5 
mm or 50% of the surrounding intima-media thickness (IMT) value or IMT >1.5 mm as 
measured from the media-adventitia interface to the intima-lumen interface based on the 
Mannheim Consensus (41).  
In Tromsø 7, plaque detection was determined online by experienced sonographers and 
documented by digital still images of each plaque. In KYH, a similar procedure was used, 
supplemented by recording of digital cine loops in transverse and sagittal views. The off-line 
reading of recorded images was performed with EchoPAC software (GE VINGMED 
ULTRASOUND Horten Norway) by an experienced cardiologist (AR). In a previous survey 
of the Tromsø Study, acceptable levels of reproducibility of carotid plaque detection were 
demonstrated (167). 
Assessment of the burden of plaque differed slightly between the two studies. In both studies, 
plaques were sought in each segment (common carotid artery (CCA), bifurcation, and 
internal carotid artery (ICA)) of both carotid arteries, a total of six carotid segments). The 
Tromsø 7 protocol explicitly further divided each segment into the far or near wall of the 
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artery, giving a total of twelve sites. However, only one plaque could be counted at each site 
because of concerns about differentiating between a single large plaque and two discrete 
plaques. In KYH however, the protocol did not involve recording the near or far wall 
location, and there was no restriction on how many plaques could be recorded for each of the 
six segments. This protocol difference could lead to an artefactually higher plaque burden in 
KYH compared to Tromsø 7. To reduce this risk, we created a total plaque score that was 
more comparable between the studies. This was done using the following rule: when three 
plaques (the maximum seen) were recorded for any one of the six carotid segments in KYH, 
this was converted to a score of two.  
Because of the lack of information relating to wall location in KYH, we also conducted a 
sensitivity analysis by using a simpler plaque score which was independent of information 
about the wall in which the plaque was located. A score of one was assigned for the presence 
of one or more plaques in each of the six carotid segments (CCA, bifurcation, and ICA of 
each carotid artery). This resulted in a consistent approach for both studies, with a maximum 
possible score of six for each individual. 
Statistical methods 
Two outcome measures were used: the presence of plaques as a binary outcome and plaque 
score. As exposures, four anthropometric adiposity measures were used: BMI, WC, WHR, 
and WHtR. To enable direct comparison of the magnitude of the effects of these measures, 
adiposity z-scores standardised to Tromsø 7 participants were created by subtracting the 
mean and dividing by the SD of each measure in Tromsø 7.  
The association between the presence of plaques and each adiposity measure was examined 
using a series of logistic regression models. The association between plaque score and each 
adiposity measure was estimated using an analogous series of linear regression models.  
First, separately for each combination of study and sex, we fitted a sequence of three models 
for each outcome and adiposity measure. Model 1 adjusted for age (in five-year age bands). 
Model 2, our main model to elucidate the association between adiposity and plaque burden, 
further adjusted for potential confounders: smoking and education. Model 3 further adjusted 
for potential mediators (systolic blood pressure, HDL cholesterol, LDL cholesterol, HbA1c, 
medical history of DM) to see to what extent the association is mediated by these factors.  
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Second, we fitted sex-specific models to the pooled data from both studies. Our simplest 
models compared outcomes (presence of plaques and plaque score) between the two studies 
using an indicator for study and adjusting for age (in five-year age bands) alone. We then 
separately added each adiposity measure to these models, to obtain pooled estimates of the 
effect of each adiposity measure, adjusting for age (Pooled Model 1). We next fitted models 
comparing outcomes between the two studies adjusting for age, smoking, and education. To 
these models we then separately added each adiposity measure (Pooled Model 2), assessing 
to what extent between-study differences were altered by adjusting for adiposity, and to allow 
pooled estimates of the confounder-adjusted effect of each adiposity measure to be obtained. 
Evidence for a difference in these associations between the two studies was examined by 
adding an interaction between study and adiposity to each Pooled Model 2: testing for 
statistical significance using likelihood ratio tests for logistic regression and Wald tests for 
linear regression. These tests of interaction were not statistically significant other than for the 
association between BMI and the presence of plaques in women (Online table 1). Given this, 
we omitted the interaction terms. Finally, we extended Pooled Model 2 by further adjusting 
for the potential mediators (systolic blood pressure, HDL cholesterol, LDL cholesterol, 
HbA1c, diabetes) (Pooled Model 3). 
STATA version 15 (Stata Corp) was used for all the analyses. 
Results  
Baseline characteristics of participants 
Table 1 shows the participants’ baseline characteristics. Median age was higher in Tromsø 7 
(61 years (range 52-65)) than KYH (56 years (range 48-63)). The age-adjusted prevalence of 
current smoking in men was much higher in KYH than Tromsø 7, but only half in women in 
KYH compared to Tromsø 7. Higher education was more prevalent in Tromsø 7 than in KYH 
for both sexes. SBP was considerably higher in KYH than in Tromsø 7. In general, cardio-
metabolic risk factor levels were less favourable in KYH.  
Adiposity 
Table 2 shows adiposity z-scores for the KYH participants standardised to the Tromsø 7 
population adjusted for age. All mean adiposity z-scores for women in KYH were 
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consistently higher than those for women in Tromsø 7 but did not differ significantly between 
men, except for WC which was lower in KYH.  
Prevalence of carotid plaques 
Table 3 compares the prevalence of carotid plaques and the mean plaque scores in the two 
studies. The prevalence of carotid plaques and the mean plaque score increased with age in 
both women and men. The burden of plaques was consistently higher in KYH than Tromsø 7 
in both sexes.  
The association between carotid plaque burden and adiposity: a pooled analysis of the two 
studies 
Table 4 shows the odds ratios for having at least one carotid plaque per 1SD increase in each 
adiposity measure by sex from the pooled analysis. After adjustment for confounders (Pooled 
Model 2), there was evidence of association between all adiposity measures and the presence 
of plaques except for BMI in women. WHR showed the largest odds ratios (women 1.15 
95%CI: 1.06, 1.25, men 1.18 95%CI: 1.06, 1.31) while BMI had the smallest. After further 
adjustment for cardio-metabolic mediators (Pooled Model 3), all odds ratios decreased 
substantially. 
Table 5 shows the difference in plaque score per 1SD increase in each adiposity measure. In 
women, adiposity was associated with an increase in plaque score, with WHR showing the 
largest effect size (increase per 1SD change 0.134 95%CI: 0.087, 0.180) and BMI the 
smallest. Additional adjustments for cardio-metabolic mediators reduced effect sizes 
substantially. For men, there was no evidence of an association between adiposity and plaque 
score. 
In the study-specific analysis, there was some suggestion that these associations were weaker 
in KYH than in Tromsø 7 (Figure 1, Online table 2, 3). However, tests for interaction were 
not statistically significant except for the association between BMI and the presence of 
plaques in women, suggesting that there is little evidence that the association between 
adiposity and plaque burden differs between the two studies. 
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The effect of adiposity on the between-study differences in carotid plaque burden 
Figure 2 compares the carotid plaque burden between the two studies with and without 
adjustment for adiposity. Without adjustment for adiposity measures, the odds ratio for 
having at least one carotid plaque in KYH compared to Tromsø 7 was 1.97 (95%CI: 1.62, 
2.38) in women and 2.78 (95%CI: 2.21, 3.49) in men (Figure 2a, online table 4a). Further 
adjustment for each adiposity measure separately had only a small effect on this odds ratio 
for both men and women. The between-study difference remained large and statistically 
significant after further adjustment for cardio-metabolic mediators (Online table 4a). 
Similarly, without adjustment for adiposity, participants in KYH had a higher mean plaque 
score than those in Tromsø 7 by 0.51 (95%CI: 0.40, 0.62) for women and 0.90 (95%CI: 0.75, 
1.05) for men; these estimates decreased slightly for women and hardly changed at all for 
men with further adjustment for adiposity (Figure 2b, online table 4b). The difference 
remained significant after further adjustment for cardio-metabolic mediators (Online table 
4b). 
Sensitivity analysis 
To investigate whether the higher plaque burden might have been caused by a systematic 
overestimation of the plaque score in KYH due to lack of information about near or far wall 
location (see Methods), we repeated the analyses using a simpler plaque score (maximum 
score 6) which is not affected by the location of plaques. The results are presented in Online 
tables 5 and 6. Overall, using a simpler plaque score had little impact on the findings.  
Discussion 
Our analysis had four major findings. First, the adiposity level in women was higher in KYH 
than in Tromsø 7, whereas it was similar in men. Second, the burden of carotid plaque was 
higher in KYH than in Tromsø 7 regardless of age and sex. Thirdly, there was no significant 
difference between the two studies in terms of the association between adiposity and plaque: 
there was evidence of an association between plaque burden and adiposity, which was largely 
mediated by cardio-metabolic risk factors. Finally, adiposity failed to explain the difference 
in the burden of plaque between the two studies. 
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General and abdominal adiposity 
The higher level of general adiposity in KYH women compared to Tromsø 7 women, and the 
similar level of adiposity in men in the two studies, agrees with previous reports. A recent 
pooled analysis showed that mean BMI in Russian women was higher than among Western 
European women, whereas mean BMI in Russian men was similar to or lower than their 
Western European counterparts (30). Although BMI is a convenient screening tool for 
obesity, it is a crude measure that provides limited information on fat distribution which is 
strongly associated with CVD. Additional information regarding body shape helps capture 
obesity-associated risks more accurately (83). In women, the differences in abdominal 
adiposity between KYH and Tromsø 7 were greater than those for general obesity assessed 
by BMI. 
Prevalence of plaques and plaque score 
Carotid plaques were more prevalent in KYH than in Tromsø 7 regardless of age and sex. 
Carotid atherosclerosis assessed by ultrasound has been used to predict CVD risk, which is 
intuitively understandable, considering atherosclerosis is the major cause of CVD. IMT 
predicts future CVD events (42). However, carotid plaque, representing a later stage of 
atherosclerosis, outperforms IMT as a predictor of CVD events (14).  
Compared to a binary measure of the presence/absence of plaques, a more continuous 
measure such as plaque score may be expected to be more informative about plaque burden. 
Several continuous plaque variables such as total plaque area and plaque height have been 
proposed and have consistently predicted future CVD risk (50, 198, 199). Although plaque 
score is a simple quantitative variable based on the number of plaques, previous studies 
showed that it had reasonable predictive ability for future CVD events (24, 48, 200). Higher 
prevalence of plaques and increased plaque score in the KYH population reflect enhanced 
CVD risk in this population, consistent with the high CVD mortality rate in Russia compared 
to Western Europe.  
Ultrasound imaging of carotid plaque has several advantages in large epidemiological studies. 
Compared to more sophisticated imaging such as coronary artery calcium and MRI, 
ultrasound assessment is more widely available and less expensive. Compared to other 
continuous plaque variables measured by ultrasound, plaque score is simpler, less operator 
dependent, less time-consuming and has similar prognostic value (24). Since atherosclerotic 
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changes occur far in advance of CVD events, imaging of carotid plaque enables us to 
compare CVD burden between apparently healthy populations with different CVD risks. 
However, caution is needed when comparing carotid plaque burden assessed by ultrasound 
across different studies. The prevalence of carotid plaques in previous reports ranges between 
25.1% and 91% (133, 200-206), reflecting various factors including different participant 
backgrounds such as age and risk profiles, different measurement site and method to assess 
plaque, and different definition of plaque, which makes a direct comparison of plaque burden 
difficult (45). Standardised protocols for plaque measurement help to strengthen 
comparisons. In our study, we used comparable methods of plaque assessment in the two 
studies and a harmonised approach to define a measure of plaque score with participants of 
similar age structure which enabled us to make a reasonable comparison of plaque burden. 
The association between carotid plaque burden and adiposity 
We found that the association between adiposity and carotid plaque burden was not 
significantly different between the two studies. A few reports have suggested regional 
differences in the association between adiposity and CVD events. For example, the 
INTERSTROKE study suggested that the association between WHR and stroke is weaker in 
Eastern and Central Europe than in high-income Western countries (116). However, in the 
present analysis, confidence intervals for WHR from the two studies largely overlapped, 
especially for women. This is reassuring because a similar benefit might be expected from an 
intervention to reduce adiposity levels in the two countries.  
In the pooled data, there was some evidence of associations between adiposity and increased 
plaque burden, which was mediated by cardio-metabolic CVD risk factors, especially among 
women, and abdominal adiposity seemed more strongly associated with carotid plaque than 
general adiposity. This result agrees with a previous study using the fifth Tromsø Study 
survey (178). Whether abdominal adiposity is a stronger CVD risk factor than BMI is 
controversial. A pooled analysis with 221,934 individuals concluded that BMI, WC, and 
WHR have similar associations with CVD events (114). On the other hand, the 
INTERHEART and INTERSTROKE studies suggested that WHR was more strongly 
associated with CVD events than BMI (115, 116). A causal role for WHR adjusted for BMI 
on CVD was recently supported by two Mendelian randomisation studies (124, 125). 
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Adiposity does not explain the difference in plaque burden between studies 
Our main finding is that none of the adiposity measures explained the higher burden of 
carotid plaque in KYH compared to Tromsø 7, and this difference remained even after further 
adjustment for potential mediators. This suggests that other CVD risk factors may play a 
more important role in the development of carotid atherosclerosis in Russia than in Norway. 
For example, a model with physical activity and diet might have explained the study 
difference better. However, physical activity and diet seem to be located in the upper stream 
of the association between adiposity and carotid burden, and they cannot be simply 
considered as confounders in this association.  
Limitations 
Our study has several limitations. First, WC was assessed differently in the two studies. 
However, the conversion equation of WC we used was derived from a relatively large sample 
size, mainly consisting of Caucasians with a similar age structure (161). The use of this 
equation seems reasonable for our population. It should be noted that WC in Tromsø 7 in this 
paper was converted, which may result in a discrepancy in the reported levels of abdominal 
adiposity between this and other publications using Tromsø 7 data. Second, there was a minor 
difference between the studies in the assessment of plaque number and in the information on 
plaque location which could have resulted in overestimation of plaque burden in KYH 
relative to Tromsø 7. However, to avoid this, the main analyses used a more comparable 
plaque score as described in the Methods. In addition, the results of a sensitivity analysis used 
a further simplified plaque score that produced results that were consistent with those from 
the main analysis. Third, we did not include alcohol in our regression models, although it is 
known to play a role in CVD mortality in Russia (168-170, 207). This was because there is a 
lack of clarity as to whether either volume of ethanol or pattern of drinking is related to 
atherosclerosis per se. Other confounders which may be important are inflammation markers 
such as high-sensitivity C-reactive protein: the level of systemic inflammation plays an 
important role in both atherosclerosis and obesity, thus including it in the model might be 
informative. Further research is needed to understand the association between atherosclerosis 
and potential risk factors such as alcohol and inflammation in Russia to facilitate effective 
strategies to reduce its exceptionally high CVD burden. Fourth, the cross-sectional study 
design did not allow us to draw any strong causal conclusions. Finally, as always, caution 
must be exercised in generalising the results we have obtained from the two cross-sectional 
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studies of inevitably selected groups in specific cities to the national populations of Russia 
and Norway.  
The study has several strengths. First, the two studies were designed to be comparable in 
terms of the main examination, which enabled us to compare quantitative carotid plaque data 
between studies. Second, this study provides the prevalence of abdominal obesity as well as 
general obesity in the general population in Russia.  
In summary, our findings suggest two directions from which cardiac health in Russia may be 
improved. First, although adiposity does not explain the excess carotid plaque burden in 
Russia, adiposity, especially abdominal adiposity, seems to be an important risk factor for 
carotid atherosclerosis in Russia as well as in Norway and an area for intervention. The 
especially high burden of adiposity in Russian women is a concern. The prevention and 
treatment of obesity are important for the reduction of the carotid plaque burden and its 
consequent CVD in Russia. In particular, control of cardio-metabolic risk factors will 
mitigate the negative effect of adiposity. Second, the determinants of excess carotid plaque 
burden explaining the high CVD burden in Russia should be explored. Further research is 
needed to investigate the role of potential determinants including alcohol intake, 
inflammation and other cardio-metabolic factors. 
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Table 1: Participant characteristics in KYH and Tromsø 7 
 KYH  
men 
(n=1389) 
Tromsø 7  
men 
(n=811) 
Age-
adjusted 
Comparison: 
KYH vs T7 
(95%CI) 
KYH 
women 
(n=1873) 
Tromsø 7 
women 
(n=989) 
Age-
adjusted 
comparison: 
KYH vs T7 
(95%CI) 
Age (year) 
median (IQR) 
56 (48-63) 61 (52-66)  55 (48-63) 60 (52-65)  
Anthropometric 
measure 
  Difference 
(95%CI) 
  Difference 
(95%CI) 
Height (cm) 174.7 (6.6) 177.9 (6.7) -3.9 
(-4.4, -3.3) 
161.1 (6.3) 164.7 (6.3) -4.1 
(-4.6, -3.6) 
Weight (kg) 84.5 (15.5) 87.5 (12.9) -3.6 
 (-4.9, -2.3) 
74.5 (16.1) 71.4 (12.9) 3.4 
(2.3, 4.6) 
BMI (kg/m2) 27.6 (4.6) 27.7 (3.7) 0.0  
(-0.3, 0.4) 
28.8 (6.2) 26.4 (4.7) 2.7 
(2.3, 3.1) 
WCa(cm) 96.8 (12.2) 98.7 (9.8) -1.3  
(-2.3, -0.3) 
90.1 (14.2) 81.8 (11.2) 9.4 
(8.4, 10.4) 
WHRa 0.95 (0.07) 0.95 (0.07) -0.00  
(-0.00, 0.01) 
0.84 (0.08) 0.79 (0.07) 0.06 
(0.05, 0.06) 
WHtRa 0.55 (0.07) 0.56 (0.06) -0.00  
(-0.00, 0.01) 
0.56 (0.09) 0.50 (0.07) 0.07 
(0.07, 0.08) 
Potential 
confounder (%) 
  Odds Ratio 
(95%CI) 
  Odds Ratio 
(95%CI) 
Non-smoker 351 (25.3) 316 (39.0) (ref) 1304 (69.6) 383 (38.7) (ref) 
Ex-smoker 518 (37.3) 377 (46.5) 1.3 
(1.1, 1.7) 
285 (15.2) 451 (45.6) 0.2 
(0.1, 0.2) 
Current 
smoker 
520 (37.4) 118 (14.6) 4.0  
(3.1, 5.1) 
284 (15.2) 155 (15.7) 0.5  
(0.4, 0.6) 
Higher 
education 
478 (34.3) 388 (47.8) 0.6 
(0.5, 0.7) 
701 (37.4) 495 (50.1) 0.5  
(0.4, 0.6) 
Potential 
mediators 
  Difference 
(95%CI) 
  Difference 
(95%CI) 
Systolic blood 
pressure 
(mmHg) 
138.6 (19.9) 132.8 
(17.9) 
7.3 
(5.6, 8.9) 
129.8(19.6) 126.4(19.4) 5.7 
(4.3, 7.2) 
Total 
cholesterol 
(mmol/l) 
5.38 (1.13) 5.42 (1.05) -0.06 
(-0.16, 0.04) 
5.68 (1.17) 5.62 (1.04) 0.13 
(0.04, 0.21) 
Triglycerides 
(mmol/l) 
median (IQR) 
1.35  
(0.95, -1.92) 
1.50  
(1.00, -
2.10) 
-0.05 
(-0.15, 0.06) 
1.23  
(0.89,-1.77) 
1.10  
(0.80, -1.60) 
0.18 
(0.11, 0.26) 
HDL 
cholesterol 
(mmol/l) 
1.32 (0.33) 1.41 (0.39) -0.09 
(-0.12, -0.06) 
1.55 (0.36) 1.78 (0.49) -0.24 
(-0.27, -0.20) 
LDL 
cholesterol 
(mmol/l) 
3.66 (0.90) 3.63 (0.99) 0.01 
(-0.07, 0.09) 
3.80 (0.95) 3.60 (0.96) 0.27 
(0.19, 0.34) 
HbA1c (%) 5.60 (0.84) 5.74 (0.57) -0.08 
(-0.14, -0.01) 
5.57 (7.69) 5.67 (0.51) -0.04  
(-0.09, 0.01) 
   Odds Ratio 
(95%CI) 
  Odds Ratio 
(95%CI) 
Existing 93 (6.7) 47 (5.8) 1.4  
(1.0, 2.1) 
182 (9.7) 52 (5.3) 2.5 
(1.8, 3.5) 
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diabetes 
mellitus (%) 
Participants were restricted to those aged between 40 and 69 years with all covariates. Data are mainly presented 
in mean values with standard deviation for continuous variables and percentages for binary variables. Age, 
triglycerides are presented in the median with inter-quintile range. 
BMI: body mass index, HDL: high-density lipoprotein, LDL: low-density lipoprotein, WC: waist 
circumference, WHR: waist-to-hip ratio, WHtR: waist-to-height ratio. 
aWC in T7 assessed at the level of the umbilicus was converted to the narrowest WC so that it can be 
comparable with WC in KYH. WHR and WHtR in T7 are calculated using converted WC. 
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Table 2 Adiposity z-scores for KYH participants standardised to the Tromsø 7 population  
 
 KYH men (n=1389) KYH women (n=1873) 
 Mean z-score (95%CI) Mean z-score (95%CI) 
BMI z-score 0.01 (-0.09, 0.11) 0.58 (0.49, 0.68) 
WC z-score -0.13 (-0.24, -0.03) 0.85 (0.76, 0.94) 
WHR z-score 0.04 (-0.04, 0.13) 0.84 (0.76, 0.92) 
WHtR z-score 0.08 (-0.02, 0.18) 1.01 (0.92, 1.10) 
Results are adjusted for categorical age (5-year interval) 
BMI: body mass index, WC: waist circumference, WHR: waist-to-hip ratio, WHtR: waist-to-height ratio 
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Table 3. The prevalence of carotid plaques and plaque score according to study and sex  
 KYH men Tromsø 7 
men 
 Age-adjusted 
comparison 
KYH vs T7 a 
KYH 
women 
Tromsø 7 
women 
Age-adjusted 
comparison 
KYH vs T7 a 
N 1389 811  1873 989  
Prevalence n 
(%) 
  Odds Ratio 
(95%CI) 
  Odds Ratio 
(95%CI) 
All age 1050 
(75.6) 
499 (61.5) 3.2 (2.6, 4.0) 1043 
(55.7) 
478 (48.3) 1.9 (1.6, 2.3) 
40-49 212/394 
(53.8) 
38/148 
(25.7) 
3.5 (2.3, 5.4) 174/570 
(30.5) 
40/189 
(21.2) 
1.7 (1.1, 2.5) 
50-59 340/450 
(75.6) 
104/191 
(54.5) 
2.7 (1.9, 4.0) 328/605 
(54.2) 
112/273 
(41.0) 
1.7 (1.3, 2.3) 
60-69 498/545 
(91.4) 
357/472 
(75.6) 
3.5 (2.4, 5.1) 541/698 
(77.5) 
326/527 
(61.9) 
2.1 (1.7, 2.7) 
Plaque score b 
mean(SD) 
  Difference 
(95%CI) 
  Difference 
(95%CI) 
All age 2.3 (2.0) 1.5 (1.6) 1.1 (1.0, 1.3) 1.2 (1.5) 0.9 (1.2) 0.5 (0.4, 0.6) 
40-49 1.1 (1.4) 0.4 (0.8) 0.7 (0.5, 0.9) 0.5 (0.9) 0.3 (0.7) 0.2 (0.05, 0.3) 
50-59 2.1 (1.9) 1.1 (1.3) 1.0 (0.8, 1.3) 1.1 (1.4) 0.7 (1.0) 0.4 (0.2, 0.6) 
60-69 3.3 (2.0) 2.0 (1.7) 1.3 (1.1, 1.5) 2.0 (1.7) 1.3 (1.4) 0.7 (0.5, 0.8) 
aAdjusted for categorical age (5-year interval) 
b In Tromsø 7, when one or more plaques exit in each carotid segment (far/near wall of common carotid artery, 
bifurcation, internal carotid artery from each carotid artery), a score of one was assigned. Each individual can 
have a maximum score of 12. Comparable plaque score was created in KYH. 
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Table 4: Odds ratios for having at least one carotid plaque per 1 SD increase in each adiposity measure: pooled results from the two studies  
 Pooled Model 1 OR 
(95%CI) 
p-value Pooled Model 2 OR 
(95%CI) 
p-value Pooled Model 3 OR 
(95%CI) 
p-value 
Men (n=2200)       
st BMI 1.12 (1.02, 1.23) 0.02 1.13 (1.03, 1.24) 0.01 1.01 (0.91, 1.12) 0.83 
st WC 1.14 (1.04, 1.25) 0.005 1.13 (1.03, 1.24) 0.009 1.02 (0.92, 1.13) 0.76 
st WHR 1.21 (1.08, 1.34) 0.001 1.18 (1.06, 1.31) 0.003 1.05 (0.93, 1.18) 0.46 
st WHtR 1.18 (1.07, 1.30) 0.001 1.17 (1.06, 1.29) 0.002 1.04 (0.93, 1.16) 0.47 
Women (n=2862)       
st BMI 1.06 (0.99, 1.14) 0.08 1.06 (0.99, 1.13) 0.09 0.94 (0.87, 1.01) 0.08 
st WC 1.12 (1.04, 1.20) 0.002 1.11 (1.03, 1.19) 0.006 0.96 (0.88, 1.04) 0.30 
st WHR 1.20 (1.11, 1.30) <0.001 1.15 (1.06, 1.25) 0.001 1.00 (0.91, 1.09) 0.94 
st WHtR 1.12 (1.04, 1.20) 0.001 1.11 (1.03, 1.19) 0.006 0.95 (0.88, 1.03) 0.23 
St BMI: body mass index z-score, st WC: waist circumference z-score,  st WHR:waist-to-hip ratio z-score, st WHtR: waist-to-height ratio z-score, OR: odds ratio, 95%CI: 
95% confidence interval 
Model 1: adjusted for categorical age (5-year) and country, Model 2: adjust for variables in Model 1 plus potential confounders (smoking and education), Model 3: adjusted 
for variables in Model 2 plus potential mediators (systolic blood pressure, HDL cholesterol, LDL cholesterol, glycated haemoglobin, diabetes) 
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Table 5: Difference in plaque score per 1 SD increase in each adiposity measure: pooled results from the two studies  
 Pooled Model 1 slope 
(95%CI) 
p-value Pooled Model 2  slope 
(95%CI) 
p-value Pooled Model 3 slope 
(95%CI) 
p-value 
Men (n=2200)       
st BMI -0.024 (-0.085, 0.037) 0.44 -0.002 (-0.062, 0.058) 0.94 -0.102 (-0.167, -0.037) 0.002 
st WC -0.010 (-0.072, 0.052) 0.75 -0.006 (-0.067, 0.054) 0.84 -0.108 (-0.174, -0.042) 0.001 
st WHR 0.057 (-0.017, 0.130) 0.13 0.032 (-0.040, 0.103) 0.39 -0.075 (-0.151, 0.002) 0.06 
st WHtR 0.023 (-0.041, 0.087) 0.48 0.021 (-0.042, 0.083) 0.52 -0.084 (-0.152, -0.016) 0.02 
Women (n=2862)       
st BMI 0.028 (-0.012, 0.067) 0.17 0.027 (-0.012, 0.066) 0.17 -0.072 (-0.114, -0.030) 0.001 
st WC 0.076 (0.035, 0.118) <0.001 0.067 (0.026, 0.108) 0.001 -0.045 (-0.091, 0.001) 0.05 
st WHR 0.162 (0.116, 0.208) <0.001 0.134 (0.087, 0.180) <0.001 0.029 (-0.021, 0.080) 0.26 
st WHtR 0.083 (0.042, 0.125) <0.001 0.073 (0.032, 0.114) 0.001 -0.043 (-0.089, 0.004) 0.07 
St BMI: body mass index z-score, st WC: waist circumference z-score,  st WHR:waist-to-hip ratio z-score, st WHtR: waist-to-height ratio z-score, OR: odds ratio, 95%CI: 
95% confidence interval 
Model 1: adjusted for categorical age (5-year) and country, Model 2: adjust for variables in Model 1 plus potential confounders (smoking and education), Model 3: adjusted 
for variables in Model 2 plus potential mediators (systolic blood pressure, HDL cholesterol, LDL cholesterol, glycated haemoglobin, diabetes)
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Figure 1: Study-specific associations between carotid plaque and adiposity  
 
a) Study-specific odds ratio for having at least one plaque for a 1 SD increase in each adiposity 
measure after the adjustment for age, smoking, and education (Model 2) 
 
  
 
 
b) Study-specific difference in plaque score per 1 SD increase in each adiposity measure after 
the adjustment for age, smoking, and education (Model 2) 
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Figure 2: Comparison of carotid plaque burden in KYH compared to Tromsø 7 with and 
without adjustment for various adiposity measure  
a) Odds ratios for having at least one plaque in KYH vs Tromsø 7 with and without adjustment for 
adiposity 
 
b) Differences (95%CI) in the mean plaque score in KYH compared to Tromsø 7 with and 
without adjustment for adiposity 
 
1) Adjusted for categorical age, 2) adjusted for variables in 1) plus potential confounders (smoking and 
education),  3)-6) adjusted for variables in 2) plus each adiposity measure separately 
 
KYH >Tromsø 7 
KYH >Tromsø 7 
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Online table 1: Interaction  
Interaction between study and adiposity 
Interaction: odds ratio for having at least one  carotid plaque per 1 SD increase in each adiposity 
measure (adiposity#country) 
Men Pooled Model 1 Pooled Model 2 Pooled Model 3 
BMI 0.22 0.35 0.39 
WC 0.15 0.30 0.33 
WHR 0.24 0.42 0.29 
WHtR 0.21 0.40 0.37 
Women    
BMI 0.11 0.044 0.21 
WC 0.33 0.20 0.41 
WHR 0.72 0.79 0.73 
WHtR 0.29 0.21 0.47 
Model 1: adjusted for categorical age (5-year) and country, Model 2: adjust for variables in Model 1 plus 
potential confounders (smoking and education), Model 3: adjusted for variables in Model 2 plus potential 
mediators (systolic blood pressure, HDL cholesterol, LDL cholesterol, glycated haemoglobin, diabetes) 
 
 
Interaction: difference in plaque score per 1 SD increase in each adiposity measure: pooled results 
from two studies (adiposity#country) 
Men Pooled Model 1 Pooled Model 2 Pooled Model 3 
BMI 0.02 0.33 0.13 
WC 0.05 0.23 0.33 
WHR 0.24 0.72 0.55 
WHtR 0.08 0.38 0.42 
Women    
BMI 0.14 0.07 0.46 
WC 0.78 0.60 0.91 
WHR 0.10 0.09 0.08 
WHtR 0.86 0.80 0.64 
Model 1: adjusted for categorical age (5-year) and country, Model 2: adjust for variables in Model 1 plus 
potential confounders (smoking and education), Model 3: adjusted for variables in Model 2 plus potential 
mediators (systolic blood pressure, HDL cholesterol, LDL cholesterol, glycated haemoglobin, diabetes) 
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Online table 2: Study-specific odds ratio for having at least one carotid plaque per 1 SD increase in each adiposity measure  
a) Men (n=2200) 
 Model 1 OR (95%CI) p-value Model 2 OR (95%CI) p-value Model 3 OR (95%CI) p-value 
KYH Men 
(n=1389) 
      
st BMI 1.08 (0.97, 1.20) 0.18 1.10 (0.98, 1.24) 0.10 0.95 (0.84, 1.09) 0.47 
st WC 1.09 (0.98, 1.22) 0.13 1.10 (0.98, 1.23) 0.11 0.95 (0.83, 1.08) 0.46 
st WHR 1.14 (1.00, 1.31) 0.06 1.13 (0.98, 1.30) 0.09 0.95 (0.81, 1.12) 0.53 
st WHtR 1.13 (1.01, 1.27) 0.04 1.13 (1.01, 1.28) 0.04 0.98 (0.84, 1.11) 0.63 
T7 Men (n=811)       
st BMI 1.22 (1.04, 1.43) 0.02 1.21 (1.03, 1.42) 0.02 1.10 (0.92, 1.32) 0.32 
st WC 1.26 (1.07, 1.48) 0.006 1.23 (1.04, 1.45) 0.02 1.11 (0.93, 1.34) 0.25 
st WHR 1.31 (1.11, 1.56) 0.002 1.28 (1.07, 1.52) 0.006 1.16 (0.96, 1.41) 0.13 
st WHtR 1.29 (1.09, 1.52) 0.003 1.26 (1.07, 1.50) 0.007  1.15 (0.95, 1.39) 0.15 
b) Women (n=2862) 
 Model 1 OR (95%CI) p-value Model 2 OR (95%CI) p-value Model 3 OR (95%CI) p-value 
KYH Women 
(n=1873) 
      
st BMI 1.03 (0.95, 1.11) 0.50 1.02 (0.94, 1.10) 0.69 0.92 (0.84, 1.00) 0.045 
st WC 1.09 (1.00, 1.18) 0.04 1.07 (0.98, 1.16) 0.13 0.94 (0.86, 1.04) 0.23 
st WHR 1.20 (1.09, 1.32) <0.001 1.15 (1.04, 1.27) 0.007 1.01 (0.90, 1.13) 0.87 
st WHtR 1.09 (1.00, 1.18) 0.045 1.06 (0.98, 1.16) 0.15 0.93 (0.85, 1.03) 0.17 
T7 Women (n=989)       
st BMI 1.18 (1.03, 1.35) 0.02 1.21 (1.05, 1.39) 0.008 1.01 (0.86, 1.19) 0.86 
st WC 1.20 (1.05, 1.38) 0.008 1.22 (1.06, 1.40) 0.006 1.02 (0.87, 1.20) 0.81 
st WHR 1.20 (1.04, 1.37) 0.01 1.16 (1.01, 1.34) 0.04 0.98 (0.83, 1.14) 0.76 
st WHtR 1.21 (1.06, 1.39) 0.006 1.22 (1.06, 1.40) 0.006 1.01 (0.85, 1.19) 0.94 
St BMI: body mass index z-score, st WC: waist circumference z-score,  st WHR:waist-to-hip ratio z-score, st WHtR: waist-to-height ratio z-score, OR: odds ratio, 95%CI: 
95% confidence interval. Model 1: adjusted for categorical age (5-year) and country, Model 2: adjust for variables in Model 1 plus potential confounders (smoking and 
education), Model 3: adjusted for variables in Model 2 plus potential mediators (systolic blood pressure, HDL cholesterol, LDL cholesterol, glycated haemoglobin, diabetes) 
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Online table 3: Study-specific difference in plaque score per 1 SD increase in each adiposity measure: pooled results from two studies 
a) Men (n=2200) 
 Model 1 Difference in 
plaque score (95%CI) 
p-value Model 2 Difference in 
plaque score(95%CI) 
p-value Model 3 Difference in 
plaque score (95%CI) 
p-value 
KYH Men 
(n=1389) 
      
st BMI -0.071 (-0.147, 0.005) 0.07 -0.036 (-0.111, 0.039) 0.35 -0.149 (-0.231, -0.068) <0.001 
st WC -0.057 (-0.134, 0.021) 0.15 -0.037 (-0.113, 0.039) 0.34 -0.153 (-0.235, -0.070) <0.001 
st WHR 0.003 (-0.094, 0.101) 0.95 -0.002 (-0.097, 0.092) 0.96 -0.132 (-0.234, -0.031) 0.01 
st WHtR -0.029 (-0.110, 0.051) 0.48 -0.015 (-0.094, 0.063) 0.70 -0.139 (-0.225, -0.053) 0.002 
T7 Men(n=811)       
st BMI 0.088 (-0.012, 0.187) 0.09 0.079 (-0.021, 0.179) 0.12 -0.015 (-0.125, 0.094) 0.79 
st WC 0.115 (0.014, 0.216) 0.03 0.088 (-0.013, 0.188) 0.09 -0.008 (-0.119, 0.103) 0.88 
st WHR 0.179 (0.073, 0.285) 0.001 0.136 (0.030, 0.243) 0.01 0.049 (-0.067, 0.165) 0.41 
st WHtR 0.146 (0.044, 0.249) 0.005 0.115 (0.012, 0.218) 0.03 0.021 (-0.093, 0.135) 0.71 
b) Women (n=2862) 
 Model 1 Difference  in 
plaque score(95%CI) 
p-value Model 2 Difference in 
plaque score(95%CI) 
p-value Model 3 Difference in 
plaque score (95%CI) 
p-value 
KYH women 
(n=1873) 
      
st BMI 0.001 (-0.047, 0.048) 0.98 -0.009 (-0.056, 0.038) 0.70 -0.107 (-0.157, -0.057) <0.001 
st WC 0.057 (0.007, 0.108) 0.03 0.038 (-0.012, 0.088) 0.14 -0.080 (-0.136, -0.025) 0.005 
st WHR 0.165 (0.107, 0.224) <0.001 0.126 (0.068, 0.185) <0.001 0.014 (-0.050, 0.079) 0.67 
st WHtR 0.062 (0.011, 0.112) 0.02 0.041 (-0.010, 0.091) 0.11 -0.081 (-0.137, -0.025) 0.004 
T7 Women (n=989)       
st BMI 0.089 (0.016, 0.162) 0.02 0.102 (0.030, 0.175) 0.006 0.009 (-0.073, 0.091) 0.83 
st WC 0.113 (0.039, 0.187) 0.003 0.119 (0.046, 0.192) 0.001 0.027 (-0.056, 0.110) 0.52 
st WHR 0.139 (0.064, 0.214) <0.001 0.122 (0.048, 0.197) 0.001 0.042 (-0.040, 0.124) 0.31 
st WHtR 0.118 (0.044, 0.192) 0.002 0.120 (0.046, 0.193) 0.001 0.025 (-0.059, 0.109) 0.56 
St BMI: body mass index z-score, st WC: waist circumference z-score,  st WHR:waist-to-hip ratio z-score, st WHtR: waist-to-height ratio z-score, OR: odds ratio, 95%CI: 
95% confidence interval 
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Online table 4: Comparison of carotid plaque burden in KYH compared to Tromsø 7 with and 
without adjustment for various adiposity measure (data of figure 2)  
 
a) Odds ratios for having at least one carotid plaque in KYH vs. Tromsø 7 with and without adjustment 
for adiposity 
 Men (n=2200) Women (n=2862) 
 OR (95%CI) OR (95%CI) 
Model 1-adiposity  3.22 (2.58, 4.01) 1.90 (1.60, 2.25) 
Model 2-adiposity 2.78 (2.21, 3.49) 1.97 (1.62, 2.38) 
Model 2  BMI 2.79 (2.22, 3.50) 1.90 (1.56, 2.30) 
Model 2  WC 2.83 (2.25, 3.56) 1.80 (1.48, 2.20) 
Model 2  WHR 2.77 (2.20, 3.48) 1.75 (1.43, 2.14) 
Model 2  WHtR 2.77 (2.21, 3.48) 1.78 (1.45, 2.18) 
Model 3 - adiposity 2.51 (1.98, 3.18) 1.63 (1.33, 2.00) 
Model 3  BMI 2.51 (1.98, 3.18) 1.63 (1.36, 2.04) 
Model 3  WC 2.52 (1.98, 3.19) 1.67 (1.36, 2.06) 
Model 3  WHR 2.51 (1.98, 3.18) 1.64 (1.33, 2.01) 
Model 3  WHtR 2.51 (1.98, 3.19) 1.69 (1.37, 2.09) 
 
b) Differences (95%CI) in the mean plaque score in KYH compared to Tromsø 7 with and without 
adjustment for adiposity 
 Men (n=2200) Women (n=2862) 
 Difference in plaque score 
(95%CI) 
Difference in plaque score 
(95%CI) 
Model 1-adiposity 1.10 (0.96, 1.25) 0.48 (0.38, 0.59) 
Model 2-adiposity 0.90 (0.75, 1.05) 0.51 (0.40, 0.62) 
Model 2  BMI 0.90 (0.75, 1.05) 0.49 (0.38, 0.60) 
Model 2 WC 0.90 (0.75, 1.05) 0.45 (0.34, 0.57) 
Model 2 WHR 0.90 (0.75, 1.05) 0.40 (0.29, 0.51) 
Model 2  WHtR 0.90 (0.75, 1.05) 0.44 (0.32, 0.55) 
Model 3 - adiposity 0.76 (0.61, 0.92) 0.37 (0.26, 0.48) 
Model 3  BMI 0.76 (0.61, 0.91) 0.39 (0.28, 0.50) 
Model 3  WC 0.74 (0.59, 0.89) 0.39 (0.28, 0.51) 
Model 3  WHR 0.76 (0.61, 0.91) 0.35 (0.24, 0.47) 
Model 3  WHtR 0.76 (0.61, 0.91) 0.40 (0.28, 0.51) 
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Online table 5 Sensitivity analysis 1: mean plaque score using original plaque score and 
simplified plaque score 
 KYH men Tromsø 7 
men 
 Age-adjusted 
comparison 
KYH vs T7 * 
KYH 
women 
Tromsø 7 
women 
Age-adjusted 
comparison 
KYH vs T7* 
Original Plaque 
score**mean(SD) 
1389 811 Difference 
(95%CI) 
  Difference 
(95%CI) 
All age 2.3 (2.0) 1.5 (1.6) 1.1 (1.0, 1.3) 1.2 (1.5) 0.9 (1.2) 0.5 (0.4, 0.6) 
40-49 1.1 (1.4) 0.4 (0.8) 0.7 (0.5, 0.9) 0.5 (0.9) 0.3 (0.7) 0.2 (0.05, 0.3) 
50-59 2.1 (1.9) 1.1 (1.3) 1.0 (0.8, 1.3) 1.1 (1.4) 0.7 (1.0) 0.4 (0.2, 0.6) 
60-69 3.3 (2.0) 2.0 (1.7) 1.3 (1.1, 1.5) 2.0 (1.7) 1.3 (1.4) 0.7 (0.5, 0.8) 
Simplified 
plaque score 
mean (SD) 
      
All age 1.9 (1.6) 1.2 (1.1) 1.0 (0.9, 1.2) 1.1 (1.3) 0.8 (0.9) 0.5 (0.4, 0.6) 
40-49 1.0 (1.2) 0.3 (0.6) 0.6 (0.5, 0.8) 0.5 (0.8) 0.3 (0.6) 0.2 (0.1, 0.3) 
50-59 1.8 (1.5) 0.9 (1.0) 0.9 (0.7, 1.2) 1.0 (1.2) 0.6 (0.8) 0.4 (0.3, 0.6) 
60-69 2.7 (1.6) 1.5 (1.2) 1.2 (1.1, 1.4) 1.7 (1.4) 1.1 (1.0) 0.7 (0.5, 0.8) 
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Online table 6  Differences (95%CI) in the mean plaque score in KYH compared to Tromsø 7 
with and without adjustment for adiposity 
 
Men 
Men (n=2200) Original score Simplified score 
 Difference in plaque score 
(95%CI) 
Difference in plaque score 
(95%CI) 
Model 1-adiposity 1.10 (0.96, 1.25) 1.03 (0.92, 1.15) 
Model 2-adiposity 0.90 (0.75, 1.05) 0.89 (0.77, 1.00) 
Model 2  BMI 0.90 (0.75, 1.05) 0.89 (0.77, 1.00) 
Model 2 WC 0.90 (0.75, 1.05) 0.88 (0.77, 1.00) 
Model 2 WHR 0.90 (0.75, 1.05) 0.89 (0.77, 1.00) 
Model 2  WHtR 0.90 (0.75, 1.05) 0.89 (0.77, 1.00) 
Model 3-adiposity 0.76 (0.61, 0.92) 0.79 (0.67, 0.90) 
Model 3  BMI 0.76 (0.61, 0.91) 0.78 (0.66, 0.90) 
Model 3  WC 0.74 (0.59, 0.89) 0.76 (0.64, 0.88) 
Model 3  WHR 0.76 (0.61, 0.91) 0.78 (0.66, 0.90) 
Model 3 WHtR 0.76 (0.61, 0.91) 0.78 (0.66, 0.90) 
 
Women 
Women (n=2862) Original score Simplified score 
 Difference in number of 
plaques (95%CI) 
Difference in number of 
plaques (95%CI) 
Model 1-adiposity 0.48 (0.38, 0.59) 0.49 (0.40, 0.57) 
Model 2-adiposity 0.51 (0.40, 0.62) 0.51 (0.42, 0.60) 
Model 2  BMI 0.49 (0.38, 0.60) 0.49 (0.40, 0.59) 
Model 2 WC 0.45 (0.34, 0.57) 0.46 (0.37, 0.55) 
Model 2 WHR 0.40 (0.29, 0.51) 0.42 (0.32, 0.51) 
Model 2  WHtR 0.44 (0.32, 0.55) 0.45 (0.35, 0.54) 
Model 3 - adiposity 0.37 (0.26, 0.48) 0.40 (0.31, 0.49) 
Model 3  BMI 0.39 (0.28, 0.50) 0.41 (0.32, 0.50) 
Model 3  WC 0.39 (0.28, 0.51) 0.42 (0.32, 0.51) 
Model 3  WHR 0.35 (0.24, 0.47) 0.38 (0.29, 0.48) 
Model 3 WHtR 0.40 (0.28, 0.51) 0.42 (0.32, 0.51) 
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9.3 The association between WHR and carotid plaque burden: Effect of 
age  
In research paper 3, I showed that adiposity, especially WHR, was associated with increased 
carotid plaque burden. In this section, I additionally looked at the effect of age on carotid 
plaque burden and compared it with that of WHR because age is clearly a strong determinant 
of carotid plaque burden. Furthermore, the effect of WHR within the same age group was 
examined. 
Methods 
First, the separate effect of age and WHR on carotid plaque burden was investigated using the 
pooled dataset from KYH and Tromsø 7. Sex-specific tertiles of WHR z-score were 
generated. Odds ratios for having at least one plaque as age group (10-year interval) or the 
tertiles of WHR z-score increases were estimated using logistic regression model including 
both the tertiles of WHR z-score and age group, which were adjusted for study, smoking, and 
education. The lowest age group and the lowest tertile of WHR z-score were used as 
reference categories. Similarly, differences in the simplified plaque score as age group or the 
tertiles of WHR z-score increases were investigated using the linear regression adjusted for 
study, smoking, and education.  
Then, the effect of WHR within each age group was examined. I divided participants into 
nine groups. Participants were divided into the tertiles of WHR z-score within each age group 
(10-year interval). Odds ratios for having at least one plaque were investigated using logistic 
regression adjusted for study, smoking, and education. The differences in the simplified 
plaque score were estimated using linear regression adjusted for study, smoking, and 
education. 
Results 
Separate effect of age and WHR 
Table 9-1 shows ORs for having at least one plaque as age group or tertiles of WHR 
increases. Increase in age was strongly associated with an increase in the presence of carotid 
plaques. Although the associations between the increase in WHR and the presence of plaques 
were weaker than that with age, most of the associations were significant and positive, 
suggesting that WHR is also a risk factor for the presence of carotid plaques. 
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Table 9-2 shows differences in the simplified plaque score as age group or tertiles of WHR 
increases. Again, age was a strong determinant of the simplified plaque score, whereas WHR 
showed positive but weaker associations than age. 
The effect of WHR within each age group 
Table 9-3 shows the distribution of the tertiles of WHR within each age group. As age 
increased, WHR considerably increased for both men and women. 
Table 9-4 shows ORs for having at least one plaque according to age group and WHR 
tertiles. ORs considerably increased as age group increased. Within each age group, ORs 
tended to increase as the tertiles of WHR increased although there were large overlaps of 
95% CIs. 
Table 9-5 shows the difference in the simplified plaque score according to age group and 
standardised WHR tertiles. Again, age was a strong determinant of increase in the simplified 
plaque score. Within each age group, the association between WHR tertile and simplified 
plaque score was not clear among men, while the increase in the tertile of WHR seemed 
associated with an increase in simplified plaque score in women.  
Comments 
This analysis showed that age was a very strong determinant of carotid plaque burden as 
expected. Although the effect of WHR on carotid plaque burden was weaker than that of age, 
an increase in the tertiles of WHR seemed associated with an increase in carotid plaque 
burden within each age group, especially among women. This finding has an important 
clinical implication. Regardless of age, the increase in WHR may contribute to carotid 
atherosclerosis. The control of abdominal adiposity is important. 
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Table 9-1 Odds ratios for having at least one carotid plaque: the effect of age and WHR 
 Men (N=2200) Women (N=2862) 
 N OR (model 2) N OR (model 2) 
Age     
40-49 years 542 1.00  [ref] 759 1.00 [ref] 
50-59 years 641 2.83 (2.19, 3.64) 878 2.63 (2.11, 3.26) 
60-69 years 1017 7.99 (6.11, 10.46) 1225 6.93 (5.53, 8.67) 
WHR tertiles     
1st  734 1.00  [ref] 954 1.00  [ref] 
2nd  734 1.29 (1.01, 1.65) 954 1.13 (0.93, 1.38) 
3rd  732 1.42 (1.10, 1.85) 954 1.46 (1.18, 1.80) 
 
Table 9-2  Differences in simplified plaque score: the effect of age and WHR 
 Men (N=2200) Women (N=2862) 
 N Difference 
 (model 2) 
N Difference 
 (model 2) 
Age     
40-49 years 542 0.00 [ref] 759 0.00 [ref] 
50-59 years 641 0.75 (0.60, 0.91) 878 0.45 (0.35, 0.56) 
60-69 years 1017 1.54 (1.40, 1.69) 1225 1.05 (0.94, 1.15) 
WHR tertiles     
1st  734 0.00 [ref] 954 0.00 [ref] 
2nd  734 0.06 (-0.08, 0.19) 954 0.05 (-0.05, 0.15) 
3rd  732 0.04 (-0.10, 0.18) 954 0.29 (0.18, 0.39) 
 
Table 9-3  Distribution of the tertiles of WHR in each age group 
 WHR 1st  WHR 2nd  WHR 3rd  Total 
Men N (%) N (%) N (%)  
40-49 years  268 (49.4) 173 (31.9) 101 (18.6) 542 
50-59 years  224 (34.9) 224 (34.9) 193 (30.1) 641 
60-69 years  242 (23.8) 337 (33.1) 438 (43.1) 1017 
Women     
40-49 years  383 (50.5) 220 (29.0) 156 (20.6) 759 
50-59 years  282 (32.1) 313 (35.6) 283 (32.2) 878 
60-69 years 289 (23.6) 421 (34.4) 515 (42.0) 1225 
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Table 9-4  Odds ratios for having at least one carotid plaque: the joint effect of age and WHR 
Age Thirds of WHR 
1st  2nd 3rd  
 Men OR (model 2) OR (model 2) OR (model 2) 
40-49 years  1.00  [ref]  1.37 (0.92, 2.05)  1.46 (0.90, 2.36) 
50-59 years  3.02 (2.05, 4.44)  3.73 (2.51, 5.52)  3.93 (2.58, 5.99) 
60-69 years  8.11 (5.31, 12.39)  10.27 (6.87, 15.36)  12.07 (8.17, 17.83) 
Women    
40-49 years  1.00 [ref]  0.96 (0.65, 1.41)  1.28 (0.85, 1.94) 
50-59 years  2.19 (1.56, 3.08)  2.92 (2.11, 4.05)  3.66 (2.60, 5.14) 
60-69 years  6.54 (4.60, 9.30)  7.16 (5.19, 9.87)  9.31 (6.78, 12.78) 
 
Table 9-5  Differences in simplified plaque score: the joint effect of age and WHR 
Age Thirds of WHR 
1st  2nd 3rd  
 Men Difference (model 
2) 
Difference (model 
2) 
Difference (model 2) 
40-49 years 0.00 [ref] 1.13 (-0.12, 0.38) 0.11 (-0.19, 0.41) 
50-59 years 0.77 (0.54, 1.01) 0.77 (0.54, 1.00) 0.95 (0.70, 1.19) 
60-69 years 1.64 (1.41, 1.87) 1.67 (1.46, 1.88) 1.56 (1.36, 1.76) 
Women    
40-49 years 0.00 [ref] -0.06 (-0.23, 0.12) 0.01 (-0.19, 0.21) 
50-59 years 0.30 (0.13, 0.46) 0.45 (0.29, 0.61) 0.68 (0.51, 0.84) 
60-69 years 0.90 (0.73, 1.07) 1.00 (0.85, 1.15) 1.29 (1.14, 1.43) 
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9.4 Comparison of strength of WHR with carotid plaques compared to 
that of conventional CVD risk factors 
In research paper 3, I showed that the associations between adiposity and carotid plaque 
burden were to a large extent mediated by cardio-metabolic mediators (SBP, LDL 
cholesterol, HDL cholesterol, HbA1c). Although this finding shows that these cardio-
metabolic mediators, combined together, are strongly associated with increased carotid 
plaque burden, paper 3 did not make direct comparisons of the strength of associations of 
these cardio-metabolic mediators with plaque burden. This final section investigates the 
association between carotid plaque burden and a 1 SD change in each cardio-metabolic 
mediator. This enables a direct comparison with the effect of a 1 SD unit increase in the 
adiposity measures of BMI and WHR, and in this way provides an important context for 
judging the importance of the adiposity associations presented in paper 3. 
 
Methods 
Z-scores for SBP, LDL-c, HDL-c, and HbA1c were generated in the same way as was used to 
create the adiposity z-scores (see paper 3 method section). Odds ratios for having at least one 
plaque were estimated per 1 SD unit increase in each cardio-metabolic mediator or adiposity 
measure using logistic regression adjusted for categorical age and study. The associations of 
the simplified plaque score with each cardio-metabolic mediator or adiposity measure 
changes were estimated using linear regression adjusted for categorical age and study. All 
analyses were done separately for men and women.  
Results 
Table 9-6 shows the odds ratios for having at least one plaque per 1 SD increase in each 
cardio-metabolic mediator or adiposity measure. SBP was the most strongly associated 
variable, notably so for men. However, the ORs for a 1 SD increase in LDL-cholesterol, and 
HbA1c were of the same magnitude as for WHR. The weakest association was shown for 
BMI. 
Table 9-7 shows the differences in the simplified plaque score per 1 SD increase in each 
cardio-metabolic mediator or adiposity measure. Again, SBP showed the largest effect 
estimates, although, for women, it was only slightly bigger than seen for WHR. Again, BMI 
showed the smallest associations for both sexes.   
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Comments 
In this analysis, 1 SD increase in WHR was as strongly associated with the presence of 
carotid plaques as 1 SD increase in traditional cardio-metabolic risk factors such as 
cholesterol and HbA1c, suggesting that WHR is an equally important risk factor for carotid 
atherosclerosis. Especially, in women, the strength of association was comparable with that 
of SBP. On the other hand, the weakest association of BMI suggests that BMI may not be 
appropriate adiposity measure to predict risk for carotid atherosclerosis.  
The associations between WHR and the simplified plaque score seemed relatively weak 
compared to traditional cardio-metabolic risk factors among men. However, this association 
was the second strongest, followed by SBP among women.  
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Table 9-6  Odds ratios for having at least one plaque per 1 SD increase in BMI, WHR, SBP, LDL 
cholesterol, HDL cholesterol and HbA1c adjusted for age and study: pooled results from the two 
studies 
 Men OR(95%CI)  
(n=2200) 
Women OR(95%CI)  
(n=2862) 
BMI (1 SD increase) 1.12 (1.02, 1.23) 1.06 (0.99, 1.14) 
WHR (1 SD increase) 1.21 (1.08, 1.34) 1.20 (1.11, 1.30) 
SBP (1 SD increase) 1.43 (1.28, 1.59) 1.29 (1.18, 1.41) 
LDL-cholesterol (1 SD 
increase) 
1.17 (1.05, 1.30) 1.22 (1.12, 1.32) 
HDL-cholesterol (1 SD 
increase) 
0.91 (0.81, 1.01) 0.78 (0.71, 0.86) 
HbA1c (1 SD increase) 1.18 (1.06, 1.32) 1.16 (1.08, 1.25) 
Table 9-7  Difference in simplified plaque score per 1 SD increase in BMI, WHR, SBP, LDL 
cholesterol, HDL cholesterol and HbA1c adjusted for age and study: pooled results from the two 
studies 
 Men difference (95%CI) 
(n=2200) 
Women difference(95%CI) 
(n=2862) 
BMI (1 SD increase) -0.021 (-0.069, 0.026) 0.023 (-0.009, 0.056) 
WHR (1 SD increase) 0.033 (-0.025, 0.090) 0.131 (0.093, 0.169) 
SBP (1 SD increase) 0.221 (0.168, 0.273) 0.159 (0.118, 0.201) 
LDL-cholesterol (1 SD 
increase) 
0.078 (0.020, 0.137) 0.102 (0.062, 0.143) 
HDL-cholesterol (1 SD 
increase) 
-0.087 (-0.148, -0.025) -0.141 (-0.188, -0.094) 
HbA1c (1 SD increase) 0.073 (0.031, 0.116) 0.094 (0.064, 0.124) 
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9.5 Summary 
 The adiposity level was substantially higher in KYH women than in Tromsø 7 women 
while men showed a similar adiposity level in both studies. 
 The burden of carotid plaque was consistently higher in KYH than in Tromsø 7 for 
both sexes regardless of age group. 
 The test for interaction suggested that the association between adiposity and carotid 
plaque burden is not significantly different between KYH and Tromsø 7. 
 Adiposity failed to explain the difference in the burden of carotid plaque between 
KYH and Tromsø 7. 
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10 Discussion 
The aim of this thesis was to examine the contribution of adiposity to atherosclerotic changes 
in the carotid artery in general population samples from Norway and Russia, which have very 
different CVD mortality rates. The two main objectives of this thesis were to: 1) investigate 
the role of general/abdominal adiposity on measures of carotid plaque assessed by ultrasound 
in population-based studies from Norway (Tromsø 7) and Russia (Know Your Heart); and 2) 
determine whether differences in carotid plaque burden (the presence of plaques, number of 
plaques) between the two populations, if any, can be statistically accounted for by various 
measures of adiposity.  
This concluding chapter is subdivided into five sections. In the first, I briefly summarise the 
main findings. This is followed by a discussion of the extent to which these results provide 
new insights into the links between adiposity and carotid atherosclerosis in Norway and 
Russia and how far differences in adiposity may explain some of the differences in 
cardiovascular disease mortality between these countries. In doing this, I will pay attention to 
the strengths and limitations of the data and analyses employed in this thesis. Finally, I 
consider the implications of my conclusions for future areas of research. 
10.1  Summary of findings 
10.1.1 Objective 1: How is adiposity associated with carotid plaque burden? 
My preliminary analysis using the Tromsø Study fourth and fifth survey (Chapters 6 and 7) 
had three main findings: First, there was some evidence of a cross-sectional association 
between adiposity and carotid plaque burden (presence of plaques, TPA) after adjustment for 
potential confounders (age, sex, smoking, education). Secondly, abdominal adiposity, 
especially WHR, seemed more strongly associated with plaque burden than general adiposity 
assessed by BMI. These associations were, to a large extent, mediated by cardio-metabolic 
CVD risk factors (SBP, LDL cholesterol, HDL cholesterol, glycosylated haemoglobin). 
These associations were confirmed in my prospective analysis (Chapter 7). Overall, the 
observed association was similar to the known association between adiposity and CVD 
events, reflecting that sub-clinical atherosclerosis is an intermediate outcome of CVD. 
In my main analysis (Chapter 9), the formal test for interaction showed little evidence of a 
difference in the association between carotid plaque burden and adiposity between KYH and 
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Tromsø 7, implying that the impact of adiposity on carotid atherosclerosis is not significantly 
different between the two studies. In spite of little evidence of interaction, however, the 
association between carotid plaque and adiposity seemed slightly weaker in KYH than in 
Tromsø 7, which agrees with previous studies suggesting a weaker association between 
adiposity and CVD events in Russia compared to Western Europe (4, 116). Nevertheless, the 
95% confidence intervals from the two studies overlapped substantially.  
 Results using the pooled data (KYH and Tromsø 7) were generally consistent with results of 
my preliminary analysis described above, despite using the plaque score based on the number 
of plaques instead of TPA. There was some evidence of an association between adiposity and 
carotid plaque burden (the presence of plaques, the plaque score), especially abdominal 
adiposity, which was mediated by cardio-metabolic CVD risk factors. This is expected 
because TPA and plaque score are correlated and behave similarly in terms of the association 
with CVD events (24).   
10.1.2 Objective 2: Can adiposity explain the inter-study difference in carotid plaque 
burden? 
Regarding the adiposity level in the two studies, the general adiposity level and the 
prevalence of general obesity in KYH women were much higher than in Tromsø 7 women 
whereas they were similar in KYH men and Tromsø 7 men (Chapters 8 and 9), which agreed 
with a previous study (30). Abdominal adiposity level and prevalence of abdominal obesity 
showed a similar pattern with considerably higher adiposity levels in KYH women than 
Tromsø 7 women and similar levels in men. However, the difference in abdominal adiposity 
level in women was even larger than in the general adiposity level. The prevalence of 
abdominal obesity was much higher than that of general obesity among KYH women, 
suggesting that using BMI alone to screen obesity might underestimate the actual obesity 
burden and obesity-related health risks in the population.  
Regarding carotid plaque, use of a comparable protocol allowed us to make a reasonable 
comparison of plaque burden between the two studies. Consistent with the substantially 
higher burden of CVD in Russia compared to Norway, the prevalence and number of carotid 
plaques were consistently higher in KYH than in Tromsø 7, regardless of age group and sex 
(Chapter 9). 
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To the best of my knowledge, this is the first study to examine the contribution of adiposity to 
excess CVD burden in Russia. In my analysis, adiposity failed to explain the higher carotid 
plaque burden in KYH not only in men (who had similar adiposity levels to Tromsø 7 men), 
but also in women who had a considerably higher adiposity level in KYH than in Tromsø 7 
(Chapter 9). The between-study difference remained large after further adjustment for cardio-
metabolic CVD risk factors, strongly suggesting that there are factors other than adiposity 
that explain the differences in carotid atherosclerosis between the two studies, despite the fact 
that adiposity in both studies is a risk factor for carotid plaque. 
10.2  Clinical/Public health implications of these findings: adiposity and 
atherosclerosis in Russia 
In my analysis, KYH women had a higher level of adiposity than Tromsø 7 women, 
regardless of the adiposity measure used. Abdominal obesity was much more prevalent than 
general obesity in KYH women with almost half the participants being affected despite the 
fact WC was assessed at the narrowest part of the trunk which would make underestimation 
of the prevalence of abdominal obesity more likely. This suggests that monitoring of 
adiposity using BMI alone may underestimate the burden of obesity and obesity-related risks 
in this population. Regular monitoring/screening of both general and abdominal adiposity 
such as WC will be beneficial for a more accurate assessment of adiposity-related risks. 
Our findings showed a higher plaque burden in the KYH population than the Tromsø 7 
population, which is accords with the fact that the CVD mortality rate in working-age people 
in Russia is higher than in high-income European countries. There was some evidence of an 
association between adiposity and carotid plaque burden, which was not statistically different 
between KYH and Tromsø 7. This is reassuring because this result implies that through 
prevention and treatment of obesity, a positive effect on cardiac health might be expected in 
Russia, as has been shown in extensive evidence from high-income European countries, 
mainly through improvement of cardio-metabolic mediators or directly. An effective strategy 
to reduce the adiposity burden will contribute to reducing the high CVD mortality in Russia, 
and is likely to further reduce levels in Norway. Improved control of cardio-metabolic 
mediators such as hypertension and hyperlipidemia will also mitigate the negative impact of 
obesity in both countries. 
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A key conclusion of my thesis is that adiposity did not explain the difference in carotid 
plaque burden between the two studies after adjustment for confounders (age, education, 
smoking), especially in men. Furthermore, even after further adjustment for cardio-metabolic 
CVD risk factors, such as high blood pressure in KYH, the difference in plaque burden 
between the two studies remained large and statistically significant. This agrees with previous 
studies which showed an excess CVD mortality rate in Russia beyond traditional CVD risk 
factors (4, 5). An implication of this is that other factors play an important role in excess 
CVD burden in Russia. In addition to interventions to reduce adiposity level and other 
traditional CVD risk factors, the identification of risk factors explaining the high plaque 
burden will be essential to improve cardiac health in Russia. Alcohol, specifically harmful 
drinking patterns, are considered to be involved in CVD development in Russia and could be 
an important candidate (170, 207, 208). Other potential risk markers include psychosocial 
risk factors and diet. 
10.3  Strengths and limitations 
Two population-based studies with similar study periods and study protocols enabled me to 
directly compare adiposity burden, carotid plaque burden, and its association with adiposity 
in the studies with a contrasting CVD mortality rate. Although carotid plaque is receiving 
more attention as an imaging biomarker to predict CVD risk, not many population studies 
have quantitative carotid plaque variables. Even among the limited studies with carotid 
plaque variables, the comparison of plaque burden between studies can be challenging due to 
the different methods of assessing carotid plaque. Comparison of quantitative carotid plaque 
in this study provided insights into different atherosclerotic changes and their association 
with adiposity between the two studies. 
However, the methods of assessing carotid plaque in KYH and Tromsø 7 are not fully 
comparable. As mentioned in detail in Chapter 5, a difference between the two studies in 
assessing plaque score may result in overestimation of plaque burden in KYH compared to 
Tromsø 7. However, as reported in Chapter 9, the results of a sensitivity analysis using a 
simplified plaque score, which is not affected by the information on the wall location of the 
plaque, showed results consistent with those using the original plaque score. Further, the 
prevalence of plaques (my other outcome, measured consistently in the two studies) was also 
substantially higher in KYH than in Tromsø 7.  
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Turning to the adiposity variable, the difference in WC measurement site between the two 
studies is another potential limitation. My calibration of WC in Tromsø 7 seems acceptable 
based on a conversion equation derived from relatively large Caucasian samples (161). 
However, the conversion using the equation does not allow for individual variability, which 
can introduce considerable imprecision. WC is a crude measure of visceral adiposity, and I 
am not aware of any previous study that shows either measurement site of WC is better than 
another in terms of the estimation of visceral adiposity and its consequences, including CVD 
events. Because neither WC is considered as a “gold standard” for assessing visceral 
adiposity, any correction of errors is not straightforward. Therefore, I chose a relatively 
simple approach and did not consider random variability when converting WC. A more 
advanced method is needed in terms of taking into account that neither of the WC measures is 
perfectly appropriate. Considering my simple approach to make two WC measurements 
comparable it is possible that differences in abdominal adiposity level between the two 
studies are under or overestimated. Although the importance of WC measurement has been 
well recognised, other studies, in addition to the current study, have used different 
measurement sites to assess WC. Standardisation of WC measurement protocols would be 
beneficial for interpretation and comparison of individual studies, which will assist the 
accumulation/synthesis of evidence. 
Furthermore, I did not correct measurement error in adiposity measures because ICCs I 
obtained might not be suitable for this purpose due to true changes in adiposity measures 
which occurred between two measurements. Heterogeneity in true changes will result in ICCs 
being reduced and correction factors being overestimated. Besides, recent research shows 
excellent reproducibility of adiposity measures, including abdominal adiposity measures 
(161, 165). Nevertheless, the associations between adiposity and carotid plaque burden in this 
study may be underestimated due to regression dilution bias.  
Another limitation regarding adiposity is the use of anthropometric measures. The three 
abdominal adiposity measures used in this study can provide information on fat distribution 
and compensate for the limitations of BMI. However, these measures cannot distinguish 
visceral adipose tissue from subcutaneous adipose tissue. Visceral adipose tissue is the most 
important player in obesity-related risk as it has a stronger association with CVD risk factors 
than subcutaneous adipose tissue (209). Although abdominal anthropometric adiposity 
measures correlated with visceral adipose tissue better than BMI, they still do not reliably 
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reflect visceral adipose tissue (83). Thus, ideally, the use of visceral adipose tissue as 
exposure will provide a more accurate picture of the association between adiposity and 
carotid plaque burden. However, it will require the use of MRI, DXA or CT scan, which, 
being more expensive and time-consuming, will probably not be suitable for large 
epidemiological studies consisting of healthy participants.  
Regarding the adiposity measures, a further limitation lies in the lack of body composition 
data. As was described in Chapter 2, the use of body composition data, especially in terms of 
lean mass, can be informative for understanding the health conditions, particularly in the 
elderly population. Several studies found that decreased lean mass was associated with an 
increase in CVD events, coronary calcium score, and arterial stiffness (210-212). Considering 
that the participants in both KYH and Tromsø 7 are relatively old, information on lean mass 
and sarcopenic obesity may be valuable, and an investigation of the association between lean 
mass and carotid plaque will undoubtedly be interesting. However, body composition was 
estimated using BIA in KYH, and DXA in Tromsø 7, and making two body composition data 
comparable was challenging. Further work is needed to investigate the role of lean mass in 
CVD burden among the Russian population. 
Finally, the statistical model in this thesis might have included other CVD risk factors such as 
physical activity and diet. In particular, physical activity is a crucial CVD risk protective 
factor. However, it was challenging to make physical activity variables comparable between 
the two studies. Further, as I mentioned in Chapter 5, physical activity is not simply 
considered as a pure confounder or a mediator regarding the association between adiposity 
and carotid atherosclerosis; physical activity is likely to be located in the upper stream of the 
causal pathway between adiposity and carotid atherosclerosis. Nevertheless, it might be 
interesting to conduct a sensitivity analysis to investigate the potential effect of physical 
activity on this association. A small sample of participants in both studies underwent an 
objective assessment of physical activity using heart rate and movement sensors. Sensitivity 
analysis using this objective measure of physical activity might be informative in the future. 
This objective measure could also be used to calibrate the two reported physical activity 
measures in the two studies. 
 Alcohol is another potential confounder which I did not include, although it may play a 
significant role in the CVD burden in Russia. As discussed in detail in Chapters 5 and 9, 
alcohol was not included in the model because comparable alcohol variables in the two 
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studies were not available when I obtained the dataset. In addition, it is questionable whether 
alcohol is considered as a confounder in the association between adiposity and carotid 
atherosclerosis: in spite of suggestive evidence between alcohol consumption and CVD 
events, it is still controversial whether alcohol is associated with atherosclerotic changes. 
Furthermore, one study showed the inclusion of hazardous drinking did not improve the 
SCORE performance in Russia (213), so the effect of alcohol on CVD might also be limited. 
Nevertheless, further research regarding the impact of alcohol is needed. 
Height may prove to be an interesting variable for inclusion in the model. Observational 
studies show that short adult height is associated with a higher risk for CVD events (214). 
This finding is supported by recent Mendelian Randomisation studies (215, 216). It seems 
that not only are environmental factors such as poor nutrition and socioeconomic status 
associated with higher CVD risk but also the genetic disposition to short height. One possible 
explanation here relates to the diameter of the coronary artery. In simple terms, taller people 
have a coronary artery with a larger diameter, which makes them less susceptible to the 
blockage of the artery (217). Because the participants in KYH were significantly shorter than 
those in Tromsø 7 (for both sexes), it is perhaps worth exploring the contribution of height to 
the association between adiposity and atherosclerotic changes in the carotid artery. 
10.4  Future areas of research 
The findings from this thesis suggest two strategies to improve cardiac health in Russia: 1) to 
monitor, prevent, and treat obesity in Russia to reduce the carotid plaque burden 2) to explore 
the critical risk factors explaining the excess carotid plaque burden in Russia. This identifies 
four domains of research questions to explore in the future. 
First, regular monitoring of adiposity in a general population in Russia will be necessary to 
estimate the accurate burden of obesity and trends in Russia. Since Russia is such a massive 
country, the population in KYH cannot be considered as being fully representative of the 
whole nation. Besides, KYH just provides a screenshot of the adiposity level instead of 
following its prospective change.  Accurate and prospective epidemiological data from more 
extensive areas will be a foundation for implementing the effective intervention. The use of 
BMI alone may result in underestimation of the obesity burden and obesity-related risks. The 
assessment of abdominal adiposity will compensate for the limitation of BMI, and help to 
capture the burden of obesity more precisely.  
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However, it should be noted that the standardised protocol of waist measurement is 
important. Although two recent population studies provide the prevalence of abdominal 
obesity in Russia (65, 191), the use of different adiposity measures (WC vs WHR) and 
different measurement sites (the mid-point between the top of iliac crest and the lower rib vs 
umbilicus site) makes the interpretation/comparison of the abdominal adiposity level 
difficult. In particular, the prevalence of abdominal obesity is considerably affected by the 
difference in measurement site of WC because the cut-off point is fixed (men: >102 cm, 
women>88 cm) regardless of the measurement site, which can lead to misleading outcomes 
(161). Monitoring abdominal obesity using a standardised WC assessment protocol, 
combined with proper staff training to reduce measurement error, is vital to providing 
comparable data among different sites. 
Second, to prevent and treat obesity in Russia, understanding of regional determinants of 
obesity will be crucial because they may be different from those in Western Europe. In 
Western Europe, generally, a low adiposity level is associated with health-conscious 
behaviours such as high educational attainment, increased physical activity, and healthy diet. 
However, this pattern might not be applicable to the Russian population. For example, a 
previous study suggests that high educational attainment is not significantly associated with a 
decrease in obesity level in Russian men, unlike Western European men (190). A relatively 
weak association between adiposity and plaque burden observed in KYH might imply that 
Russian participants with low adiposity levels have different characteristics from 
Norwegians; for example, being more likely to engage in unhealthy behaviour. 
A few studies have investigated the determinants of obesity in Russia (189, 218). However, 
these data are relatively old and may not be relevant today. Investigation of the determinants 
using contemporary data will be needed. Since the KYH Study has data on most of the 
potential determinants of obesity, such as detailed physical activity variables and educational 
attainment, it will be a useful dataset for further exploration. However, the limitation of the 
KYH Study for this purpose is that information on diet and nutrition is limited to a simple 
diet quality score. A previous study pointed out that diet might be an important factor to 
determine obesity in Russia (219). Russian diet seems different from Western European diet, 
being characterised by high animal food and fat and low fruit consumption (220). An 
investigation into the impact of diet and nutrition on obesity based on a detailed diet 
questionnaire would be informative. 
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Third, although this cross-sectional study can serve as a baseline study to explore the role of 
adiposity on carotid atherosclerosis in Russia, further research with better study design will 
be needed to confirm our findings. The prospective association between adiposity and carotid 
plaque burden will be important to estimate the longitudinal impact of adiposity on carotid 
atherosclerosis. In particular, the impact of the change in adiposity level on the progression of 
atherosclerotic change will be clinically informative. A study using visceral adipose tissue 
assessed by MRI, CT, and DXA instead of anthropometric measures will provide a more 
accurate estimation of the effect of adiposity. However, a study regarding adiposity, no 
matter how well designed, will be susceptible to residual confounders. Mendelian 
Randomisation studies may help to overcome this problem and elucidate this association 
more clearly. For example,  investigation of the association of genetic score of BMI and 
WHR with carotid plaque variables might provide better information on a causal pathway 
between carotid atherosclerosis and adiposity, and reduce the effect of residual or 
unmeasured confounders. 
Finally, since adiposity failed to explain the higher carotid plaque burden in Russia, 
determinants for excess carotid plaque need to be explored. Potential risk factors such as 
alcohol consumption, diet, and psychological factors should be explored. Quantitative carotid 
plaque variables could be useful outcomes in future studies. 
10.5  Concluding remarks 
The disproportionally high CVD burden in Russia compared to high-income Western 
European countries must be addressed. The rise in obesity prevalence is an increasing 
concern for both high-income Western European countries and Russia and may lead to 
further CVD burden in Russia. The current study provides insights into the impact of 
general/abdominal adiposity on carotid atherosclerosis in Russia compared to Norway, and 
the contribution of general/abdominal adiposity to the excess carotid plaque burden in Russia. 
The abdominal adiposity level seemed more problematic than the general adiposity level in 
Russian women. The burden of carotid plaque was consistently higher in both sexes in 
Russia, which agreed with the high burden of CVD in Russia. Although no adiposity measure 
was a determinant of excess carotid plaque burden in Russia, adiposity, especially abdominal 
adiposity, seemed to have a similar negative impact on carotid atherosclerosis in the two 
populations, suggesting that prevention and treatment of obesity will be as beneficial to 
reducing the CVD burden in Russia as it has been in high-income European countries. 
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Therefore, even if adiposity makes little contribution to explaining inter-country differences 
in CVD risk, the level of adiposity in both countries needs to be reduced to lessen the burden 
of CVD.  In Russia, epidemiological data on obesity are limited compared to Norway and 
other CVD low-risk countries. Therefore, in addition to a recent attempt to provide the 
prevalence of abdominal obesity, regular and prospective monitoring of both general and 
abdominal obesity will be beneficial in Russia. Moreover, an investigation of the 
determinants of obesity in Russia will help to implement effective interventions to reduce the 
obesity burden in Russia. Further research on the prospective association between adiposity 
and carotid plaque burden will be needed to confirm these findings.  
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Appendix A  
A.1 Systematic literature review search term 
Search term of systematic literature review 
1. Obesity-related terms: Obesity OR Overweight OR Body Mass Index OR “Body 
Weights and Measures” OR obes* OR obesity OR BMI OR Body mass index OR Body-mass 
index OR Weight for height OR Weight-for height OR Body fat OR Body fat percent* or 
Percent* body fat OR Fat mass OR Adiposity OR Waist circumference OR Waist 
measurement OR Waist-Hip ratio OR A Body Shape Index 
              AND 
2. Carotid ultrasound related terms: Carotid Intima-Media Thickness OR Intima*media 
thickness OR Carotid intima*media thickness OR Arterial thickness OR Arterial wall 
thickness OR carotid plaque OR plaque size OR plaque echogenicity 
               AND  
3. Adult 
              AND  
3. human 
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A.2 Systematic literature review: Data extraction sheet 
*Reference (first author/year):  
*country:  
*Study design: 
*year: 
*characteristic of population 
Sample size 
total 
 
N male  
N female  
Age lower range  
Age upper range  
Age mean  
ethnicity  
Source of 
sample 
 
Study 
population 
 
other  
Source of sample: 1. random sample 2. Non-random volunteer 3. Non-random other 4. Not 
clear 
Study population: 1. community 2. health check-up 3. Specific occupation 4. other   
*measure of adiposity (only one used in analysis) 
adiposity BMI WC WHR WHtR other other 
Mentioned?       
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Objective 
measurement? 
      
 
DEXA bioimpedance CT MRI  
     
 
*IMT measurement: 
1.R 2.L 3.Both  
1.CCA 2.Bulb 3.ICA  
1.far 2.near wall 
3.both 
 
Angle(single/multiple)  
Cardiac cycle (1. 
Diast 2.other 9.?) 
 
Max/average/both  
IMT calculation  
Use of software (0.1)  
definition  
other  
Assessor blinding  
 
*Plaque measurement: 
1.R 2.L 3.Both  
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1.CCA 2.Bulb 
3.ICA 
 
1.far 2.near wall 
3 
 
definition  
Mannheim 
Consensus 
 
Use of software  
Quantitative? 
(0.1) 
 
Quantitative 
measure 
 
Assessor 
blinding 
 
 
*Result 
Total population: 
Obesity/overweight prevalence: 
Plaque prevalence: 
Population IMT: 
Prevalence of thick IMT:  
History of CVD: 
Used adiposity var: binary/categorical/con  
Used IMT var: binary/con  
Association mentioned 1 (adiposity and 
IMT/plaque) 
 
association  
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Adjusted for  
(Statistical method)  
Association mentioned 2  
association  
Adjusted for  
(Statistical method)  
Association mentioned 3  
association  
Adjusted for  
(Statistical method)  
 
Male: 
Obesity/overweight prevalence: 
Plaque prevalence: 
Population IMT: 
Prevalence of thick IMT:  
Used adiposity var: binary/categorical/con  
Used IMT var: binary/con  
Association mentioned 1 (adiposity and 
IMT/plaque) 
 
association  
Adjusted for  
(Statistical method)  
Association mentioned 2  
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association  
Adjusted for  
(Statistical method)  
Association mentioned 3  
association  
Adjusted for  
(Statistical method)  
 
Female: 
Obesity/overweight prevalence: 
Plaque prevalence: 
Population IMT: 
Prevalence of thick IMT:  
Used adiposity var: binary/categorical/con  
Used IMT var: binary/con  
Association mentioned 1 (adiposity and 
IMT/plaque) 
 
association  
Adjusted for  
(Statistical method)  
Association mentioned 2  
association  
Adjusted for  
(Statistical method)  
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Association mentioned 3  
association  
Adjusted for  
(Statistical method)  
 
Conclusion: 
*Note: 
This article is.. 
Reference to check 
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A.3 Systematic literature review: quality assessment sheet 
Quality 
assessment 
criteria 
Acceptable(*) Yang Yeboah Youn Yun     
Selection  1 1 2 1     
Representativeness 
of the sample 
Truly representative of the 
average in the target 
population. 
Somewhat representative  
- * * -     
Sample size Justified and satisfactory - - - -     
Non-respondents Comparability between 
respondents and non-
respondents characteristics is 
established, and the response 
rate is satisfactory 
- - - -     
Ascertainment of 
the exposure  
Validated measurement tool 
 
* - * *     
Comparability  2 0 2 2     
The study controls 
for the most 
important 
factor(age/sex?) 
Yes * - * *     
The study controls 
for any additional 
factor 
 *  * *     
Outcome  3 2 2 2     
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Assessment of the 
outdcome 
Independent blind 
assessment** 
Validated measurement* 
** * * *     
Statistical test The statistical test used to 
analyse the data is clearly 
described and appropriate, 
and the measurement of the 
association is presented, 
including CI and p-value 
* * * *     
Overall quality 
score 
 6 3 6 5     
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A.4 The measurement of anthropometric measures (extracts from Know 
Your Heart protocol) 
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10.0 Waist and Hip Circumference 
 
10.1 Preparation 
7.1.1 Equipment needed 
 Seca measuring tape 
 
10.2 Procedure 
 
10.2.1 Explain to participant you are now going to measure their waist 
and hip circumference. 
 
10.2.2 Ask participant to remove bulky clothing and bulky objects from 
pocket. Participant should be wearing only 1 layer of thin clothing. 
Give them plastic tray for any objects they may have in their 
pockets. 
 
10.2.3 Participants should lift up the top half of their clothing (i.e. so 
participant naked at the waist and measurement is done on bare 
skin, not over clothes) to make it easier to assess position of the 
waist. Ask participant to stand with feet one foot apart and with 
arms folded across the chest. This is to keep arms out of the way 
during measurement. The participant should continue to hold 
their clothes up during measurement. 
 
10.2.4 Standing to the back of the participant, identify the waist as the 
smallest part of the trunk (i.e. natural indent). If it is not possible 
to locate the natural indent of the trunk, identify the umbilicus 
(“belly button”) and measure the circumference at this level. 
 
10.2.5  Working side on to participant hold the seca measuring tape in 
your left hand and pass the tape measure around the 
participant’s body with your right hand. Check tape measure is 
horizontal and not twisted. Insert the white plastic end of the 
tape into the groove of the housing, and ask participant to relax 
and breathe in and out slowly. The button on the measuring tape 
should be facing upwards. 
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10.2.6 While participant is breathing out, tighten or loosen measuring 
tape using button catch of the spring coil. Tape should fit 
comfortably around the participant without feeling either loose or 
tight. As participant slowly breathes out, but before they breathe 
in again record waist circumference on the proforma. Measure in 
centimetres accurate to the nearest millimetre - if it falls 
between two millimetres round upwards. 
 
10.2.7  With participant remaining in the same position slide the seca 
measuring tape to the widest part of the hips, checking it is 
horizontal and not twisted. Record hip circumference on the 
proforma. Measure in centimetres, accurate to the nearest 
millimetre – if it falls between two millimetres round upwards). 
 
10.2.8  Repeat measurement of both waist and hip circumference and 
record on the proforma. Two measurements of both waist and 
hip circumference should be recorded in total.  
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11.0 Height 
 
11.1 Preparation 
 
11.1.1 Equipment 
 
 Seca Portable Height measure 
Assemble height measure before starting. 
11.2 Procedure 
 
11.2.1 Explain to participant you are going to measure their height. 
 
11.2.2 Participant should be barefoot. 
 
11.2.3 Ask participant to stand with their back against the vertical scale, 
feet parallel to each other, toes pointing forward and soles flat on 
the floor. Check participant is standing unsupported, with legs 
straight and with buttocks and shoulder blades touching the 
vertical scale. Their shoulders should be relaxed, with arms by 
sides and they should not be slouching or leaning to one side 
 
11.2.4  Ensure participant has no neck problems or recent neck surgery 
prior to positioning head then ask participant if it is ok to position 
their head. If so, gently position participants head so they are 
looking straight forward (not nose in the air), with their ear holes 
in the same horizontal plane as the lower border of their eye 
sockets (Frankfurt Plane). 
 
11.2.5  Ask participant to stand as tall as possible and take a deep breath 
in. While they are doing this bring the horizontal measure down 
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on top of their head. Record measurement on proforma in 
centimetres, accurate to the nearest millimetre (if falls between 
two millimetres round upwards). 
 
 
11.2.6  Repeat height measurement and record in the proforma (2 
height measurements in total). Ask participant to walk around 
room in between height measurements. 
 
 
12.0 Weight, body composition analysis 
 
12.1 Preparation 
 
12.1.1 Equipment 
 
 Tanita body composition analyser 
 Laptop with the software “Tanita” 
 
The platform for the Tanita body composition analyser should be wiped with 
disinfectant wipe between participants. Metal handles of the Tanita body 
composition analyser should be wiped with disinfectant wipe between 
participants. 
 
12.2 Procedure 
 
12.2.1 Ask participant if they have a pacemaker or if female if they are 
pregnant.  
 
If answer is "yes" explain to the participant you are going to measure their 
weight and switch body composition analyser to weight only mode (go to 
section 12.4).  
 
If answer is "no" explain to the participant you are going to measure their 
weight and assess body composition. Explain analyser measures body 
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composition by passing a small electric current through body. If participant 
wishes to undergo this procedure then use body composition mode 
(section 12.3). If participant does not wish to undergo this procedure then 
use weight only mode instead (section 12.4) 
 
 
12.3 Measurement using Tanita body composition analyser (Standard) 
 
12.3.1 Ask the participant to remove their shoes and 
socks/stockings/tights. Participants should be barefoot. Bulky 
clothing and bulky item should have been removed from pockets. 
Participant should be wearing only 1 layer of thin clothing.  (see 
section 10 on measurement of waist circumference). Take 
measurement in body composition mode  
 
 
12.3.2  Enter information on clothing weight (1 kg). In the “name” field, 
fill in the participant ID (no not fill in the actual name). 
 
12.3.3 Ask participant to place their bare feet on analyser platform’s 
markings and not to move their feet. Ask the participants to use 
their hands to grip the two metal handles firmly with arms 
hanging loosely by sides. Participant’s arms should not touch their 
sides and inner thighs should not be touching. 
 
12.3.4 Enter information on: 
 Body type (designate as standard) 
 Gender 
 Date of birth (15th of the month/ month /year not actual date 
of birth) 
 Height (cm) 
 
12.3.5 The analyser measures weight first. After measuring weight ask 
the participant to firmly hold on to the two metal handles, their 
hands need to hang freely at their side. The analyser emits a 
“beep” each time it measures body impedance (make sure beep 
setting is on). It emits a “beep beep” noise to indicate it has 
finished measuring both weight and body impedance. 
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12.3.6 Ask participant to step off device.  
 
 
12.3.7 Save results of body composition analysis directly to laptop (no 
paper record). If there is a problem with saving to the laptop a 
paper printout should be obtained directly from the Tanita 
device. 
 
12.4 Measurement of weight only (alternative method) 
 
Note: Use this method if participant has a pacemaker, is pregnant or refuses 
body composition measurement. 
 
12.4.1 Explain to the participant you are going to measure their weight. 
Participant should remove footwear heavy jewellery, bulky 
clothing and bulky item should have been removed from pockets. 
Participant must be barefoot. Participant should be wearing only 
1 layer of thin clothing (see section 10 on measurement of waist 
circumference). 
 
12.4.2 Participants should stand with weight equally distributed on legs, 
looking straight ahead, arms hanging loosely by their side not 
holding on to anything. 
 
12.4.3 Make sure the body composition analyser is switched to weight 
only mode, perform and record measurement of weight. 
 
12.4.4 Record weight measurement in the proforma accurate to the 
nearest 0.1 kg 
 
12.4.5 Ask participant to step off scale.
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A.5 The mean value of waist circumference before and after the 
conversion in Tromsø 7 visit 1 participants 
 Men Women 
Age category 
(year) 
Original 
umbilicus WC  
Mean (SD)(cm) 
Converted 
Minimal WC 
Mean (SD)(cm) 
Original 
umbilicus WC 
Mean (SD)(cm) 
Converted 
Minimal WC 
Mean (SD)(cm) 
40-44 98.58  
(11.79) 
95.96  
(11.14) 
88.40 
(12.89) 
80.05 
(11.63) 
45-49 99.87 
(11.80) 
97.64 
(11.14) 
90.03 
(13.69) 
81.67 
(12.35) 
50-54 99.64  
(11.25) 
97.90  
(10.63) 
89.42 
(12.99) 
81.28 
(11.72) 
55-59 100.29  
(10.65) 
98.99  
(10.06) 
91.31 
(12.42) 
83.15 
(11.20) 
60-64 100.34 
(11.08) 
99.52 
(10.48) 
91.22 
(12.42) 
83.23 
(11.20) 
65-69 101.09 
(11.37) 
100.69 
(10.75) 
92.16 
(12.59) 
84.23 
(11.36) 
WC: waist circumference 
Umbilicus WC: measured at the level of the umbilicus, minimal WC: measured at the 
smallest part of the trunk 
 
Original umbilicus waist circumference was converted using the following conversion 
equations taken from Mason et al.  
Women: -1.02517 + 0.03207*age + 0.90184*original waist  
Men:  -1.19141 + 0.09503*age + 0.94491*original waist  
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A.6 Protocol for ultrasound examination 
  
  
 
Study of Cardiovascular Disease in Russia 
 
Title: Standard Operating Procedures for Ultrasound Image Acquisition  
Document number: SOP9 Version number:1.6 
Creation Date: 08/11/2013 Number of pages: 24 
Comment: This SOP is based on draft imaging and instrumental protocol produced in 
Novosibirsk 23/5/12 Name:Andrey Ryabikov, Sofia Malyutina 
Content 
originators 
Name: Andrey Ryabikov, 
Sofia Malyutina 
Signed: Date: 
SOP Production Name: Sarah Cook Signed: Date: 
Content Approval Name:  Signed: Date: 
Contact: sarah.cook@lshtm.ac.uk 
 
Amendment Record  
Version 
number 
Date Changes Made Reasons for 
Changes 
Changes 
made by 
1.1 20/11/13 Incorporation of 
comments from Darryl 
Leong and Alun 
Hughes 
Further 
development of 
protocol 
Sarah Cook 
1.2 24/11/13 
20/01/14 
Incorporation of 
comments from 
Andrey Ryabikov, Sofia 
Malyutina 
Further 
development of 
protocol 
Andrey 
Ryabikov, 
Sofia 
Malyutina 
1.3 12/02/14 Incorporation of 
comments from 
project meeting 
Meeting points from 
Henrik Schrimer, Elisiv 
Mathiesen, Darryl 
Leong,Alun Hughes, 
Andrey Ryabikov, Sofia 
Malyutina 
Further 
development of 
protocol 
Andrey 
Ryabikov, 
Sofia 
Malyutina 
1.4 (1) 24/04/14 
 
 
Incorporated 
comments from GE 
London (7.1; 9.1-9.3) 
Further 
development of 
protocol 
Natan Simcox 
 
 
1.4 (2) 26/06/14 
 
Incorporated 
comments from Nov 
training session 
Further 
development of 
protocol 
Andrey 
Ryabikov, 
Sofia 
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Points form Nov team 
(Tab 1, Tab 4; 7.1; 
7.2;7.4 7.5;9.0); 
Malyutina 
 
1.4 28/09/14 Incorporated 
comments from GE 
Moscow (9.2-9.3) 
Further 
development of 
protocol 
Denis 
Rusakov,  
Ilya Botvin 
1.4 24/10/14 Comments from 
Tromsoe 
Further 
development 
H. Schirmer 
1.5 06/03/15 
04/08/15 
10/09/15 
After Tromsoe 
comments & after 
Pilot 
Further 
development 
Andrey 
Ryabikov, 
Sofia 
Malyutina 
1.6 12/01/16 Patient’s initials 
format; 
AUS update (NOV 
optional US study); 
Minimal clarification 
Echo (Frame rate, PW 
AoV);  
VUS preferable 
position 
Further 
development 
Dave Leon 
comments 
Andrey 
Ryabikov 
Sofia 
Malyutina 
 
 
1.0 Purpose 
The purpose of this SOP is to provide the correct procedure for ultrasound 
examinations. 
 
2.0 Responsibilities 
 
 
 
 
 
3.0 Definitions and abbreviations 
 
Terminology Definition 
SOP Standard Operating Procedure 
ECHO Echocardiography 
VUS Vascular Ultrasound 
AUS Abdominal Ultrasound 
QC Quality Control 
CRL Central Reading Laboratory 
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LAN Local Area Network  
IQC Internal Quality Control 
EQC External Quality Control 
IMT Intima Media Thickness 
CCA Common carotid artery 
ICA Internal carotid artery 
ECA External carotid artery 
IVC Inferior Vena Cava 
Nov Novosibirsk 
Arkh Arkhangelsk 
SW Software 
AF Atrial Fibrillation 
 
 
4.0 Staff, training, quality control 
4.1 The staff for ultrasound team should satisfy formal criteria: to be certified 
physicians in Ultrasound with experience in ECHO and vascular ultrasound; 
optionally in Novosibirsk - should also have experience in abdominal 
ultrasound. The number of specialists should be at least 4 per centre to 
ensure examination 2 terms a day and potential substitution. 1 medical 
nurse is needed to assist ultrasound exam at each site/district within 
participating centre.  
4.2 The team should read SOP and organize at least one local “hands-on” 
training for standardized ECHO and vascular examination under supervision 
of local senior specialist (AR –Nov, AK-Arkh). Each observer should prepare 
1 test record for review in Central Reading Lab (CRL, Nov).  
Test record should correspond to the following criteria: 
- fulfilled on digital ultrasound machine (GE’s Vivid family preferable). 
Otherwise the scanner selection among available is to be advised by CRL 
supervisor (AR); 
- include still images and cine loops for Echo/VUS/AUS(Nov) depending on 
observer’s responsibility in the project; 
- correspond to SOP according to image acquisition (required views and 
modalities), system setting and image quality; 
- recorded in original raw format for Vivid or in DICOM (other machines), 
otherwise recorded as sequence of files containing still images (*.jpg) and 
cine loops (*.avi; *.mpeg); 
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- records from each observer should be collected in one folder and 
followed with inventory file containing Centre number, observer ID 
number, type of Exam, date of record, list of image files; 
- the folder(s) are to be saved on DVD disks and sent to CRL for qualification 
review; DVD should be marked with permanent marker: indicate number of 
disk, centre name, personal ID’s of observers included, and mark as ”Test 
Records” project into cover box from physical damage; 
- CRL should fulfil review of test records and provide “Quantification 
ECHO/VUS QC scan review”; 
 
4.3 The team will attend centralised training sessions and read SOP. Training 
for all ECHO, VUS (and AUS) observers and readers should take place in a 
central location (e.g. headquarters of the GE company in Moscow). The 
sessions will include “hands-on” training for standardized acquisition/ 
standardized ECHO and vascular examination procedure/data storage.  
 
4.4 Timelines:  
- test records preparing and sending to CRL - April 2014, CRL review – 
May 2014); 
- centralized training session – 1-2 October 2014; 
4.5  Internal quality control (IQC) – senior specialist at site will monitor the 
technical quality of ultrasound performance from all specialists in pre-pilot 
period, in pre-survey period and once a month across survey period; 
encode study quality in IQC worksheet; 
4.6 External QC (EQC) – the supervisor(s) from CRL (Novosibirsk) and from 
comparative centre (Tromso) will visit all centres in 3 months after field 
work started, then once a year during the course of study. 
 
5.0 Related documents 
5.1 SOP for vascular ultrasound 
5.2 SOP for EchoCG (ECHO) 
5.3 SOP for abdominal ultrasound  
5.4 SOP for image analysis  
5.5 Table with cine loops to be acquired and their sequence for use during 
examination  
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6.0 Health and Safety  
 
7.0 Ultrasound Image Acquisition 
 
7.1 Preparation 
7.1.1 Equipment needed: 
 Ultrasound machine (Vivid q) 
 Correct probe for Ultrasound ( phased array Sector 
probe M4S-RS for ECHO, Linear probe 12L-RS for VUS, 
Convex probe 4C-RS for AUS) 
 Desktop/Laptop workstation running EchoPAC SW  
 High capacity external HD/USB memory stick 
 Examination couch 
 Lubricating jelly, tissue towels, disposable linen 
(sheets) 
 Electrocardiogram leads and disposable electrodes 
7.1.2 Setting up machine. 
 Linear probe should be attached to the scanner before 
plug in (Vivid q can only have 1 probe attached at a time) 
 Turn on the power on main unit, wait till machine 
complete it’s loading 
7.1.3 Log on as USR (No password required), select “Archive” and “Create 
new patient”.  
- Upload patient’s ID number with barcode scanner: place the blinking 
cursor in the {Patient ID} box & scan the barcode by reader (this should 
fulfil the Patient ID box with the details contained in the barcode), 
check this with paper copy).  
- Add to Patient’s ID suffix with a “V” for Vascular, “E” for Echo, “A” for 
Abdominal exam. 
- Enter patient’s Initials ; Birth date in the format 15/mm/19yy; enter an 
operator’s personal ID, enter appropriate {Echolab} as “Nov” or “Ark” 
and select examination type (start with “Vascular”); then push “Start 
exam” button on the screen. 
- [Application] – select the {12L-RS / M4S-RS / 4C-RS} probe, then the 
{Project name} preset. Change to ‘AF’ preset if patient is in atrial 
fibrillation (AF). 
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- At the end of the Vascular procedure press [Patient], {Create New 
Patient/Exam} and repeat the procedure above to create a new patient 
ID for the Echo / Abdominal exams. 
 
7.1.4 Linear barcode IDs should be used throughout. Study ID consists of 7 
digits (centre-specific digit which allow identification of study centre by 
co-ordinators, check digits, order number and reporting unit number).  
 
 
 
 
 
 
7.2  Timing 
Diagram of the ECHO & US consequence and timing (totally 75 min per participant). 
i. Patient 
preparations 
ii. Vascular 
Ultrasound 
iii. BP 
measurement* 
iv. EchoCG v. Abdominal 
Ultrasound 
vi. Data 
archiving 
(5 min) (20 min) (5 min) (30 min) (10 min) (5 min) 
 
*For BP measurement use dominant arm (the same arm as during survey).  
 
7.3 Participant Preparation 
 
7.3.1 Explain to participant you are now going to carry out an ultrasound of 
their blood vessels, heart and abdomen. This should take approximately 
1 hour. 
 
7.3.2 Ask participant to remove top half of their clothing. 
 
7.3.3 Position participant appropriately.  
 
7.3.4 Place 3 electrocardiogram leads on the participant’s chest wall in 
positions that will not interfere with positioning of the ultrasound 
probe during image acquisition. In general, leads should be placed as 
follows: 1 near the right shoulder, 1 near the left shoulder and 1 on the 
lower ribs near the right abdomen. The most important is that a clear 
QRS signal is seen on the screen with no noise in the signal. 
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7.4 Vascular Ultrasound Procedure 
 
7.4.1 Vascular carotid ultrasound (VUS) should be performed first (before 
ECHO)  
7.4.2 The VUS examination should take approximately 20 minutes 
7.4.3 In addition to this SOP sonographers should be given a table 4 detailing 
the cine loops and still images to be recorded and their sequence which 
can be used during the VUS 
7.4.4 Attach ECG leads with stable ECG curve on the screen, provide high 
voltage 
7.4.5 Patient position: supine 
 Thin (half empty) pillow could be used as under-neck 
support to achieve moderate extension in short-
necked; it also helps on muscular compliance in 
stooped patients 
 Light head rotation opposite to examined site is 
recommended to improve submandibular acoustic 
window (rotation angle is unspecified) 
7.4.6 Both sides will be examined (Left & Right) 
 always start from the left 
 repeat for right side 
7.4.7 Image acquisition: 
- B-mode is a basic regimen for all obligatory images and videos.  
- Harmonics and Colour flow Doppler could be used for better plaque 
detection and defining its surface. 
- Preparing to measure intima-media thickness: 
- 10 consecutive cardiac cycles should be acquired for each image (in case of 
atrial fibrillation or otherwise)  
- Use for visualization that probe position which is closer to the vessel and 
where intima/lumen interface is better discernible 
- indicate in a commentary sheet probe position (A-anterior, L-anterolateral, P-
posterolateral) 
- probe should be perpendicular to the intima-media surface 
- use highest probe frequency (not sacrificing clear visualisation) 
- only 1 focal zone is required (to increase frame rate) 
- frame rate (FPS) should be the highest (not less than 40/sec if “Vivid q” is 
used) 
- don’t use 2nd harmonics for IMT video clip.  
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- don’t use “Virtual convex” (or “Wide view” or “Trapezoid view”) option 
- use magnified images with high frame rate (but not zoomed images)  
- The following images will be acquired with the participant in supine position: 
7.4.8 Longitudinal view (B-mode): 
 ECG-gated longitudinal view of at least 10-mm at the far wall 
of the distal CCA for further measurement of IMT and 
interadventitial diameter, preferably in plaque-free zone 
(Video clip) 
 Fast scanning of common carotid arteries (CCA) with branches 
whatever is visible to assess the anatomy and atherosclerotic 
lesions (video clip of CCA, bulbus, ICA, ECA). 
 Plaque is defined as a focal structure encroaching into the 
arterial lumen of at least 0.5 mm or 50% of the surrounding 
IMT value, or demonstrates a thickness 1.5 mm as measured 
from the media-adventitia interface to the intima-lumen 
interface (Mannheim Consensus, 2006). 
 In case of suspected plaque and/or intima bulging freeze the 
image; still image and additional video should be stored to 
assess plaque length and morphology 
7.4.9 Turn the probe 90 degrees clockwise for left side and counter clockwise 
for the right to acquire transverse views. 
7.4.10 Transverse view (B-mode): 
 Repeat careful scanning of CCA with branches whatever is 
visible to assess the anatomy and atherosclerotic lesions 
(video clip of CCA, bulbus, ICA, ECA). In case of plaque and/or 
local thickening freeze the image; still image should be stored 
to assess plaque circumference at most prominent segment 
7.4.11 Complete the procedure by BP measurement on dominating arm (in 
clinostasis) 
 
7.5 ECHO Procedure 
 
7.5.1 The ECHO examination should take approximately 30 minutes 
 
7.5.2 In addition to this SOP sonographers should be given a table detailing 
the cine loops and still images (Table 1) to be recorded and their 
sequence which can be used during the ECHO. 
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7.5.3 Patient position: left decubitus 
 
7.5.4 Image acquisition: 
For all 2D images, optimisation of gain, depth and sector width settings should be 
performed to maximise endocardial and epicardial definition and to achieve a frame 
rate at least 50/sec. Frame rate above Only 1 focal zone is required (to increase 
frame rate). Keep 2D image frozen in M-mode and spectral Doppler recording (PW, 
TDI). Always use breath hold to optimize image quality for TDI measurements; for 
other images, only if necessary.  
If the participant is in atrial fibrillation, 10 cardiac cycles should be acquired for each 
image; otherwise 5 consecutive cardiac cycles should be acquired.  
The following images will be acquired  
The manipulations are arranged by approach order and by technology. 
Parasternal long-axis.  
 2D images of the left ventricle (LV), aortic root and left atrium (LA).  
 B-guided M-mode of the basal left ventricle. The image acquisition plane 
should be as close as possible to perpendicular to the long-axis of the LV. 
M-cursor is positioned anatomically below the tips of mitral valve 
cooptation point, on mitral chordae. 
 Parasternal long-axis M-mode of aorta (AO) and left atrium. The image 
acquisition plane should be as close as possible to perpendicular to the 
long-axis of the LA. 
 Colour-flow Doppler recordings to search for MR and AoR. 
 Parasternal long-axis 2D with depth adjusted to enlarge image of the 
aortic annulus together with adjacent left ventricle outflow tract (do not 
use Zoom function; increase frame rate by reducing sector width). 
Parasternal short-axis. 
 2D level of aorta and left atrium. PW Doppler recording in pulmonary 
artery. 
 Optionally: 2D of LV in appropriate levels if myocardial asynergy present. 
 Repeat Parasternal long-axis B-guided M-mode of the basal left 
ventricle. 
4-chamber apical view.  
 2D of LV and LA with maximal chamber dimensions, good LV endo-
/epicardial definitions, and including right chambers. 
 Colour-flow Doppler recordings of mitral valve. 
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 Pulsed-wave Doppler with the sample volume positioned in LV cavity at 
the mitral leaflet tips. 
 Colour-flow Doppler recordings in tricuspid valve and CW Doppler 
recordings for detection of tricuspid regurgitation, if any (adjust CW 
velocity scale lower, start with 3-4 m/sec at least). 
Off-plane 4-chamber apical 2D image of right ventricle (RV). View focusing on the 
RV between 4- and 5-chamber view (showing the maximum RV 
transversal diameter). The depth adjusted so that tricuspid annulus is 
at the bottom. Imaging should be performed during breath hold. 
Off-plane 4-chamber apical  
 M-mode with the imaging plane through the lateral tricuspid annulus. 
For this image, the position of the heart within the imaging sector 
should be such that the plane of movement of the lateral tricuspid 
annulus is as close to vertical as possible. Use the patient’s breath hold 
to avoid excessive heart movement. 
3-chamber apical view;  
 continuous-wave Doppler (CW) with the cursor placed in mainstream 
of AO transvalvular flow.  
 3-chamber apical; pulsed-wave Doppler (PW) with the sample volume 
placed in the centre of the left ventricular outflow tract with just one 
of two leaflet closure signals present. 
4-chamber apical 2D image of the left ventricle, with the depth setting adjusted so 
that the mitral annulus is at the bottom of the sector throughout the 
cardiac cycle, and with the sector width adjusted to encompass the 
entire thickness of the left ventricular myocardium with the frame rate 
within 50-80 fps.  
2-chamber apical 2D image of the left ventricle, with the depth setting adjusted so 
that the mitral annulus is at the bottom of the sector throughout the 
cardiac cycle, and with the sector width adjusted to encompass the 
entire thickness of the left ventricular myocardium with the frame rate 
within 50-80 fps and with the anterior wall optimally visualized, if 
necessary during breath hold. 
4-chamber apical 2D image of the left atrium, with the depth setting adjusted so 
that the left atrial roof is at the bottom of the sector throughout the 
cardiac cycle, and with the sector width narrowed to encompass only 
the entire left atrium. Change focus position accordingly. Frame rate is 
to be within 50-80 fps 
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2-chamber apical 2D image of the left atrium, with the depth setting adjusted so 
that the left atrial roof is at the bottom of the sector throughout the 
cardiac cycle, and with the sector width slightly narrowed to encompass 
the entire left atrium. Frame rate is to be within 50-80 fps 
4 chamber apical; Mitral Annular Doppler Tissue Imaging: the DTI PW Doppler 
sample volume is placed at the medial (septal) corner (5 beats) and, 
subsequently, at the lateral corner of the mitral annulus (5 beats). ‘Tilt’ 
function could be used for better alignment between cursor and wall. 
(Optimally this is achieved by changing probe position). Always keep 
breath hold at expiration. 
 
7.6 Abdominal ultrasound* 
* Abdominal sonography is to be performed in NOV only (optional for 
Arkhangelsk) 
 
 
 
 
8.0 Transducer Cleaning 
8.1 All transducers must be cleaned after every use. 
8.1.1  After every exam, ensure the acoustic coupling gel is completely wiped 
off the transducer. Transducers should not be left soaking in gel 
8.1.2  Remove any transducer cover, biopsy guides, or protective devices 
from the transducer. 
8.1.3  Use a moistened soft cloth or wipe to remove any remaining 
contaminants that remain on the transducer or cable. Do not re-use 
cloths or wipes. Soap, detergents or enzymatic cleaners should be used 
in accordance with the manufacturer’s instructions. (Notes: Cleaning 
products should be as close to neutral PH as possible. Any gel, cleaning 
or disinfectant products containing concentrations surfactants, 
methanol, ethanol, benzyl or methyl alcohol, bleach, methyl or ethyl 
paraben, polyethylene glycol, mineral oil, lubricant oil, oil based lotions, 
acetone, ammonia, anhydrous ammonia, iodine, iodine compounds, 
acids with 5PH or greater may damage or discolour your transducer. 
The use of any type of brush is not recommended as bristles may 
damage lens materials. Ultrasonic cleaning should not be performed. 
8.1.4  If rinsing is required, use caution not to expose the system connector 
to moisture or liquids.  
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9.0 Data storage and transfer 
 
9.1 All exams (images/cine loops) should be stored in RAW format on 
machine’s internal HD and copied to Workstation running EchoPac SW 
(capacity 0.5 Tb) located in ECHO room. Files should be backed up at 
regular basis (weekly). 
 
9.2 Coping of examinations from the scanner to EchoPAC PC done offline 
The procedure is to be done by dataflow manager or supervisor at regular 
basis (weekly). There are two options to copy data : using external HD 
/Memory stick OR by direct connect or network with EchoPac Workstation. 
When reconnected, copy the data (images, demographics, measurements 
and report) for the examination(s) done offline to USB HD and EchoPAC PC by 
the following steps: 
 
1. Press PATIENT on the Front panel, then select Patient List. 
The Search/Create Patient window is displayed 
2. Select the source archive in the Dataflow field: Local Archive-Int.HD: 
exports data from the local archive.). 
3. Press Export in the Search/Create Patient window. 
4. Select the following destination from the Destination drop-down menu: 
- USB HD/Memstick Archive (to copy to USB HD/Memstick) or  
- Remote Import/Export Archive (to copy to EchoPAC PC by direct connect 
or network): exports raw and DICOM (if present) data. 
 
5. To FORMAT USB HD/ Memstick as required. 
Insert the USB external HD (or USB Memory Stick) and press {Config} от the 
panel, go to {Connectivity}, then to the {Tools}, select {USB Memstick} from 
the dropdown menu; insert the name into the “Label” box (if needed), press 
{Format}, press {ok}. 
6. Search and Select the patient records/examinations to export in the 
Patient list. 
The following selection methods can be used: 
- Press and hold down SHIFT while selecting patient records/examinations to 
select several consecutive items at a time. 
- Press and hold down CTRL while selecting patient records/examinations to 
select several discrete items. 
- Press Select all in the Export patient window to export all patient records. 
7. Adjust the following settings: 
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• Tick Copy images 
• Caution: NOT tick “Delete selected patient(s) after copy”!  
8. Press Copy. 
If one or more patient examination is already present in the destination 
archive the Export/Import conflict window is displayed. For each conflicting 
item, select: 
Keep: to keep the existing examination in the destination archive. 
Replace: to replace the existing examination with the corresponding item in 
the source archive. 
Press OK to resume export. 
A progress indicator is displayed. When done a status window is displayed 
showing the number of patient records that have been successfully exported. 
9. Press OK. 
A check mark is displayed in the Copied field in the Export patient window for 
each item exported. 
A status message is displayed for each item exported. 
Make sure that the operation was successful for each item exported. 
10. Press Done in the Export patient window to complete the process. 
11. If copy to USB HD/Memstick - then press [Alt + E] to bring up the eject 
menu. Select the {USB HD} from the eject list & wait for the USB 
HD/Memstick to be ready to disconnect (message at bottom of screen) 
before removing. 
 
12. Copy the data from USB HD/Memstick to EchoPac Workstation 
(if direct connection or network is not used for data flow) 
To copy these images to the EchoPac Workstation - log in to the EchoPac 
application as ADM. Insert the USB HD/Memstick & go to {Import}, select 
{USB HD/Memstick} from the dropdown menu. On this Import screen 
highlight the studies to be imported (use CTRL or SHIFT to select multiple 
studies), then press {copy}. Once copying to the EchoPac Workstation has 
completed select {Done}, then [Alt + E] to bring up the eject menu. Select the 
{USB HD} from the eject list & wait for the Memstick to be ready to 
disconnect (message at bottom of screen) before removing. 
13. Review on the EchoPAC PC Workstation 
-  Select the Local Archive-Int.HD dataflow on the EchoPAC PC (can be 
configured as default dataflow). 
- Press Archive and select the patient to be reviewed. 
In case of copy via network - do NOT open a study on the EchoPAC PC 
Workstation before the study is closed on the scanner. 
 
9.3  Аcquired data (images/cine loops) should be later exported from EchoPac 
Workstation to external HD (high capacity USB memory stick) for reading 
and back-up copy in following steps: 
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- To copy exams on to USB Memory stick log on to the EchoPac application as 
ADM in the EchoPAC Workstation; 
- Insert the USB Memory stick and go to {Import}, select {USB Memstick} from 
the dropdown menu; 
- SELECT patients from EchoPac server to be exported; select ECHO, VUS (+AUS 
in NOV) for the same patient (notice if summary capacity of selected 
records is not higher that capacity of memory stick); 
- On this IMPORT/EXPORT screen highlight the studies to be exported (use 
CTRL or SHIFT to select multiple studies), then press {COPY}.  
- To FORMAT USB Memory Stick (if needed): 
Insert the USB Memory stick and press {Config} от the panel, go to 
{Connectivity}, then to the {Tools}, select {USB Memstick} from the 
dropdown menu; insert the name into the “Label” box (if needed), press 
{Format}, press {ok}. 
- Once copying to the Memory stick has completed select {DONE}, then [Alt + 
E] to bring up the eject menu. Select the {USB HD/Memstick} from the 
eject list and wait for the Memory stick to be ready to disconnect 
(message at bottom of screen) before removing; 
- Repeat all steps for second copy (local storage); 
- Sign/mark memory sticks with permanent marker: indicate number of stick 
and centre name. Each data carrier should be supplied by inventory form 
which include number of stick, centre name, IDs of records included, and 
mark as ”CRL” or “Local”; place into cover box from physical damage. 
 
9.4 There should be regular checks by one member of team collecting ECHO 
and ultrasound data that all data is being saved correctly. 
 
9.5 Memory sticks with ECHO, VUS (+AUS in NOV) are to be periodically 
transferred to Central Reading Lab (CRL) for qualitative assessment, 
calculations and analysis by independent readers. 
 
9.6 To ensure enough capacity of ultrasound scanner to save new RAW data – 
the data copied on EchoPAC PC Workstation should be deleted from 
scanner’s internal HD when internal HD is loaded for 75-80%. Before 
erasing, local senior specialist should check the presence of relevant 
records on EchoPAC PC Workstation and register the batch of records 
deleted (ID’s range or dates range) in IQC worksheet. 
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9.7 Data backup should be provided by local centre for local storage. Backup 
data might be used locally in order to provide clinical conclusion for 
examined patients 
 
10.0 Image analysis (reading) 
10.1 Independent off-line analysis will be carried out by Central Reading 
Lab (CRL) using EchoPAC workstations   
-  In CRL (NOV) two senior readers with established good inter-reader 
reproducibility and 2 trained readers will be involved.  
- -Periodic joint reading sessions will train for parallel reading styles.  
- -Repeated reading of same images will be done periodically to check 
temporal drift. 
- -To establish intra-reader and inter-reader variability, a double blind 
reading of image samples (30 records) will be done within Novosibirsk CRL 
between all readers at the initial stage of reading period and annually.  
- For compatibility purposes, also a double blind reading (30 records) per 
year will be done between Novosibirsk Reading Centre and Tromsø 
Reading Centre. 
 
10.2 The reading for ECHO, VUS and AUS will include quantitative 
measurements/calculations and grading listed in Tables 2 and 3 (ECHO), 
Tables 5 and 6 (VUS), Tables 8 and 9 (AUS).  
 
10.3 Reading strategy : 
- Batch read when possible to minimize systemic temporal drifts. 
- Repeat reading of same images periodically to check temporal drift. 
- -Average measures for multiple beats (minimum 3 in regular rhythm, 5 in 
atrial fibrillation). 
 
10.4 ECHO, VUS (+AUS in NOV) report which will be fed back to participants 
will be done independently of standardised reading for study within 1 
month of ultrasound examination. 
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Table 1. Sequence and type of echocardiographic images to record (each ECHO site) 
Echocardiographic window and view Type of images (still / loop) 
Parasternal long-axis: 
2D of LV: 5 beats cine loop 
M-mode cursor perpendicular through LV below the mitral leaflet: 5 beats  Still 
M-mode cursor perpendicular through AO and LA: 5 beats 
Additional M-mode scan for LA if necessary (in case of enlarged Valsalva sinuses) 
Still 
- 2D of LVOT and Ao annulus: 5 beats. cine loop 
- Colour-flow Doppler recordings to search for MR and AoR: 5 beats cine loop 
Parasternal short-axis view with perpendicular approach from long axis kept: 
- 2D at level of AO and LA: 5 beats. cine loop 
- PW Doppler recording in PA: 5 beats. Still 
- Optional: 2D of LV in appropriate level in case of a-/ hypokinesia: 5 beats. cine loop 
  
- Repeated M-mode of LV Parasternal long-axis: 5 beats Still 
Apical 4-chamber view: 
- 2D of LV and LA: 5 beats with max chamber dimensions, good LV epi/endocardial 
definition and both right chambers visualised. 
 
cine loop 
- PW Doppler transmitral flow with sample volume at leaflet tips during diastole: 5 
beats 
Still 
- Colour-flow Doppler of mitral valve: 5 beats cine loop 
- Colour-flow Doppler in tricuspidal valve: 5 beats 
- CW Doppler for TR: 5 beats 
cine loop 
still 
Off-plane RV between 4- and 5-chamber: 
- 2D of RV: the depth adjusted so that tricuspid annulus is at the bottom; max RV 
transversal diameter and area: 5 beats 
cine loop 
Off-plane apical 4-chamber view for Tricuspid Annulus: 
- M-mode: cursor perpendicular through the lateral Tricuspid annulus: 5 
beats 
Still 
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Apical 3-chamber view (LV) 
- CW Doppler Ao valve: 5 beats Still 
- PW Doppler of LV outflow tract (in case of Ao stenosis and for SV 
calculation): 5 beats 
Still 
Apical 4-, 2-chamber view for LV (strain): 
- A4C 2D of LV: 5 beats, the depth adjusted so that mitral annulus is at 
the bottom of image sector 
cine loop 
- A2C 2D of LV: 5 beats, the depth adjusted so that mitral annulus is at 
the bottom of image sector 
cine loop 
Apical 4- & 2-chamber view for LA (strain, volume): 
- A4C 2D of LA: 5 beats with depth adjusted so that the LA roof is at 
the bottom 
cine loop 
- A2C 2D of LA: 5 beats with depth adjusted so that the LA roof is at 
the bottom 
cine loop 
Apical 4-chamber view for Mitral Annular DTI: 
- Apical 4C. Mitral Annular DTI: the DTI PW Doppler at the septal 
corner (5 beats) and, at the lateral corner (5 beats).  
Still 
229
 Title: Standard Operating Procedures for Ultrasound Acquisition 
Document number: SOP9 Version number 1.6 
Creation Date: 08/11/2013 Number of pages 24 
 
 
 20 
Table 2. Quantitative echocardiographic measurements by ECHOPAC software (Central Reading Lab) 
Echocardiographic window 
and view 
Measurements Calculated variables 
Parasternal long-axis; M-
mode (short axis might 
also be used) 
LV internal dimension (LVID), interventricular septal 
(IVS) and posterior wall (PW) thicknesses measured 
at end-diastole (d) and end-systole (s) 
LV structure - LV mass, relative 
wall thickness 
LV systolic function - systolic 
endocardial fractional shortening, 
ejection fraction 
Parasternal long-axis; M-
mode 
Left atrial dimension (end-systole), aortic root 
dimension 
 
Parasternal long-axis; 2D LVOT diameter (systole)  LV systolic function - Doppler 
stroke volume  
3-chamber apical; Pulsed 
Doppler of LVOT 
Velocity-time integral (VTI)  
4-chamber apical; 2D LV cavity volume measurements at the end diastole 
and end systole (methods of discs), LV long axis.   
LV systolic function – ejection 
fraction 
4-chamber apical; Pulsed 
Doppler of transmitral flow 
Peak early diastolic mitral flow (E peak) and late 
diastolic mitral flow (A peak, atrial filling fraction) 
wave velocities, deceleration times of E peak and 
duration of A peak 
LV diastolic function – E/A ratio 
4-chamber apical; M-mode 
of lateral site of tricuspid 
annulus 
Tricuspid annulus.  
 
RV systolic function – motion 
amplitude of tricuspid annulus  
4-chamber apical; Tissue 
Doppler of septal and 
lateral corner of mitral 
annulus 
Mitral annulus. Peak systolic myocardial (Sm), early 
diastolic myocardial (Em), and late diastolic 
myocardial (Am) velocities. 
LV diastolic function:   
– Em/Am ratio,  
– E/Em ratio 
4-chamber + 2-chamber 
apical; LV 2D strain Echo 
(2DSE) (Speckle Tracking) 
AFI technology. Aortic Valve closure (AVC) time; LV 
endocardial border tracing - to calculate longitudinal 
peak systolic LV strain (LVPSS LAX, A4C, A2C) 
and Strain Rate (LVSR LAX, A4C, A2C).  
LV systolic function: 
 – global LV strain (LV GSS), 
– peak systolic & peak diastolic 
myocardial strain  
 – Strain Rate (LV SR) 
4-chamber and 2-chamber 
apical;  LA 2DSE (Speckle 
Tracking);  
AFI novel technology ( LV program). P wave onset; 
LA endocardial border tracing to calculate peak 
positive, peak negative and total LA strain (A4C, 
A2C); LA Strain Rate (late negative, early negative, 
positive). 
LA structure & function: 
– global LA strain (3 measures);  
 – global LA Strain Rate (3 meas);  
4-chamber and 2-chamber 
apical;  LA 2D 
LA cavity volume measurements at the end diastole 
and end systole (methods of discs, A4C, A2C), LA 
long axis 
LV diastolic function:   
–  LA volume index (LAVI) 
- Table 3. Grading of Valvular Regurgitation and Stenosis 
- Semi-quantitative 
evaluation 
- Valvular 
disorder 
- Echocardiographic window and images 
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- 1 – mild 
- 2 – mild to 
moderate 
- 3 – moderate 
- 4 – severe 
- MR, MS - PSLA – colour-flow 
- Apical 4-chamber: colour-flow, CW, PW 
- AR, AS - PSLA – colour-flow 
- Apical 4-chamber and long-axis: colour-
flow, CW, PW  
- TR - Apical 4-chamber and long-axis: colour-
flow, CW 
 
Table 4. Sequence and type of vascular images to record (each VUS site) 
Site, position and view Type of images 
(still / cine loop) 
Carotid arteries left  
2D longitudinal view; anterior (preferable) or anterolateral or posterior position (wherever 
IMT visualization is the best and closer to the probe), distal CCA left, 10 beats 
To register position of IMT visualization and to mark the image (A, L, P) 
cine loop 
2D longitudinal view; to document key regions where plaques could exist;  CCA, bulbus, 
ICA, ECA (left), 10 beats 
cine loop 
2D transverse view; to document key regions where plaques could exist; CCA, bulbus, 
ICA, ECA (left), 10 beats 
cine loop 
In case of plaque or intima bulging: longitudinal view of relevant segment in 
CCA/bulbus/ICA/ECA  
still 
In case of plaque or intima bulging: transverse view of relevant segment in 
CCA/bulbus/ICA/ECA 
Indicate the number of plaques in comments to records 
still 
Carotid arteries right 
2D longitudinal view; anterior (preferable) or anterolateral or posterior position (wherever 
IMT visualization is the best and closer to the probe),  distal CCA left, 10 beats 
To register position of IMT visualization and to mark the image (A, AL, P) 
cine loop 
2D longitudinal view; to document key regions where plaques could exist; CCA, bulbus, 
ICA, ECA (right), 10 beats 
cine loop 
2D transverse view; to document key regions where plaques could exist; CCA, bulbus, 
ICA, ECA (right), 10 beats 
cine loop 
In case of plaque or intima bulging: longitudinal view of relevant segment in 
CCA/bulbus/ICA/ECA 
still 
In case of plaque or intima bulging: transverse view of relevant segment in 
CCA/bulbus/ICA/ECA 
Indicate the number of plaques in comments to records 
still 
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Table 5. Quantitative vascular measurements by ECHOPAC software (Central Reading Lab) 
Vascular site and view Measurements Calculated variables 
2D; Anterior position (preferable), 
longitudinal view of CCA left;  
* anterolateral or posterior 
IMT (at end diastole) on ECG-gated 
longitudinal view at 10-mm segment of the far 
wall of distal CCA in plaque-free zone 
(automatic; min, mean, max ; 3 cycles);  
CCA diameter  
To register position of IMT measurement 
- 
2D; Anterior position (preferable), 
longitudinal view of CCA right;  
*anterolateral or posterior 
IMT (at end diastole) in ECG-gated longitudinal 
view at 10-mm posterior segment of the far 
wall of the distal CCA in plaque-free zone 
(automatic; min, mean, max ; 3 cycles);  
CCA diameter  
To register position of IMT measurement 
- 
In case of  plague:  
2D; CCA/bulbus/ICA/ECA; longitudinal 
view; transverse view 
Number of plaques; stenosis % (diameter, 
ECST); stenosis % (area) ;  
 
- 
 
Table 6. Grading of vascular abnormalities 
Semi-quantitative 
evaluation 
Vascular abnormalities: 
abbreviation/ definition 
Vascular site and images 
0 – no plaques 
1 – single plaque 
2 – multiple plaques 
(indicate number of 
plaques) 
PL 
Plaque is a focal structure 
encroaching into the arterial 
lumen of at least 0.5 mm or 50% of 
the surrounding IMT value, or 
demonstrates a thickness 1 1.5 mm 
as measured from the media-
adventitia interface to the intima-
lumen interface (Mannhein 
Consensus, 2006). 
CCA/bulbus/ICA/ECA: 2D; 
longitudinal view; transverse 
view  
 
0 – no triple line pattern 
of carotid wall 
1 – triple line carotid 
pattern 
TLP 
Triple pattern is defined as 
divergence from the normal 
double line pattern of carotid 
wall, characterised by 
additional discernable 
reflection line in intima-media 
compartment of the far wall. 
CCA/bulbus: 2D; longitudinal 
view; transverse view  
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A.7 The original number of plaque in KYH and plaque score in Tromsø 7 
according to carotid segment 
 
  Number of plaque N (%) Plaque score 
  KYH men KYH women T7 men T7 women 
Right CCA 0 1237 (89.1) 1805 (96.4) 778 (95.9) 973 (98.4) 
 1 125   (9) 66     (3.5) 29   (3.6) 15  (1.5) 
 2 26     (1.9) 2       (0.1) 4     (0.5) 1     (0.1) 
 3 1        (0.1) 0   
Right bulb 0 639  (46.0) 1196 (63.9) 436 (53.8) 664 (67.1) 
 1 602  (43.3) 576   (30.8) 238 (29.4) 243 (24.6) 
 2 148  (10.7) 99     (5.3) 137 (16.9) 82   (8.3) 
 3 0 2       (0.1)   
Right ICA 0 981  (70.6) 1620 (86.5) 751 (92.6) 950 (96.1) 
 1 378  (27.2) 234   (12.5) 53   (6.5) 37  (3.7) 
 2 30     (2.2) 19     (1.0) 7     (0.9) 2    (0.2) 
 3 0 0   
Left CCA 0 1180 (85.0) 1765 (94.2) 764 (94.2) 966 (97.7) 
 1 169   (12.2) 97     (5.2) 46   (5.7) 21   (2.1) 
 2 35     (2.5) 10    (0.5) 1     (0.1) 2     (0.2) 
 3 5        (0.4) 1       (0.1)   
Left bulb 0 604 (43.5) 1162 (62.0) 439 (54.1) 649 (65.6) 
 1 606 (43.6) 607  (32.4) 251 (31.0) 255 (25.8) 
 2 176  (12.7) 103   (5.5) 121 (14.9) 85   (8.6) 
 3 3      (0.2) 1        (0.1)   
Left ICA 0 988 (71.1) 1618 (86.4) 765 (94.3) 966 (97.7) 
 1 354 (25.5) 235  (12.6) 41   (5.1) 23 (2.3) 
 2 46   (3.3) 19    (1.0) 5      (0.6)  
 3 1     (0.1) 1      (0.1)   
CCA: common carotid artery, bulb: bifurcation, ICA: internal carotid artery 
 
